Program at a glance
The 123rd Annual Meeting of the Japanese Dermatological Association
Kyoto International Conference Center
Room 1Room 2

Room 3

Room 4

Room 5

Room 6

Room 71F
Main Hall

1F
Sakura2F
Room A

2F
Room B-1

2F
Room B-2

1F
Room D

1F
Room E

8：00

9：00

10：00

Advanced

Basic／Advanced

Basic

Advanced／Update

Educational Lecture 1
Educational Lecture 2 Educational Lecture 3 Educational Lecture 4『Updates on『Prurigo『Updates on viral『Updates onunderstanding the〜From the basics to
infectious diseasescleroderma pathology
pathology of atopic
clinical practice〜』
guidelines』
and treatment』
dermatitis』

Advanced

Oral Session 1『Viral, bacterial, andfungal infections』

Oral Session 2『Epithelial tumors,
nervous system
tumors』

Basic

Educational Lecture 5 Educational Lecture 6『Essentials and『Letʼs learn about skincutting-edge ofpathology!:dermatology
How to learn aboutsubspecialty』
skin pathology』

11：00
11：15
Luncheon Seminar 1『Significance of C1
inhibitor replacement
therapy in hereditaryangioedema (HAE)』

12：00

Luncheon Seminar 2『Jumihaidokuto intimes like these〜Different uses ofheat-refreshing
agent〜』

Luncheon Seminar 3 Luncheon Seminar 4『Skin disease treat- 『Latest topics on thement and cosmetic
pathologicalapplications of lasers mechanism of atopic
and RF』
dermatitis』

12：15
12：20

Special Lecture 1『The past and presentof collagen-specific
Presidentʼs Special
molecular chaperone
Program 2
Hsp47』
13：00『Please let us listen
Special Lecture 2
your lecture for『Autophagy: The cellʼs
student!』
guardian against
disease and aging』

13：40
14：00
14：10

Master of Dermatology（Maruho）Award
Ceremony and Lecture
Basic／Advanced

Basic／Advanced

Advanced

Oral Session 6
Educational Lecture 12 『Treatment drugs,
treatment methods』
Educational Lecture 10『Skin infections that
Sponsored
Educational Training
15：00 『The current state of Educational Lecture 11 Presidentʼs Special dermatologists would
Program 3
Symposium 1
Seminardermatology AI /want to cover
15：10『Updates on contact『Meet legends in『Latest treatment for “Dermatopathology”
remote medical〜Bacterial infections,dermatitis treatment』
Global Dermatology』
atopic dermatitis』 『Melanocytic tumors』
treatment / online
non-tuberculous
medical treatment』
mycobacteria, leprosy,
Oral Session 7
and fungal diseases〜』『Eczema,erythroderma』

16：00
16：10
Only forpreregistrant

17：00

17：50
18：00

18：50
19：00

Evening Seminar 1『Cutting-edge
research of themechanism of itching〜Treatment of prurigo
nodularis explained
from pathology〜』

Evening Seminar 2
Evening Seminar 3『Must listen!
Mechanism and 『UP TO DATE on atopic
treatment of skindermatitis』
problems』

Level Basic : For doctor in training Advanced : For specialist and/or superviser Update : Update outside your field (Brush-up program for supervisor)2

Lecture in English

Kyoto International Conference Center【Day 1】June 6 (Thu.), 2024

The Prince Kyoto Takaragaike

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

1F
Room C-1

1F
Room C-2

1F
Annex Hall 2

1F
Room 157

B2F
Prince Hall

B2F
Gold Room

Kyoto International
Conference Center

Poster Corporate
Venue Exhibition
1F
1F
Event Hall＋
New Hall Annex Hall 1

8：00
Digital Poster Viewing
from your PC or app
From June 6, 8：00am toJune 9, 5：00pm
Basic／Advanced

Basic／Advanced

Oral Presentation in
Oral Session 5
Oral Session 3
English 1『Vasculitis, collagen『Birthmarks,
Educational『Basic research,disease, autoimmulymphoma, andLecture 7
Allergic disease,nity, and soft tissue
malignant tumors』
『So
much
has
Congenital disease』
granuloma』
changed! Latest
treatment forhemangioma
vascular malforma- Presidentʼs Special
Oral Session 4
Program 1
Oral Presentation in tions and varicose『Keratosis, bullous
English 2『Cutting-edge
veins』
disease, anddermatology『Tumor』
pustulosis』
research: Part 1』

Educational
Lecture 8『Genetic skindisease 2024
updates』

9：00

Advanced

Educational
Lecture 9
Educational Lecture『Insects16and skindisease『Psoriatic arthritis:〜Letʼs first learn
2024 updates』
about the ecology
of insects!〜』

10：00
Put up
Posters

11：00
11：15

Luncheon Seminar 5 Luncheon Seminar 6 Luncheon Seminar 7『Logical reconsidLuncheon Seminar 8
eration of treatment 『Pathology of 『Treatment goals to
drug-induced
pursue for disease 『Updates on drugof male patterntherapy for skinburden of atopic
baldness: Including hypersensitivity
malignancies』
dermatitis pastandard treatment syndrome and its
biomarkers』
tients!』and red LEDs』

12：00
12：15

13：00

Basic／Advanced

Advanced

Basic／Update

Advanced

Oral Presentation in
English 3
Educational
Educational『Treatment,
Lecture 13
Lecture 15
Autoimmune『Utilizing knowl『Photoaging
disease』
Educational
Educationaledge in skin surgery
prevention〜
Lecture 14
Lecture 16
treatment from
Functions and the『Updates on vitiligo『Psoriatic arthritis:
tomorrow!
correct use of
Oral Presentation in 〜Learning thevulgaris』
2024 updates』
sunscreen products
Oral Session 9
English 4
ABCs ofthat will help guide『Adnexal diseases,『Diagnosis,
dermatology
frompatients
frombasic researh
Inflammatory
experts〜』
tomorrow〜』
diagnostic
disease, Infectious
methods』
disease』
Oral Session 8『Urticaria, drug
eruption』

14：00
14：10
PosterViewing
Corporate
Exhibi- 15：00
tions
15：10

16：00
16：10
16：15
Posterdiscussion(odd
number)PosterPresentation by a
Grant
Recipient

Evening Seminar 4『Pathology ofpustular psoriasis
considered fromcytokines』

Evening Seminar 5『Up to date onalopecia areata
treatment』

PosterViewing

17：00

17：45
17：50
18：00

18：30
18：50
19：00

3

Program at a glance
The 123rd Annual Meeting of the Japanese Dermatological Association
Kyoto International Conference Center
Room 1Room 2

Room 3

Room 4

Room 5

Room 6

Room 71F
Main Hall

1F
Sakura2F
Room A

2F
Room B-1

2F
Room B-2

1F
Room D

1F
Room E

8：00

9：00
9：10

10：00

11：00
11：10
11：20
11：40
12：00
12：10

Advanced

Advanced／Update

Basic／Advanced

Advanced

Educational Lecture 17
Presidentʼs Special Educational Lecture 21
Educational Lecture 18 Educational Lecture 19 Educational Lecture 20
Program 4
Educational Training『Medical ethics:『Topics that dermaSeminar『Goals of cosmetic 『Updates in skin tumor 『“Seeing” disease:
Thinking about ethics 『Cutting-edge skintologists should know
“Dermoscopy” 1
research』
dermatology』
pathology』
in clinical practice andCutting-edge imaging about collagen diseaseresearch』
research』
and related diseases』

Special Lecture 3

Only forpreregistrant

Special Lecture 4『Introduction to『“Scary and smelly matters”inepigenetics―From its scarring alopecia：How fragrances
molecular mechanism to may damage hair follicle stem
clinical applications―』 cells in frontal fibrosing alopecia』

Luncheon Seminar 12
Luncheon Seminar 10
Luncheon Seminar 13
Luncheon Seminar 11 『Learning from and『New treatment『Reconsidering the
Luncheon Seminar 9
option for psoriasis
agreeing with
『Potential ofmanagement ofusing biosimilars『Evolution of atopic
specialists:
Dermacosme
collagen diseases
dermatitis treatment』 〜Expectations for the 〜From acne to UVUnderstanding the〜Skin lesions andarrival of ustekinumab
alopecia areata
care〜』
13：00
systemic lesions〜』
BS〜』
treatment guidelines』

13：10
13：20

13：50
14：00
14：25

14：55
15：00

Basic／Advanced

Luncheon Seminar 14『Communication
between physicians
and patients in
hyperhidrosis
treatment』

Presidential Lecture『Mystery of the Skin
Skin more than Deep』
Dohi Memorial
Award Lecture『A Commotion in the Skin: Developing Melanoma Immunotherapies』

Minami Seigo Award Lecture『Activation of the pentose phosphatepathway in macrophages is crucial for
granuloma formation in sarcoidosis』

Award Ceremony

15：25

16：00
Special Lecture 5『Time passes nomatter what you do;
My research history』

17：00
17：10

18：00
18：10

Evening Seminar 6『Litfulo: A new option
for patients aged 12
years or older withalopecia areata』

Evening Seminar 7『Pathology andtreatment of chronic
urticaria』

Evening Seminar 11
Evening Seminar 8
Evening Seminar 9『What is hereditary『Hereditary angio- 『Treatment of benign Evening Seminar 10
angioedema (HAE)
edema: Actual clinical pigmentary diseases 『Up to date on atopic
treatment, which aims
practice and future using 750-picosecond dermatitis treatment』
for a daily life free of atreatment strategies』
laser』
disease burden?』

19：00

Level Basic : For doctor in training Advanced : For specialist and/or superviser Update : Update outside your field (Brush-up program for supervisor)4

Lecture in English

Kyoto International Conference Center【Day 2】June 7 (Fri.), 2024

The Prince Kyoto Takaragaike

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

1F
Room C-1

1F
Room C-2

1F
Annex Hall 2

1F
Room 157

B2F
Prince Hall

B2F
Gold Room

Kyoto International
Conference Center

Poster Corporate
Venue Exhibition
1F
1F
Event Hall＋
New Hall Annex Hall 1

8：00

8：30

Basic／Advanced

Educational
Lecture 22『Genetic analysis
and diagnosis:
The basics of thebasics』

Basic／Advanced／Update

Advanced／Update

Advanced

9：00
9：10

UpdateEducational
Sponsored
Educational
Educational
Lecture 25
Educational
Symposium 2
Lecture 23
Lecture 24『Latest treatment
Lecture 26『Say NO to『Updates on『Presidentʼs Special
for skin cancer『Expanding world“itching”!
granulomatous
Program: How tousing immuneofBeyond improving
disease pathology,
develop your careercheckpoint
autoinflammatory
the disease burden
diagnosis, andand leadershipinhibitors:
diseases』
in atopic dermatitis
treatment』
skills?』From basics totreatment!』
clinical practice』

10：00

11：00
11：10
Digital Poster Viewing
from your PC or app
From June 6, 8：00am toJune 9, 5：00pm

12：00
12：10

Luncheon Seminar 15
Presidentʼs Special『Are you seeing more Luncheon Seminar 16
Luncheon Seminar 17
Program 5
patients with hand 『Psoriasis treatment『Messages to young 『Up-to-date on
sweating? 〜Efficacy strategy considerdermatologists： neurofibromatosis
of Apohide
ing Psoriatic
type 1 treatment』
How to develop
lotion in actual
Disease』
your clinical skills?』
clinical practice』

13：00

PosterViewing

Corporate 13：10
Exhibitions

14：00

15：00

16：00

17：00
17：10

Evening Seminar 13
Evening Seminar 12
Evening Seminar 14
Special Lecture 6『Vitiligo treatment『How to increase『Clinical practiceusing regenerative 『Thinking about thepatient adherence
using themedicine〜How to
future of vaccine
in the topicalnext-generation
use melanocytedevelopment andtreatment of tinea
model 6.78-MHz
containing autologous barrier research』
unguium』
monopolar RF』
cultured epidermis〜』

17：30

18：00
18：10
Posterdiscussion(evennumber)

19：00
19：10

5

Program at a glance
The 123rd Annual Meeting of the Japanese Dermatological Association
Kyoto International Conference Center
Room 1Room 2

Room 3

Room 4

Room 5

Room 6

Room 71F
Main Hall

1F
Sakura2F
Room A

2F
Room B-1

2F
Room B-2

1F
Room D

1F
Room E

8：00

Morning Seminar 1
Morning Seminar 2
Morning Seminar 3
Morning Seminar 4『Considering the disease『Diagnosis and『Optimal patient『Treatment strategies
burden of idiopathic
treatment of interstitial profile for ixekizumab
for itching
chronic urticaria as Typelung disease associated in psoriasis treatment〜From basic and2 inflammatory disease
with systemic
based on actual clinicalclinicaland indications forsclerosis』
practice』
perspectives〜』
biologic drugs』

9：00
9：10

Advanced

Basic／Advanced

Advanced／Update

Sponsored
Symposium 3
Educational Lecture 27 Educational Lecture 28『JDA-Novartis
10：00 Partnership Education 『Alopecia diagnosis 『Latest information on Presidentʼs Special Educational Lecture 29
Program 6『Updates on
and treatment updates
school health andProgram 2024
『How to publish your autoimmune bullous
pediatric―Learn from Global that should be utilized
work?』
disease』
in medical treatment』
dermatology』
Top Experts forStudent&Residency
Oral session

Immunodermatology―』

Educational Training
Seminar“Dermatopathology”『Soft tissue tumors・Merkel cell carcinomas』

11：00
11：10
11：25

Only forpreregistrant

Presidentʼs Special
Program 8

Luncheon Seminar 20
Luncheon Seminar 22
Luncheon Seminar 18 『International Societies for Luncheon Seminar 19『Essence of picosec- Luncheon Seminar 21 『Treatment strategies『The Future of
Investigative Dermatology『Potential of Dovobet®
『Reskilling
the
study
of
ond
alexandrite
laser
for achieving goals
2023 highlights: Learning foam three years after
Dermatological
12：00
perspiration』〜Usefulness for〜Considering external
about the cutting-edge ofInvestigation』
release』
dermal lesions〜』
therapy〜』
dermatology research inJapanese』

12：25
12：30
12：35
13：00
13：20
13：30

Presidentʼs Special
Program 9『What is ILDS?』

Presidentʼs Special
Program 11『Understanding skin
『Cutting-edge
pathology through reasoning dermatology research:―spongiosis vs. vacuolar
Part 2』Presidentʼs Special
Program 10

degeneration, granulomas―』
Basic／Advanced

Advanced

Basic

Presidentʼs Special
Program 12
Sponsored
Presidentʼs Special『What happens when
Educational Lecture 34
Sponsored
Symposium 6
Program 13
Educational Lecture 35
being seconded from a
Symposium
5『Basic knowledge and『“Intuitive” andEducational Lecture 36『From research to『Taking charge ofdermatology
latest findings on food 『Maruho symposium“Narrative” aspects ofgeriatic dermatology 『Medical history ofdepartment to the social implementation,
allergies necessary for―Decoding Itchinflammatory skindermatology』
translational researchtreatment in thegovernment?
daily medical
Pathogenesis and IL-31
disease treatment〜
is achieved with
community』〜Diverse careers fortreatment』
Involvement―』
Based on must-readstartups』
people seconded topapers〜』
15：00
ministries andagencies〜』

14：00

15：30
15：40

Special Lecture 8
Cultural Lecture 1

16：00 『Happiness planningtechniques』

16：20
16：25

Cutting Edge in Dermatology: Genetic Skin Disorders
and Adverse Drug
Reactions

Special Lecture 7『The current status of
iPS cell research andefforts toward medical
17：00
applications』

17：10
17：20

Evening Seminar 15
Evening Seminar 18
Evening Seminar 19
Evening Seminar 17 『Bridge perception『Fundamentals,『Shortening downtime
Evening Seminar 16
innovations, andgaps between『Considering new
after cosmetic
applications in psoriasis 『Considering atopic clinical applications of dermatologists andtreatments
treatment〜From the dermatitis treatment』 anti-IL-17 receptor
patients in prurigo―Proposal focused on
perspective of hospitals
nodularis and chronic
antibodies』
skin repair』
and clinics〜』
spontaneous urticaria』

18：00
18：20
18：40
19：00
19：25

Dermato Orchestra &ChorusSocial Gathering 19:25~21:10
Venue: 1F Sakura, Swan, Lobby, Garden

Level Basic : For doctor in training Advanced : For specialist and/or superviser Update : Update outside your field (Brush-up program for supervisor)

6

Lecture in English

Kyoto International Conference Center【Day 3】June 8 (Sat.), 2024

The Prince Kyoto Takaragaike Kyoto International Conference Center

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Room 14

1F
Room C-1

1F
Room C-2

1F
Annex Hall 2

1F
Room 157

B2F
Prince Hall

B2F
Gold Room

5F
Room 510

Educational
Lecture 30『Latest topics on
urticaria that willpique yourintellectual
curiosity』

Basic

1F
1F
Event Hall＋
New Hall Annex Hall 1

8：00

Morning Seminar 5 Morning Seminar 6 Morning Seminar 7
Morning Seminar 8『【Cutting-edge 『Best treatment based 『Treatment strategy『Learning thevitamin C】New
on immunogenicity provided by fosravucomechanism bycosmetic treatment 〜Early intervention nazole〜What is thewhich nanoscale
methods using
and long-term
treatment for tinea
water particles act
multifunctional
strategy for palmo- unguium that patientson the skin』
provitamin C』
plantar pustulosis〜』
truly seek?〜』
Advanced

Poster Corporate
Venue Exhibition

Digital Poster Viewing
from your PC or app
From June 6, 8：00am toJune 9, 5：00pm

8：45

Basic

9：00
9：10

Basic

Educational
Sponsored
Lecture 33
Symposium 4『Methods for
Educational
Educational『Thinking about the Presidentʼs Special
understanding
Lecture 31
Lecture 32
pathology anddermoscopy
Program 7
treatment of atopic『Diagnosis and『Learning from the findings assuming『Learnabout
dermatitis from thetreatment ofbasics: Diagnosis
histopathologicaldermatology
non-melanoma skin perspective of Typeand treatment offindings that areworldwide: Part 1』
2 inflammation
malignancies』
nail diseases』
useful in daily
medical treatment〜Trinity theory and(divided into four
latest findings〜』
skin areas)』

Luncheon Seminar 23『Up to date on the Luncheon Seminar 24 Luncheon Seminar 25 Luncheon Seminar 26 Luncheon Seminar 27 Luncheon Seminar 28『Treatment of『Skin on Skin: Moist
treatment of『Psoriasis treatment 『For effective『Reconsidering the
ingrown toenails
skin created withadvanced-stage
with expanding
topical therapy for treatment sequence
BRAF -positiveandfine fibers andfuture potential.』 atopic dermatitis』
for psoriasis』
melanoma learned onychomycosis』
pseudo-ceramides』
from experts』

Educational
Training Seminar“Dermatologic
Surgery”『Basic』

10：00

PosterViewing

11：00
11：10
11：25
Only forpreregistrant

12：00
12：25

Corporate
Exhibitions
Advanced

Basic／Advanced

Advanced

Educational
Educational
Sponsored
Lecture 38
Presidentʼs Special
Presidentʼs Special
Educational
Lecture 37
Symposium 7『Updates on
Program 15
Program 14
Lecture 39『New diagnosis and『Pathophysiology
treatment for atopic『Learn about『The science of『New and notable
treatment in theand latest treatdermatitis
dermatology
beauty』
drug eruptions』 ments for chronic
field of
〜What to do ifworldwide: Part 2』
dermatology』
skin diseases』
remission cannot be
induced?〜』

13：00

13：30

14：00
Student &Residency
Educational
PosterTraining Seminar discussion“Dermatologic
Surgery”『Addvance』

15：00

15：30

16：00
16：10
Only forpreregistrant

17：00
Evening Seminar 20
Evening Seminar 23『Immediately
Evening Seminar 21
Evening Seminar 22 『How to utilize
useful! Small『Skin barrier
treatment device『Future opened up
ultraviolet lightfunction and〜Mobile HIFU andby IL-31』
therapy equipment
cleaning tips』
medium-frequency
in medical settings』
electric drying〜』

PosterViewing
Evening Seminar 24『Utilization of
cosmetics to assist
in the prevention
and treatment ofskin diseases』

17：20
17：30

18：00
18：20

19：00
Social Gathering 19:25~21:10
Venue: 1F Sakura, Swan, Lobby, Garden

7

Program at a glance
The 123rd Annual Meeting of the Japanese Dermatological Association
Kyoto International Conference Center
Room 1Room 2

Room 3

Room 4

Room 5

Room 6

Room 71F
Main Hall

1F
Sakura2F
Room A

2F
Room B-1

2F
Room B-2

1F
Room D

1F
Room E

8：00
Morning Seminar 9『Treatment for
pustular psoriasis』

9：00
9：10

Basic／Advanced／Update

Morning Seminar 10
Morning Seminar 12 Morning Seminar 13『Updates on picosecond lasers and Japanʼs Morning Seminar 11 『Prevention measures 『Importance of a
『Acne Inflammatory
first approved
and topical drug
comprehensive skin
Disease』
phototherapy device
selection for atopic
care routine in(IPL)〜Bruise treatdermatitis』
dermatology practice』
ment, facial treatment』
Advanced

Advanced

Basic／Update

Educational Lecture 41
Sponsored
Symposium 8
Presidentʼs Special
Educational Lecture 42 Educational Lecture 43『From understanding
Educational
Lecture40
10：00
Program 16
the basic pathophysi- 『Drug selection for 『Understanding the 『How to heal wounds Educational Training『Updates on acne・Seminarology of psoriasis to atopic dermatitis with pathology of chronic『Listen to the stories of〜How to use therosacea pathology and“Dermoscopy” 2treatment updates,
an eye toward
legends〜Japanpyoderma and its
newly revised
treatment』
and collaboration
long-term remission inedition〜』
management』
guidelines〜』
between clinics』
Japan and overseas』

11：00
11：10
11：20
Cultural Lecture 2『Golf and life
philosophy』

12：00

Only forpreregistrant

Special Lecture 9『The Golden Age of
Dermatologic Drugs
Finally Has Begun』

Special Lecture 10『Story of PD-1: a thirty
year journey fromdiscovery』

12：40
12：50
Luncheon Seminar 30
Luncheon Seminar 32
Luncheon Seminar 33 Luncheon Seminar 34
Luncheon Seminar 31
13：00 Luncheon Seminar 29

13：50
14：00

『Pathology and『New era in thetreatment goals oftreatment of childhood
inflammatory skinatopic dermatitis
diseases, including〜New treatment
psoriasis and psoriatic
options〜』
arthritis』
Basic

Basic

『Topics of skin mycosis『New horizon for『Dermatological『Golden standard of Luncheon Seminar 35
that you want to dig
alopecia areata
treatment andcosmetic skin
『Considering
deeper into because oftreatments based onaftercare / potential oftreatment
treatment for rosacea』
its depth
updated pathology
hot spring water〜IPL and medical hair
―Dermatomycosis
and diagnostics』
ingredients』
removal〜』More Than Deep―』
Advanced

Advanced

UpdateAdvanced2024 psoriasis/atopic
dermatitis molecularEducational Lecture 48
Educational Lecture 52
Educational Lecture 53『Re-learning hospital Educational Lecture 49 targeted drug safety Educational Lecture 50 Educational Lecture 51『Updates on skinmeasures seminar
infection
controland『Lasertreatment
that『Various
15：00『Cutting-edge sweat『Food and skinbarriers that can be(Videolecture)medical safety based dermatologists should
granulocyte-related
treatment 2024』
diseases』
used to treat skinon the COVID-19
know about』
skin diseases』
diseases』
pandemic experience』

15：30

16：00

17：00

18：00

19：00

Level Basic : For doctor in training Advanced : For specialist and/or superviser Update : Update outside your field (Brush-up program for supervisor)8

Lecture in English

Kyoto International Conference Center【Day 4】June 9 (Sun.), 2024

The Prince Kyoto Takaragaike Kyoto International Conference Center

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Room 14

1F
Room C-1

1F
Room C-2

1F
Annex Hall 2

1F
Room 157

B2F
Prince Hall

B2F
Gold Room

5F
Room 510

Poster Corporate
Venue Exhibition
1F
1F
Event Hall＋
New Hall Annex Hall 1

8：00
Morning Seminar 16
Morning Seminar 15
Morning Seminar 17
Morning Seminar 14『Fighting Shingles『Up-to-date on『Current state of―2024 updates on『Letʼs treat vitiligo!』
urticaria treatment』
azelaic acid』
shingles vaccine―』

Basic

Basic

Basic

Morning Seminar 18『Latest strategies
for melasma andred face: Great
potential of pulsed
microneedle RF』

Digital Poster Viewing
from your PC or app
From June 6, 8：00am toJune 9, 5：00pm

9：00
9：10

Advanced

Hands-on Venue
Educational
Kyoto International
Presidentʼs Special
Educational
Educational
Lecture 46
Conference Center
Educational
Program 17
Lecture 45
Lecture 47
Sponsored『UJA X ENGAGE-TF:
1F Swan
Lecture 44『Cutting-edge lipid
10：00
Symposium 9 『Decision making in『Letʼs start clinicalStudy abroad『Treatment ofresearch
research frommelanomarecommendations 『New solution for
cutaneous〜Approaching thequestions in daily―How to addressleaving psoriasis
2024@Annual
Sponsored
lymphoma that
relationshipdermatology
difficult-to-treat
behind』
Meeting of theHands-on Seminaranyone can do』 between lipids andpractice!』
cases―』
Japanese Dermato『Examine the skin.
inflammation〜』
logical Association』
Estimate thepathology.
Poster
11：00
ConsiderViewing
treatment
11：10
strategies
Corporate〜For a long-term
Exhibiremission of atopic
tions
dermatitis〜』

12：00
Only forpreregistrant

12：50
13：00

Luncheon Seminar 37
Luncheon Seminar 39
Luncheon Seminar 38 『The actual circumLuncheon Seminar 36 『Basics of ultraviolet
light therapy and 『What are the best stances of cutting-edge『Viral warts
prospects forchemical peelingtreatments for〜Cutting-edge
applicable diseases〜
ingrown toenail 〜Evolution of treatment
treatment 2024〜』
UVB (excimer light andand usefulness ofpatients?』
UVB-LED) and UVA1〜』
manuka honey〜』
Basic

13：50
14：00

Basic／Advanced／Update

Presidentʼs Special Presidentʼs Special
Educational
Program 18
Program 19
Educational
Lecture 55『I am a physician, 『Basic knowledge
Lecture 54『Case study by a
but also a business and the usage of『What is required of female physician
personsocial media
specialist
and guide to〜the power ofnecessary for
instructors』
becoming aphysicians utilized
medicalLecture for
vasculitis specialist』
in companies〜』
professionals』 Speciality Nurse in
Dermatology

14：30

Open Lecture『Prevention andskin care forcommon skinproblems』

Educational
Training Seminar“Patch test,
Prick test”

RemovePosters

15：00

16：00
Only forpreregistrant

16：30

17：00

18：00

19：00

9

Floor Map

10

19:25~21:10

11

12

Conference Information(1) Registration[On-site registration]
The registration desk will be open throughout the conference at the following schedule:- Location: Entrance Hall, 1st floor Main Lobby, Kyoto International Conference Center- Date & Time:

June 6 (Thu.)

8:00 − 18:00

June 7 (Fri.)

6:45 − 18:00

June 8 (Sat.)

7:30 − 19:00

June 9 (Sun.)

7:30 − 14:00

Please settle the registration fee and receive your name badge. A name badge will be used to access all conference
areas, therefore we kindly request that you wear your name badge at all times during the conference.

-Onsite Registration Fee:
1) Member: JPY 20,0002) Japanese Student/Overseas Student/Resident*: JPY 15,000
3) Non-Member (Company member): JPY 40,000
4) Non-Member (Others): JPY 25,000
5) Accompanying Person**: JPY 3,000* Students including undergraduates and postgraduates are requested to submit a proof of their status such as a photocopy of a valid student ID card or a letter from the dean, the department head or the research director with theirsignature.
** The Accompanying Person’s registration fee is available only to partners and/or family members of paid delegatesregistered to attend the Conference. It covers the only admission for Corporate Exhibition venue, Social Gathering and
Dermato Orchestra & Chorus. Accompanying persons cannot access the lecture rooms except for them.

[Online registration]
If you cannot come to the venue in person, or if you would like to avoid a long queue at the reception desk, you canregister online. Please access 123rd JDA website (https://jda123.jp/english.html).
If you participate online on the day of the meeting
You will need to provide the ID/password listed in the registration completion notification email which you received
after registration payment. Please carry the print out.
If you participate offline on the day of the meeting
Please bring the registration completion notification email issued at the time of registration. When you show theprinted e-mail, registration staff will hand you your name badge at the JTB counter located near the registration areaon the 1st floor of the Kyoto International Conference Center. And please write your name there.
Please be sure to wear your name card inside the venue.

(2) Program and Abstract Book
One Program and Abstract is sent in advance to members of Japanese Dermatological Association. Program and
Abstract Book is also available at the venue for 2,000 yen.

(3) Livestreaming
Even if you cannot come to the venue (Kyoto International Conference Center) on the day, you can participate onlinefrom your home or your affiliated institutions. During the meeting, the content of the lecture will be delivered on the same
day and as per schedule.
14You can browse the livestream in cooperation with the electronic abstract service (MICEnavi) described later. Pleaserefer (5). App (MICEnavi) in this page.
Please follow the steps below. But MICEnavi service is only Japanese. We are terribly sorry.
1) Click on “123rd JDA Livestream and MICEnavi” on the meeting website (https://jda123.jp/).
2) The electronic abstract service (MICEnavi) will be displayed. Click the session being held from the schedule to display
the session details.
3) Click the “LIVE” button on the screen with session details.
4) Log in with the ID printed on the registration completion notification email or mailed participation certificate (namecard). (First time only)5) You can now watch the live stream.
* Secretariat will live stream only the sessions with the permission from the speaker and co-sponsoring companies.

(4) Sponsored Seminar* These are held in Japanese only except Luncheon seminar 9, 14, 31, Evening seminar 18.
- Morning Seminars: Light snack and drink will be provided.
- Luncheon Seminars: Lunch boxes and drink will be provided.
- Evening Seminars: Sweets and drink will be provided.
< Lunch box Ticket >If you would like to attend Luncheon Seminar, please get a ticket for Lunch box beforehand.

[Ticket distribution (for free)]- Location:

1st Floor Main Lounge, Kyoto International Conference Center- Time:June 6 (Thu.)

8:00 − 10:45 (App 9:00 − 10:45)

June 7 (Fri.)

6:45 − 11:40 (App 7:45 − 11:40)

June 8 (Sat.)

7:30 − 10:55 (App 8:30 − 10:55)

June 9 (Sun.)

7:30 − 12:20 (App 8:30 − 12:20)* This ticket will expire 5 minutes after the session starts.
From meeting App.
You may apply from meeting App (Japanese only, Distribution time is different from on-site).
Please refer (5). App (MICEnavi) in this page.

(5) App (MICEnavi)
The meeting app (JDA2024 can be downloaded for iOS in the App Store and for Android in the Google Play.)
The password is “skindeep123”**Japanese only・Scheduled release date: Mid May 2024
・Usage fee: Free (Communication fee will be charged separately for downloading the application)- Compatible models: iOS: 14.0 or later. Compatible with iPhone and iPad.
Android: 7.0 or above. Compatible with smartphones and tablets.
*Schedule contents registered for each of the web version and the application version can be synchronized with eachother.

15

(6) Miscellaneous
1. Congress bag, Refreshment Corner and Corporate Exhibition
Location:
Date & Time:

Event hall, 1st Floor, Kyoto International Conference Center
June 6 (Thu.)

9:00 − 18:00

June 7 (Fri.)

9:00 − 17:30

June 8 (Sat.)

9:00 − 17:30

June 9 (Sun.)

9:00 − 14:00

You could get a congress bag at by trading your voucher which is in your name badge. Congress bag quantities arelimited. It is offered only to the first 4,000 people.
Here is rest station and please enjoy snacks and drink.
We also prepare refreshment corner and corporate exhibition at Annex hall 1, Kyoto International ConferenceCenter.

2. Cloak Room
Location:

1st Floor Room F, G and existing Cloak, Kyoto International Conference Center2nd basement Floor, The Prince Kyoto Takaragaike

Opening hours:

June 6 (Thu.)

8:00 − 19:20 (The Prince Kyoto Takaragaike: 8:00 − 16:30)

June 7 (Fri.)

6:45 − 19:40 (The Prince Kyoto Takaragaike: 8:30 − 11:40)

June 8 (Sat.)

7:30 − 21:30 (The Prince Kyoto Takaragaike: 8:30 − 18:50)

June 9 (Sun.)

7:30 − 16:30 (The Prince Kyoto Takaragaike: 7:30 − 17:00)

3. To everyone who has questions[On-site] Please follow the chair’s instructions and use a microphone to state your affiliation and name before making any remarks.
[Online] If you have a question, please post your question from our live streaming site during the session.

4. Photography
Photography and recording are not allowed without permission of the secretariat.

5. Press Registration
Press card will be issued to the journalists only if they received permission from the president before the meeting.
Please check our website regarding the details of press registration (Japanese only). We would not accept press
registration on site.

6. Wi-FiFree Wi-Fi is available at Kyoto International Conference Center and The Prince Kyoto Takaragaike.
SSID: Icck_Public_WiFi *no password (Kyoto International Conference Center)
SSID: PRINCE-HOTEL *welcomeph (The Prince Kyoto Takaragaike)

7. Social Gathering
Venue: 1F Sakura, Swan, Lobby and Garden, Kyoto International Conference Center
Date: June 8 (Sat.) 19:25 − 21:10

8. Dermato Orchestra & Chorus
It will be held at the Room 1 (1F Main Hall) from 18:40 on Saturday, June 8.

16Instruction for Oral Presentation(1) Presentation time
1. The time schedule is very tight. Please keep the allotted time strictly.
Oral sessions: 5 minutes for presentation and 2 minutes for discussion.
Oral presentation in English: 5 minutes for presentation and 2 minutes for discussion.
Invited lecture: You are informed your presentation and discussion time in advance.
- Timer is set at the podium. Yellow light will turn on at one minute before the end of the session. Red light will turn on at
the end of the session.
- Please be seated at the Next Speaker’s Seat (in front of the podium) 15 minutes prior to your presentation time.

(2) Presentation Data
1. Only computer presentation is available. (Slide aspect is 16:9)
2. Data in USB flash memory drive or PC are accepted.
*We do not accept date from Mac Keynote. If you would like to use Mac Keynote, Please bring your own PC.
3. Operating systems available are Windows. There will be no Macintosh computers available at the venue. Please bringyour own PC if you wish to use Macintosh.
4. Application software available are Windows PowerPoint 2021
5. There are no limits of number of your slide page but please do not exceed your data capacity 300MB.
6. Liquid-crystal display monitor, keyboard, and mouse will be set on the podium. Please turn to the next page by yourself. If you have difficulties with PC operations, please inform the secretariat in advance.
7. All speakers must disclose any COI (Conflict of Interest) on your slide of the presentation.

(3) Data Acceptance
Please check your data at the PC Center at least 30 minutes prior your session.
Location:

Room H, 1st Floor, Kyoto International Conference Center
Lobby, 2nd basement Floor, The Prince Kyoto TakaragaikeOpen hours:

June 6 (Thu.)

8:00 − 17:50 (The Prince Kyoto Takaragaike: 8:00 − 14:10)

June 7 (Fri.)

8:00 − 17:00 (The Prince Kyoto Takaragaike: 8:00 − 11:30)

June 8 (Sat.)

7:30 − 17:20 (The Prince Kyoto Takaragaike: 8:00 − 17:20)

June 9 (Sun.)

7:30 − 14:00 (The Prince Kyoto Takaragaike: 8:00 − 14:30)

When bringing your data in notebook computers- Western Japan, including Kyoto, is on 100 V, 60 Hz. The plug type in Japan is type A with two flat blades without aground pin, the same type widely used in the US and Canada.
- Speakers’ notebook computers must be equipped with a D-Sub 15-pin output, standard monitor terminal. Some thin,light-weighted notebook computers, such as SONY VAIO Note and Apple PowerBook G4 may not have built-in ports.
- Speakers are requested to bring their own adapter for connection between PC and projector, and/or an electric transformer when these are necessary.
- All energy-conserving functions such as screen-savers, sleep/power saving modes should be disabled on laptops to be
used in the presentation.
- After you checked your presentation data at PC Center, please bring your PC to the operator at the left side of yourlecture room, 15 minutes prior to your presentation time.
- Image resolution is Full HD (1920 * 1080).

17

When bringing your data in USB memory- After saving the presentation data on the USB memory, please confirm that the data can be activated at other PCs.
- The data will be copied onto the server and USB memory will be returned to the speaker.
- Presentation files should be named as “Presentation number_name”.
i.e.) E1-01_JohnBrown, LS2-02_MarySmith (presentation file extensions may be.ppt or.pptx)- Use standard fonts on the OS. Use of specialized fonts may cause garbling and displacement.
[Recommended fonts]
Arial or Times New Roman- Animations and movies may be used, though it is highly recommended to be used with your own notebook computer.
When bringing them in USB memory, comply with the below:
a. We accept video files in MP4 format (wmv format is also acceptable if you are using a Windows machine).
b. Save the movie data in the same folder, so the link with the PowerPoint will be maintained.
c. It is recommended that you bring your own PC as backup to the movie data.
d. Please let the operator know if you are using sound data.
- The presentation data will be deleted by the secretariat responsibly.

18

Instruction for Poster presentation(1) Poster presentation
All accepted abstracts, including oral presentations, are requested to prepare a paper poster and a digital poster.

[Paper poster]
1. All posters must be prepared in English.
2. The poster venue is located at 1F New hall, Kyoto International ConferenceCenter.
3. Poster mounting and removal hours are as follows:
Mount posters:

June 6 (Thu.)

8:00 − 13:00

Remove posters:

June 9 (Sun.)

14:00 − 16:00*If you are unable to come during the poster mounting time, please consider applying for our paid poster printing and posting service, available until Sunday, June
2nd. (https://jda123.jp/info_author/gakupos_E.pdf)

4. Posters should be posted on the designated board space of 180 cm height and90 cm width.
5. Abstract Numbers, pins and equipment necessary for mounting posters will be
prepared by the secretariat at the venue.
6. Title, Author’s name, Affiliation should be prepared by yourself.
7. Poster discussion is open-ended.
Speakers should stand by in front of the poster at the poster discussion time.
The poster discussion times are as follows:
Poster Number- Odd numbers*:

June 6 (Thu.)

16:15 − 17:45

Poster Number- Even numbers*:

June 7 (Fri.)

18:10 − 19:10*The last digit of poster number. (e.g. EP1-1 → Odd number, EP1-2 → Even number)[Digital poster submission]
You are required to prepare your digital poster data in advance.
Deadline for Digital Poster: Wednesday, May 22, at noon (Japan Standard Time)* Registration will not be extended, so please register within the period. After the deadline and on-site, we could not
accept modifying. Please be careful when you prepare the data.
Access is expected to be concentrated near the deadline, so please register as soon as possible.
You could submit your digital poster by PDF or PowerPoint file (no narration).

[Preparing your digital poster data]
・All Poster Presenters must disclose COI (Conflict of Interest) on your poster.
・Please prepare your poster data including title, author’s name, affiliation.
・Please prepare your digital poster data as 1 page poster (PDF) or within 20 slides in PPT (including title and COI),
5MB or less.

19

*For Macintosh users;
If you make your presentation data by Keynote, please check your data (character skew etc.) after changing to MS
PowerPoint.
・Please use standard fonts on the OS.
・When you submit your digital poster, even if you use animation, movie, sound, these contents do not play.
・Please refrain from writing in note area of your slide.
・When registering data, please use the following environment.
-Windows users: Microsoft Edge, Firefox 34 or later, and the latest version of Chrome-Macintosh users: Safari 9 or later, Firefox 34 or later, and the latest version of Chrome* Registration is not possible with Internet Explorer.
・Registered digital posters can be viewed by “MICEnavi” (Web version, application version) during the meeting.
・Secretariat office will delete your digital poster data responsibly after the meeting.
[Question & Answer for Digital Poster]・Participants can view the digital posters in their app during the meeting, from June 6 (Thu.) 8:00 to June 9 (Sun.)
17:00.
・Questions from online participants will be accepted using the online question posting function of the “MICEnavi”.
・Please download the app and ask each speaker a question. (Questions are asked in a registered name.)
・Details on how to ask questions and answer are available in the PDF “How to Answer Questions” posted on the meeting website. (https://jda123.jp/english.html).

(2) Oral presentation
If you have been accepted for both Oral and Poster presentations, you also need to prepare oral presentation data.
Please refer to the page 17 of “Instruction for Oral Presentation”.

20

JDA 2024 Program
JDA2024 lectures are held in 14 locations at Kyoto International Conference Center, The Prince Kyoto Takaragaike andonline.
You are invited to attend as many as you desire to.
The follows are excerpted version of programs, in which lectures will be spoken in English.

Day1, Thursday, June 6 Room 3 2F Room A
Presidentʼs Special Program 3

14:10〜16:10

Meet legends in Global Dermatology……………………………………………Chairs：Masayuki Amagai（Keio University）
Kenji Kabashima（Kyoto University）
SP3-1．
14 : 10〜14 : 40

SP3-2．
14 : 40〜15 : 10

SP3-3．
15 : 10〜15 : 40

SP3-4．
15 : 40〜16 : 10

22

What’s New in Pigmentary Disorders
Seemal R. Desai1,2,3）
President, American Academy of Dermatology1），Founder ＆ Medical Director,
Innovative Dermatology2），Department of Dermatology, The University of Texas
Southwestern Medical Center, Dallas, Texas, USA3）
Lessons from my career in medical research：how to succeed without being smart
John R. Stanley
Department of Dermatology, University of Pennsylvania, Philadelphia, USA
Risk of cancer and opportunistic infections：JAK inhibitors versus biologics
Martin Röcken
Department of Dermatology, Eberhard Karls Universität Tübingen, Germany
How failure can lead to a career in scientific dermatology
Alexander Enk
Department of Dermatology, Heidelberg University Hospital, GermanyDay1, Thursday, June 6 Room 6 1F Room D
14:10〜16:10

Sponsored Symposium 1

Latest treatment for atopic dermatitis……………………Chairs：Norito Katoh（Kyoto Prefectural University of Medicine）
Riichiro Abe（Niigata University）
SSY1-2． New Opportunity for AD Treatment - Targeting IL-13 with Lebrikizumab
Thomas Bieber1,2）
Medicine Programs at the Kühne-Foundation, Medicine Campus Davos, Switzerland1），
Bieber Dermatology Consulting, Bonn, Germany2）
Cosponsor：Eli Lilly Japan K.K.

Day1, Thursday, June 6 Room 9 1F Room C-2
Oral Presentation in English 1

9:00〜10:00

Basic research, Allergic disease, Congenital disease……………………………………Chairs：Sayaka Shibata（The University of Tokyo）
Takashi Sakai（Oita University）
E1-1（EP1-6） Imiquimod-induced oxidative stress and cell death are through p53/Nrf2 axis.
○Shu-Hao Chang1），Chu-Hsuan Hsueh1），Jeng-Jer Shieh1,2,3）
Institute of Biomedical Sciences, National Chung Hsing University, Taichung1），
Department of Education and Research, Taichung Veterans General Hospital,
Taichung2），Rong Hsing Research Center for Translational Medicine, National Chung
Hsing University, Taichung3）
E1-2（EP1-4） Analysis of antigen specificity of tumor-infiltrating B lymphocytes in TLS+ melanoma○Kanta Hori1,3），Yoshihiko Hirohashi1），Tomoyuki Minowa2），Kenji Murata1），
Hisashi Uhara2），Toshihiko Torigoe1）
Department of Pathology, Sapporo Medical University School of Medichine, Sapporo1），
Department of Dermatology, Sapporo Medical University School of Medichine,
Sapporo2），Department of Urology, Sapporo Kosei Hospital, Sapporo3）
E1-3（EP1-5） Aryl Hydrocarbon Receptor in Dorsal Root Ganglion May Involve in Histamine-induced
Itching○Alafate Abudouwanli1），Ge Peng1），Wanchen Zhao1），Arisa Ikeda1,2），Quan Sun1），
Ko Okumura1），Shigaku Ikeda1），Hideoki Ogawa1），Francois Niyonsaba1,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Nephrology, Juntendo University Graduate School of
Medicine, Tokyo2），Faculty of International Liberal Arts, Juntendo University, Tokyo3）23

E1-4（EP10-3） Lesion-specific Loss of Langerhans Cells in Progressive Symmetric Erythrokeratodermia○Umi Tahara1,2），Kyoko Masuda1），Takashi Sasaki1,3），Kazuhiko Nakabayashi4），
Masayuki Amagai1），Akiharu Kubo1,5）
Department of Dermatology, Keio University School of Medicine, Tokyo1），Departmentof Dermatology, Kawasaki Municipal Hospital, Kawasaki2），Center for
Supercentenarian Medical Research, Keio University School of Medicine, Tokyo3），
Department of Maternal-Fetal Biology, National Center for Child Health andDevelopment, Tokyo4），Division of Dermatology, Department of Internal Related, Kobe
University Graduate School of Medicine, Kobe5）
E1-5（EP10-5） Real-World Experience of Dupilumab and JAK Inhibitors in Epidermolysis Bullosa Pruriginosa○Ping-Chen Hou1），Wilson Jr Aala2），Wei-Ting Tu1），John A. McGrath1,3），
Chao-Kai Hsu1,2,4）
Department of Dermatology, National Cheng Kung University Hospital, College ofMedicine, National Cheng Kung University, Tainan1），Institute of Clinical Medicine,College of Medicine, National Cheng Kung University, Tainan2），St Johns Institute of
Dermatology, School of Basic and Medical Biosciences, Kings College London,
London3），International Center for Wound Repair and Regeneration, National Cheng
Kung University, Tainan4）
E1-6（EP7-1） Three Phases of Pathology in Skin Eruptions of Chronic Urticaria using Mathematics○Sungrim Seirin-Lee1,2），Shunsuke Takahagi3），Michihiro Hide3,4）
ASHBi, Kyoto University Institute for Advanced Study, Kyoto University, Kyoto1），
Department of Mathematical Medicine, Graduate School of Medicine, Kyoto University,
Kyoto2），Department of Dermatology, Graduate School of Biomedical and Health
Sciences, Hiroshima University, Hiroshima3），Department of Dermatology, Hiroshima
City Hiroshima Citizens Hospital, Hiroshima4）
E1-7（EP7-2） Correlation of specific IgE with total IgE in atopic dermatitis patients○Norika Akashi，Mariko Ogawa-Momohara，Tomoki Taki，Ryo Fukaura，Satoshi Kamiya，Yuta Yamashita，Haruka Koizumi，Takuya Takeichi，
Yoshinao Muro，Masashi Akiyama
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya
E1-8（EP7-3） Real-world effectiveness of abrocitinib and transcriptome analysis in atopic dermatitis○Mayu Ohtaka，Akihiko Uchiyama，Keiji Kosaka，Mai Ishikawa，Yuuta Inoue，Sei-ichiro Motegi
Department of Dermatology, Gunma University, Maebashi

24Oral Presentation in English 2

10:00〜11:00

Tumor …………………………Chairs：Taku Fujimura（Tohoku University）
Hayakazu Sumida（The University of Tokyo）
E2-1（EP9-3） Activated Akt expression has the prognostic value for relapse in acral melanomas○Takeshi Namiki1），Kohei Nojima1），Masahiro Hayashi2），Atsushi Tanemura3），
Tamio Suzuki2），Masashi Ishikawa4），Naoya Yamazaki5），Ichiro Katayama3），
Yoshiyuki Sasaki6），Naoko Okiyama1）
Department of Dermatology, Tokyo Medical and Dental University, Tokyo1），
Department of Dermatology, Yamagata University, Yamagata2），Department of
Dermatology, Osaka University, Suita3），Department of Dermatology, Saitama Cancer
Center Hospital, Kitaadachi4），Department of Skin Oncology, National Cancer Center
Hospital, Tokyo5），Clinical Dental Research Promotion Unit, Faculty of Dentistry,
Tokyo Medical and Dental University, Tokyo6）
E2-2（EP9-6） Relationship Between Tumor Thickness and Histological Invasion Level in Acral Melanoma○Shigeru Koizumi1），Yukiko Kiniwa2），Tatsuya Takenouchi3），Jun Asai4），
Takuya Miyagawa5），Takamichi Ito6），Noriki Fujimoto7），Shigeto Matsushita8），
Yosuke Yamamoto9），Yasuhiro Nakamura1）
Department of Skin Oncology/Dermatology, Saitama Medical University International
Medical Center, Hidaka1），Department of Dermatology, Shinshu University School of
Medicine, Matsumoto2），Department of Dermatology, Niigata Cancer Center Hospital,
Niigata3），Department of Dermatology, Kyoto Prefectural University of Medicine,
Kyoto4），Department of Dermatology, The University of Tokyo, Graduate School of
Medicine, Tokyo5），Department of Dermatology, Graduate School of Medical Science,
Kyushu University, Fukuoka6），Department of Dermatology, Shiga University of
Medical Science, Otsu7），Department of Dermato-Oncology/Dermatology, NHO
Kagoshima Medical Center, Kagoshima8），Department of Dermatology, Department of
Dermatology, Chiba University Graduate School of Medicine, Chiba9）
E2-3（EP9-7） KS-EMPD-1：a novel cell line of primary extramammary Paget’s disease○Takamichi Ito，Yuka Tanaka，Toshio Ichiki，Yumiko Kaku-Ito，Takeshi Nakahara
Department of Dermatology, Kyushu University, Fukuoka
E2-4（EP9-10） Analysis of surgical margins and prognostic factors in 116 Japanese DFSP patients○Yusuke Muto1,2），Taku Fujimura2），Akira Takahashi3），Kenjiro Namikawa4），
Dai Ogata4），Eiji Nakano4），Shunichi Jinnai3），Akira Hashimoto2），Asano Yoshihide2），
Naoya Yamazaki4）
Department of Dermatology, South Miyagi Medical Center, Shibata1），Department of
Dermatology, Tohoku University Graduate School of Medicine, Sendai2），Dermatologic
Oncology, National Cancer Center Hospital East, Kashiwa3），Dermatologic Oncology,
National Cancer Center Hospital, Tokyo4）E2-5（EP9-15） 18F-FDG PET/CT Correlation with Tumor Stage in Acral Melanoma：A Retrospective Study○Wei-Ting Liu，Yi-Han Chang，Tak-Wah Wong
Department of Dermatology, National Cheng Kung University Hospital, College ofMedicine, National Cheng Kung University, Tainan25E2-6（EP9-13） Experimental and clinical evidence suggests S100A7 may be involved in melanoma
development○Quan Sun1），Ge Peng1），Wanchen Zhao1），Alafate Abudouwanli1），Arisa Ikeda1,2），
Ko Okumura1），Hideoki Ogawa1），Shigaku Ikeda1），Francois Niyonsaba1,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Nephrology, Juntendo University Graduate School of
Medicine, Tokyo2），Faculty of International Liberal Arts, Juntendo University, Tokyo3）
E2-7（EP9-16） GSDME promotes melanoma progression by regulating chromatin accessibility of PLK4
○Juan Du，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
E2-8（EP9-9） Sarcopenia is a prognostic factor in advanced BRAF wild-type malignant melanoma in Asians○Kohei Yamakawa1），Yusuke Kurita2），Hideyuki Ishikawa1），Shingo Kato2），
Yukie Yamaguchi1）
Department of Environmental Immuno-Dermatology, Yokohama City University
Graduate School of Medicine, Yokohama1），Department of Gastroenterology andHepatology, Yokohama City University School of Medicine, Yokohama2）

Oral Presentation in English 3

14:10〜15:10

Treatment, Autoimmune disease…………………………………………Chairs：Rei Watanabe（Juntendo University）
Takuya Takeichi（Nagoya University）
E3-1（EP3-9） Polydopamine nanoparticles mitigate UVB-induced skin damage via ferroptosis inhibition○Yuqi Zhou1），Jia Zhang1），Zhaoting Jiang1），Bo Wang1），Qi Wang1），
Zeqian Wang1），Mingfeng Zhang1），Ziwei Deng2），Chunying Li1），Zhe Jian1）
Department of Dermatology, Xijing Hospital Fourth Military Medical University,
Xiʼan1），Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of
Education, Shaanxi Key Laboratory for Advanced Energy Devices, Shaanxi
Engineering Lab for Advanced Energy Technology, School of Materials Science andEngineering, Shaanxi Normal University, Xiʼan2）
E3-2（EP8-2） Anti-eIF2B antibody Detection by ELISA in Japanese Patients with Systemic Sclerosis○Haruka Koizumi1），Yoshinao Muro1），Yuta Yamashita1），Satoshi Kamiya1），
Norika Akashi1），Mariko Ogawa-Momohara1），Takuya Takeichi1），
Yasuhiko Yamano2），Yasuhiro Kondoh2），Masashi Akiyama1）
Department of Dermatology, Nagoya University, Nagoya1），Department of Respiratory
Medicine and Allergy, Tosei General Hospital, Seto2）
E3-3（EP8-3） Inhibition of IgG Extravasation to Mucous Membranes with TKIs in a Murine Pemphigus
Model○Yukako（Duerna）Akamatsu（Tie）1），Takashi Nomura1,2），Kenji Kabashima1）
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto1），
Department of Drug Development for Intractable Diseases, Graduate School of
Medicine, Kyoto University, Kyoto2）26

E3-4（EP8-7） The role of IL-7/IL-7R mediates stem cell-like Hobit+CD8+ TRM in vitiligo recurrence○Yuqian Chang，Shuli Li，Chunying Li
Department of Dermatology, Xijing hospital, Fourth Military Medical University, Xiʼan
E3-5（EP3-6） Objective and Subjective Assessment of Effect of Exosomes against Androgenic Alopecia○Yishan Liu1），Cheuk-Kwan Sun2），Ju-Fang Wu3）
I-Shou University College of Medicine；E-Da Hospital Department of Dermatology,
Kaohsiung1），I-Shou University College of Medicine；E-Da Hospital Department ofEmergency Medicine, Ksohsiung2），Kaohsiung Municipal United Hospital Departmentof Pharmacy, Kaohsiung3）
E3-6（EP8-5） DNA methylation analysis Reveals Epigenetic Perturbations of Vitiligo Tregs○Jianru Chen，Xinju Wang，Wei Wu，Qingrong Ni，Kaiqiao He，Luling Huang，Weiwei Sun，Jinrong Fan，Shuli Li，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
E3-7（EP8-10） Oxidative Stress-Induced S100B：Enhancer of Immune Responses in Vitiligo○Shuli Li，Wei Wu，Xinju Wang，Jianru Chen，Jinrong Fan，Luling Huang，Weiwei Sun，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
E3-8（EP8-11） Dimethyl itaconate halts vitiligo depigmentation by suppressing DC-CD8+ T cell responses○Yinghan Wang，Yuhan Chen，Jingjing Ma，Shuli Li，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University（AirForce Military Medical University）, XiʼanOral Presentation in English 4

15:10〜16:10

Diagnosis, Inflammatory disease, Infectious disease………………………………………Chairs：Takehiro Takahashi（Tohoku University）
Seitaro Nakagawa（Osaka University）
E4-1（EP6-2） Inflammatory myopathy following COVID-19 mRNA vaccination in a patient with VEXAS
syndrome○Masakazu Kakurai1），Rie Honda1），Akihiro Kuroda2），Naomi Tsuchida3,4,5），
Ayaka Maeda5），Yuri Uchiyama3,4），Naomichi Matsumoto3），Shusaku Ito1）
Division of Dermatology, Hitachi General Hospital, Hitachi1），Division of Hematology,
Hitachi General Hospital, Hitachi2），Department of Human Genetics, Yokohama City
University Graduate School of Medicine, Yokohama3），Department of Rare Disease
Genomics, Yokohama City University Hospital, Yokohama4），Department of Stem Celland Immune Regulation, Yokohama City University Graduate School of Medicine,
Yokohama5）27E4-2（EP6-5） Burdock-derived Arctiin may alleviate psoriatic symptoms via PI3K-Akt signaling pathway○Mengyao Yang1,2,3），Tao Wang4），Xuefei Du2,3），Wanchen Zhao1），
Alafate Abudouwanli1），Quan Sun1），Arisa Ikeda1,5），Ge Peng1），
Francois Niyonsaba1,6），Long Geng2,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Dermatology, The First Hospital of China Medical University,
Shenyang2），NHC Key Laboratory of Immunodermatology, Ministry of Education Key
Laboratory of Immunodermatology, National Joint Engineering Research Center for
Diagnosis and Treatment of Immunologic Skin Diseases, The First Hospital of China
Medical University, Shenyang3），Department of Urology, The Peopleʼs Hospital of
Liaoning Province, Shenyang4），Department of Nephrology, Juntendo University
Graduate School of Medicine, Tokyo5），Faculty of International Liberal Arts, Juntendo
University, Tokyo6）
E4-3（EP6-6） AMP-IBP5 Attenuates Psoriatic Symptoms via LRP1 Signaling○Ge Peng1），Saori Yoshiba1），Lixia Cui2），Wanchen Zhao1），Alafate Abudouwanli1），
Quan Sun1），Ko Okumura1），Hideoki Ogawa1），Shigaku Ikeda1），Francois Niyonsaba1,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Dermatology, the Second Affiliated Hospital of Hainan Medical
University, Hainan2），Faculty of International Liberal Arts, Juntendo University,
Tokyo3）E4-4（EP11-2） Influence of Risk Factors and Therapies on Prognosis of Herpes Zoster○Marika Matsuya1），Motoshi Sugawara2），Takeshi Iwasaki3），Motoshi Kinouchi1）
Department of Dermatology, Asahikawa Red Cross Hospital, Asahikawa1），
Department of Dermatology, Asahikawa Medical University, Asahikawa2），Nishino
Dermatology Clinic, Sapporo3）
E4-5（EP2-5） Monocyte-to-Lymphocyte Ratio and Eosinophils-to-Lymphocyte Ratio for Scabies diagnosis○Ha Thi Thao Mai1），Nguyen Hoang Viet2），Espinoza Luis3）
Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho1），Hanoi
Medical University, Hanoi2），Faculty of Health Sciences, Kanazawa University,
Kanazawa3）
E4-6（EP6-4） Schnitzler syndrome with an immunoglobulin A gammopathy exacerbated by COVID-19
infection○Yasuaki Ikuno，Toshifumi Takahashi，Takuya Nagata，Shuji Sugiura，Akihiko Yamaguchi，Noriki Fujimoto
Department of Dermatology, Shiga University of Medical Science, Otsu
E4-7（EP11-1） Disseminated Mucocutaneous Leishmaniasis Coinfected by Two Distinct Species○Yuki Kobayashi1），Takeshi Ouchi1），Takashi Okada2），Kenta Kobayashi1），
Haruka Omasa1），Takayuki Fusumae1），Sayuka Arakawa1），Chizu Sanjoba3），
Yasuyuki Goto3），Takeru Funakoshi1）
Department of Dermatology, Keio University School of Medicine, Tokyo1），Department
of Otorhinolaryngology, Keio University School of Medicine, Tokyo2），Laboratory of
Molecular Immunology, Department of Animal Resource Sciences, Graduate School of
Agricultural and Life Sciences, The University of Tokyo, Tokyo3）28

E4-8（EP2-2） Clinical and Immunological profiles of BP180 NC16A CLEIA false negative case ofPemphigoid○Masahiro Tsutsumi1），Hiroshi Koga1），Kwesi Teye2），Norito Ishii1），
Takekuni Nakama1）
Department of Dermatology, Kurume University School of Medicine, Kurume1），
Kurume University Institute of Cutaneous Cell Biology, Kurume2）

Day1, Thursday, June 6 Room 11 1F Room157
10:00〜11:00

Presidentʼs Special Program 1

Cutting-edge dermatology research: Part 1……………………Chairs：Chikako Nishigori（Hyogo Japanese Red Cross Society）
Saeko Nakajima（Kyoto University）
SP1-1．
10 : 00〜10 : 30

SP1-2．
10 : 30〜11 : 00

Diagnosis and Targeted Treatment of Inﬂammatory Skin Diseases Guided by Immune
Expression Modules
Michel Gilliet
Department of Dermatology, Lausanne University Hospital CHUV, Switzerland
Keratinocyte cancers：Rational management based on pathogenesis
Kiarash Khosrotehrani
The University of Queensland Frazer Institute, Australia

Day2, Friday, June 7

Room 1 1F Main Hall
12:10〜13:10

Luncheon Seminar 9

Evolution of atopic dermatitis treatment…………………Chair：Tetsuya Honda（Hamamatsu University School of Medicine）
LS9-2．

JAK inhibitors：One class, unique medicines
Melinda Gooderham
SKiN Centre for Dermatology, Queenʼs University, Canada
Cosponsor：AbbVie GK29

13:50〜14:25

Dohi Memorial Award Lecture

Chair：Masayuki Amagai（Keio University）
DML．

A Commotion in the Skin: Developing Melanoma Immunotherapies
Martin Röcken
Department of Dermatology, Eberhard Karls Universität Tübingen, Germany

Day2, Friday, June 7

Room 2 1F Sakura
11:20〜12:00

Special Lecture 4

Chair：Taisuke Ito（Hamamatsu University School of Medicine）
SL4．

Scary and smelly matters in scarring alopecia：How fragrances may damage hair follicle
stem cells in frontal fibrosing alopecia
Ralf Paus
Dermatology, University of Miami Miller School of Medicine, Miami, FL, USA

Day2, Friday, June 7
Luncheon Seminar 14

Room 6 1F Room D
11:40〜13:10

Communication between physicians and patients in hyperhidrosis
treatment ……………………………Chair：Hiroyuki Murota（Nagasaki University）
LS14-3．

Disease Burden of Patients with Focal Hyperhidrosis in the United States and the IHHS’s
Efforts
Dee Anna Glaser
Glaser Dermatology ＆ Aesthetics
Cosponsor：Maruho Co., Ltd.

30

Day2, Friday, June 7

Room 10 1F Annex Hall 2
9:10〜11:10

Sponsored Symposium 2

Say NO to ”itching”! Beyond improving the disease burden in atopic
dermatitis treatment! ………Chairs：Takeshi Nakahara（Kyushu University）
Mayumi Komine（Jichi Medical University）
SSY2-3． Mechanism of action and place of JAKi in the management of AD
Stephan Weidinger
Chair and Director, Department of Dermatology and Allergy, University Hospital
Schleswig-Holstein, Kiel, Germany
SSY2-4． Understanding the burden of disease in your patients with atopic dermatitis
Rodney Sinclair
Professorial Fellow, University of Melbourne Department of Medicine（St.Vincentʼs
Hospital）,Director, Sinclair Dermatology
Cosponsor：Pfizer Japan Inc.

12:10〜13:10

Presidentʼs Special Program 5

Messages to young dermatologists：How to develop your clinicalskills? …………………………………Chairs：Manabu Ohyama（Kyorin University）
Naotomo Kambe（Kyoto University）
SP5-1．
12 : 10〜12 : 40

SP5-2．
12 : 40〜13 : 10

Messages to Young Dermatologists：How to Develop Your Clinical Skills
William D. James
Professor Emeritus, University of Pennsylvania, PA, USA
Messages to young dermatologists：How to develop your clinical skills
Jean L. Bolognia
Yale University School of Medicine, New Haven, CT, USA

Special Lecture 6

17:10〜18:10

Thinking about the future of vaccine development and barrier
research ………………………………Chair：Shinichi Imafuku（Fukuoka University）
SL6-1．

Interactions between host and pathogens at the barriers
Cevayir Coban
Division of Malaria Immunology, Department of Microbiology and Immunology, IMSUT,
the University of Tokyo

31

Day2, Friday, June 7
Educational Lecture 24

Room 11 1F Room157
9:10〜11:10

Presidentʼs Special Program: How to develop your career andleadership skills? ……Organizers：Yayoi Tada（Teikyo University）
Yukie Yamaguchi（Yokohama City University）［Level：Advanced／Update］
EL24-1． How to develop your career and leadership skills
9 : 20〜9 : 35
Jean L. Bolognia
Yale University School of Medicine, New Haven, CT, USA
EL24-2． How to develop your career and leadership skills
9 : 35〜9 : 50
John A. McGrath
St Johnʼs Institute of Dermatology, Kingʼs College London, London U.K.
EL24-3． Career and Leadership Development―Lessons for Japanese Dermatologists
9 : 50〜10 : 05
Pawinee Rerknimitr
Department of Medicine, Chulalongkorn University, Bangkok, Thailand
EL24-4． Fostering Gender Equity in Academic Dermatology
10 : 05〜10 : 20
Dedee F Murrell
The George Institute for Global Health, University of NSW, Sydney, Australia
EL24-5． Career and Leadership Development. Lessons for Japanese Dermatologists
10 : 20〜10 : 35
Akemi Yamamoto
Asahikawa Medical University

Day2, Friday, June 7
Educational Lecture 26

Room 13 B2F Gold Room
9:10〜11:10

Expanding world of autoinflammatory diseases……………………………Organizers：Naotomo Kambe（Kyoto University）
Nobuo Kanazawa（Hyogo Medical University）［Level：Update］
EL26-1． Update in Autoinflammatory Disease
9 : 20〜9 : 50
Lori Broderick1,2）
Division of Allergy, Immunology ＆ Rheumatology, University of California,
San Diego1），Rady Childrenʼs Hospital, San Diego, USA2）

32

Day3, Saturday, June 8 Room 1 1F Main Hall
Sponsored Symposium 3

9:10〜11:10

JDA-Novartis Partnership Education Program 2024―Learn from
Global Top Experts for Immuno-dermatology―………………………………………Chairs：Hiroyuki Murota（Nagasaki University）
Manabu Fujimoto（Osaka University）
SSY3-1． Epithelial barrier theory and allergic skin diseases
Cezmi A. Akdis
The Swiss Institute of Allergy and Asthma Research（SIAF）
Zurich University Medical Faculty, Switzerland
SSY3-2． Specific B cell responses in Allergen-specific Immunotherapy
Mübeccel Akdis
The Swiss Institute of Allergy and Asthma Research（SIAF）, Switzerland
SSY3-3． Psoriatic inflammation
Alexander Enk
Department of Dermatology, University of Heidelberg, Germany
SSY3-4． Fine-tuning skin immunity：from infantile rashes to the microbes inside us
Samuel T. Hwang
Dermatology, University of California Davis School of Medicine, USA
Cosponsor：Novartis Pharma K.K.

Presidentʼs Special Program 9

12:35〜13:20

What is ILDS?…………………………Chair：Manabu Fujimoto（Osaka University）
SP9-1．
12 : 35〜12 : 47

SP9-2．
12 : 47〜12 : 59

SP9-3．
12 : 59〜13 : 11

What is ILDS
Lars E. French1,2）
Department of Dermatology and Allergy, University Hospital, Ludwig Maximilan
University（LMU）Munich, Munich, Germany1），Dr. Philip Frost Department of
Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine,
Miami, FL, USA2）
25th World Congress of Dermatology July 2023 Brief report
Roy ChanSkin Research Institute, Republic of Singapore
Looking forward to the 26th World Congress of Dermatology Guadalajara
Jorge Ocampo Candiani1,2）Presidente Congreso Mundial de Dermatologia Guadalajara 20271），ExPresidente del
CILAD（Colegio Iberolatinoamericano）2）

33

Day3, Saturday, June 8 Room 2 1F Sakura
13:30〜15:30

Sponsored Symposium 5

Maruho symposium―Decoding Itch Pathogenesis and IL-31
Involvement―…………Chairs：Takahiro Satoh（National Defense Medical College）
Takaharu Okada（RIKEN Center for Integrative Medical Sciences）
SSY5-1． Cellular origins of IL-31 in atopic dermatitis and prurigo nodularis
Takashi Hashimoto
Department of Dermatology, National Defense Medical College
SSY5-2． Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch
Takaharu Okada
Laboratory for Tissue Dynamics, RIKEN Center for Integrative Medical Sciences.
SSY5-3． Recent insights into the immunopathogenesis of atopic dermatitis and prurigo nodularis
Bernhard Homey
Department of Dermatology, University Hospital Düsseldorf, Medical Faculty, HeinrichHeine-University Düsseldorf, Germany
SSY5-4． Itch in the Elderly Patient - Origin, Diagnostics, Management
Martin Steinhoff
Department of Dermatology and Venereology, Hamad Medical Corporation, Doha,
Qatar
Cosponsor：Maruho Co., Ltd. Medical Affairs Dept.

Day3, Saturday, June 8 Room 3 2F Room A
Presidentʼs Special Program 11

12:30〜13:20

Cutting-edge dermatology research: Part 2………………………………………Chairs：Yasuyuki Amoh（Kitasato University）
Ken Igawa（Dokkyo Medical University）
SP11-1． Atopic dermatitis from bedside to bench ＆ beyond：focusing on itch ＆ environmental
12 : 30〜12 : 55
exposures
Chih-Hung Lee
Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung,TaiwanSP11-2． Uncovering the Biology of Regulatory T cells in Skin
12 : 55〜13 : 20
Michael Rosenblum
UCSF Deptartment of Dermatology, USA34

15:40〜16:20

Special Lecture 8

Cutting Edge in Dermatology：Genetic Skin Disorders and Adverse
Drug Reactions……………Chairs：Katsuto Tamai（Osaka University, Stem Cell Therapy Science）
Riichiro Abe（Niigata University）
SL8-1．

SL8-2．

Molecular characterization of genodermatoses：rare and new phenotypes and prospects for
improved therapies
John A. McGrath
St Johnʼs Institute of Dermatology, Kingʼs College London, London U.K.
Severe Cutaneous Adverse Drug Reactions：Update 2024
Lars E. French1,2）
Department of Dermatology and Allergy, University Hospital, Ludwig Maximilan
University（LMU）Munich, Munich, Germany1），Dr. Philip Frost Department of
Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine,
Miami, FL, USA2）

Day3, Saturday, June 8 Room 4 2F Room B-1
Presidentʼs Special Program 6

9:10〜11:10

How to publish your work?
…………Organizers：Shigetoshi Sano（Kochi University）
Takafumi Kadono（St. Marianna University School of Medicine）
SP6-1．
9 : 10〜9 : 40

SP6-2．
9 : 40〜10 : 10

How to publish your work from UK
John A. McGrath
St Johnʼs Institute of Dermatology, Kingʼs College London, London U.K.
How to publish your work from China
Qianjin Lu
Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union
Medical College, China

35

Day3, Saturday, June 8 Room 6 1F Room D
17:20〜18:20

Evening Seminar 18

Chair：Michihiro Hide（Hiroshima Citizens Hospital）
ES18．

Bridge perception gaps between dermatologists and patients in prurigo nodularis andchronic spontaneous urticaria
Martin Metz
Charité-Universitätsmedizin Berlin, Germany
Cosponsor：Sanofi K.K.

Day3, Saturday, June 8 Room 9 1F Room C-2
Presidentʼs Special Program 14

13:30〜15:30

The science of beauty Chairs：Teruki Dainichi（Kagawa University）
Yuki Yamamoto（Wakayama Medical University）
SP14-1． Skin Deep：The Science of Aesthetic Dermatology
Rachel Watson1,2）
A*STAR Skin Research Labs1），Skin Research Institute of Singapore, Republic ofSingapore2）
SP14-2． ABO blood type sugars in brick and mortar
14 : 00〜14 : 30
Jin Ho Chung
Department of Dermatology, Seoul National University College of Medicine, Seoul
National University, Seoul, Korea
13 : 30〜14 : 00

36

Day3, Saturday, June 8 Room 10 1F Annex Hall 2
9:10〜11:10

Sponsored Symposium 4

Thinking about the pathology and treatment of atopic dermatitis fromthe perspective of Type 2 inflammation〜Trinity theory and latest
findings〜 ………………………………Chair：Kenji Kabashima（Kyoto University）
SSY4-2． Role of Type 2 inflammation in AD - What have targeted therapies taught us?
Lisa A. Beck
University of Rochester Medical Center School of Medicine and Dentistry, USA
Cosponsor：Sanofi K.K. ／Regeneron Japan K.K.

Day3, Saturday, June 8 Room 11 1F Room157
Presidentʼs Special Program 7

9:10〜11:10

Learn about dermatology worldwide: Part 1…………………………………………Chairs：Hayato Takahashi（Keio University）
Satoshi Nakamizo（Kyoto University）
SP7-1．
9 : 10〜9 : 40

SP7-2．
9 : 40〜10 : 10

SP7-3．
10 : 10〜10 : 40

SP7-4．
10 : 40〜11 : 10

Recent Advancements and New Perspectives in Understanding the Pathogenesis of Vitiligo
Sang Ho Oh
Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute,
Yonsei University College of Medicine, Seoul, Korea
Landscape of Psoriasis Management in Thailand
Pravit Asawanonda
Chulalongkorn University, Bangkok, Thailand
What’s New in the Pipeline for Pemphigus?
Dedee F Murrell
Department of Dermatology, St George Hospital, University of NSW, Sydney, Australia
Communication between internal stem cell niche and the external environment：insight fromhair follicles
Sung-Jan Lin1,2）
Departments of Biomedical Engineering and Dermatology and Research Center for
Developmental Biology and Regenerative Medicine, National Taiwan University1），
Center for Frontier Medicine and Department of Dermatology, National Taiwan
University Hospital, Chinese Taipei2）37

13:30〜15:30

Presidentʼs Special Program 15

Learn about dermatology worldwide: Part 2…………………………Chairs：Jun Yamagami（Tokyo Womenʼs Medical University）
Akihiko Kitoh（Kyoto University）
SP15-1． Overcoming Immune Checkpoint Inhibitor Resistance to Improve Melanoma Therapy
Nikolas Haass
Frazer Institute；Faculty of Medicine；The University of Queensland；Brisbane,
Queensland, Australia
SP15-2． Innovations in Scar management outline
13 : 54〜14 : 18
Hong Liang Tey
National Skin Centre, Republic of Singapore
SP15-3． Hair and nail relationship
14 : 18〜14 : 42
Dongyoun Lee
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University,
Seoul, South Korea
SP15-4． Cutting-edge insights into the use of photodynamic therapy in dermatology
14 : 42〜15 : 06
Leihong Flora Xiang
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
SP15-5． Atopic Dermatitis in Taiwan：A translational approach
15 : 06〜15 : 30
Chia-Yu Chu
Department of Dermatology, National Taiwan University Hospital and National Taiwan
University College of Medicine, Chinese Taipei
13 : 30〜13 : 54

Day3, Saturday, June 8 Room 13 B2F Gold RoomSponsored Symposium 7

13:30〜15:30

Pathophysiology and latest treatments for chronic skin diseases……………………………………………Chairs：Kenji Kabashima（Kyoto University）
Akiharu Kubo（Kobe University）
SSY7-4． The pathology and treatment mechanism of psoriasis
Johann E. Gudjonsson1,2,3,4）
Department of Dermatology, University of Michigan1），Department of Internal
Medicine, Division of Rheumatology, University of Michigan2），Mary H. Weiser Food
Allergy Center, University of Michigan3），Taubman Medical Research Institute, USA4）
Cosponsor：Torii Pharmaceutical Co., Ltd.

38

Day4, Sunday, June 9

Room 2 1F Sakura
11:20〜12:00

Special Lecture 9

Chair：Shigaku Ikeda（Juntendo University）
SL9．

The Golden Age of Dermatologic Drugs Finally Has Begun
Ervin Epstein, Jr.
San Francisco, California, USA

Day4, Sunday, June 9
Luncheon Seminar 31

Room 3 2F Room A
12:50〜13:50

New horizon for alopecia areata treatments based on updated
pathology and diagnostics ………Chair：Manabu Ohyama（Kyorin University）
LS31-1．

LS31-2．

How to identify mimickers of alopecia areata by trichoscopy
Lidia Rudnicka
The Department of Dermatology at the Medical University of Warsaw, Poland
A modern management strategy for alopecia areata
Rodney Sinclair
The Department of Medicine, at the University of Melbourne, Sinclair Dermatology,
Australia
Cosponsor：Pfizer Japan Inc.

39

Day4, Sunday, June 9

Room 4 2F Room B-1
9:10〜11:10

Sponsored Symposium 8

Drug selection for atopic dermatitis with an eye toward long-term
remission in Japan and overseas Chairs：Hideyuki Ujiie（Hokkaido University）
Kenji Kabashima（Kyoto University）
SSY8-3． Which AD patients to treat with AdtralzaⓇ?
Jacob Pontoppidan Thyssen
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,Denmark
LEO Pharma A/S, Ballerup, Denmark
Cosponsor：LEO Pharma

Day4, Sunday, June 9
Educational Lecture 46

Room 11 1F Room157
9:10〜11:10

UJA X ENGAGE-TF: Study abroad recommendations 2024@Annual
Meeting of the Japanese Dermatological Association………………………………………Organizers：Saeko Nakajima（Kyoto University）
Takeya Adachi（Keio University）［Level：Basic］
EL46-4． Exploring the migration of immune cells in the skin：contributions of Japanese dermatologists
9 : 43〜10 : 03
to chemokine biology
Samuel T. Hwang
Dermatology at the University of California Davis School of Medicine, USA40

Day4, Sunday, June 9Sponsored Symposium 9

Room 12 B2F Prince Hall
9:10〜11:10

New solution for leaving psoriasis behind…………………………………………Chairs：Yayoi Tada（Teikyo University）
Ryuhei Okuyama（Shinshu University）
SSY9-4． Global Perspectives on Psoriasis Therapy
Diamant Thaci
Comprehensive Center for Inflammation Medicine, University of Luebeck, Germany
Cosponsor：UCB Japan Co. Ltd.

41

Poster Viewing

Date and Time：
June 6（Thu.）13：00〜18：30（Discussion Time 16：15〜17：45（Order Number - Odd numbers））
June 7（Fri.）8：30〜19：10（Discussion Time 18：10〜19：10（Order Number - Even numbers））
June 8（Sat.）8：00〜19：00
June 9（Sun.）8：00〜14：00
Poster Venue（1F New Hall, Kyoto International Conference Center）
Participants can view these digital posters in their app during the meeting,from June 6th（Thursday）8：00 to June 9th（Sunday）17：00.

Basic research ………………………………………………………………………………
EP1-1

EP1-2

EP1-3

EP1-4
（E1-2）

EP1-5（E1-3）

42

On-line Monitoring of Minerals in Human Sweat○Yanbei Zhu1），Kenshin Takemura2），Yuichi Watanabe2），Wataru Iwasaki2），
Kazuya Kikunaga2），Takashi Fukuda2），Kazumi Inagaki1）
National Institute of Advanced Industrial Science and Technology, Research Institutefor Material and Chemical Measurement, Tokyo1），National Institute of Advanced
Industrial Science and Technology, Sensing System Research Center, Tsukuba2）
Inverse relationship between MZB1+B cells and disease severity of alopecia areata○Takayoshi Komatsu-Fujii，Toshiaki Kogame，Keigo Takase，Akitaka Hata，
Kenji Kabashima
Department of Dermatology, Kyoto University, Kyoto
Cholesterol sulfate is increased in the stratum corneum of AD and psoriasis○Shown Tokoro1），Tadayuki Ogawa2），Ken Igawa1）
Department of Dermatology, Dokkyo Medical University, Shimotsuga1），
Comprehensive Research Facilities for Advanced Medical Science, Dokkyo Medical
University, Shimotsuga2）
Analysis of antigen specificity of tumor-infiltrating B lymphocytes in TLS+ melanoma○Kanta Hori1,3），Yoshihiko Hirohashi1），Tomoyuki Minowa2），Kenji Murata1），
Hisashi Uhara2），Toshihiko Torigoe1）
Department of Pathology, Sapporo Medical University School of Medichine, Sapporo1），
Department of Dermatology, Sapporo Medical University School of Medichine,
Sapporo2），Department of Urology, Sapporo Kosei Hospital, Sapporo3）
Aryl Hydrocarbon Receptor in Dorsal Root Ganglion May Involve in Histamine-induced
Itching○Alafate Abudouwanli1），Ge Peng1），Wanchen Zhao1），Arisa Ikeda1,2），Quan Sun1），
Ko Okumura1），Shigaku Ikeda1），Hideoki Ogawa1），Francois Niyonsaba1,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Nephrology, Juntendo University Graduate School of
Medicine, Tokyo2），Faculty of International Liberal Arts, Juntendo University, Tokyo3）

EP1-6（E1-1）

EP1-7
EP1-8

Imiquimod-induced oxidative stress and cell death are through p53/Nrf2 axis.
○Shu-Hao Chang1），Chu-Hsuan Hsueh1），Jeng-Jer Shieh1,2,3）
Institute of Biomedical Sciences, National Chung Hsing University, Taichung1），
Department of Education and Research, Taichung Veterans General Hospital,
Taichung2），Rong Hsing Research Center for Translational Medicine, National Chung
Hsing University, Taichung3）
Withdrawn
M1 Macrophage may regulate innate immune system in wound healing through interleukin-1β○Wei-Cheng Fang1），Hsuan Cheng2），Shu-Mei Huang2,3），Cheng-Che E Lan2,3）
Department of Dermatology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung1），
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung2），
Department of Dermatology, Collage of Medicine, Kaohsiung Medical University,
Kaohsiung3）

Diagnosis ……………………………………………………………………………………
EP2-1

EP2-2
（E4-8）

EP2-3

EP2-4

EP2-5
（E4-5）

Tentative new terminology：Initial comedonal phase of acne vulgaris○Ichiro Kurokawa1），Yuko Nomura2），Toshitatsu Nogita3）
Department of Dermatology, Meiwa Hospital, Tokyo1），Nomura Dermatology Clinic,
Yokohama2），Shinjuku Minamiguchi Dermatology Clinic, Tokyo3）
Clinical and Immunological profiles of BP180 NC16A CLEIA false negative case ofPemphigoid○Masahiro Tsutsumi1），Hiroshi Koga1），Kwesi Teye2），Norito Ishii1），
Takekuni Nakama1）
Department of Dermatology, Kurume University School of Medicine, Kurume1），
Kurume University Institute of Cutaneous Cell Biology, Kurume2）
Clinical significance of papular acne scar
○Toshitatsu Nogita1），Ichiro Kurokawa2），Yuko Nomura3）
Shinjuku Minamiguchi Dermatology Clinic, Tokyo1），Department of Dermatology
Meiwa Hospital, Tokyo2），Nomura Dermatology Clinic, Yokohama3）
An elder case of Subcutaneous panniculitis-like T-cell lymphoma○Natsumi Hara，Hikaru Kawahara，Natsuko Sasaki，Yu Sawada
Department of Dermatology, University of Occupational and Environmental Health,
Kitakyushu
Monocyte-to-Lymphocyte Ratio and Eosinophils-to-Lymphocyte Ratio for Scabies diagnosis○Ha Thi Thao Mai1），Nguyen Hoang Viet2），Espinoza Luis3）
Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho1），Hanoi
Medical University, Hanoi2），Faculty of Health Sciences, Kanazawa University,
Kanazawa3）

43

Treatment ……………………………………………………………………………………
EP3-1

EP3-2

EP3-3

EP3-4

EP3-5

44

Measurement of Clinical Outcomes of Netherton Syndrome After Treatment with Upadacitinib○Ryo Fukaura1），Chiaki Murase1），Naoto Yamada2），Natsuno Izuchi1），
Hidesada Adachi2），Tomoki Taki1），Shinya Hara3），Takuya Takeichi1），
Masashi Akiyama1）
Department of Dermatology, Nagoya University, Nagoya1），Toyota Memorial Hospital
Department of Dermatology, Toyota2），Toyota Memorial Hospital Department ofPaediatrics, Toyota3）
Noble Melanoma Targeted ChemoThermoImmunoTherapy by Melanogenic NPrCAP
Nanoparticle○Kowichi Jimbow1），Shosuke Ito2），Kazumasa Wakamatsu2），Akira Ito3），
Hiroyuki Honda4），Tokimasa Hida5），Yasuaki Tamura6），Toshihiko Torigoe6）
Institute of Dermatology ＆ Cutaneous Sciences, Sapporo1），Institute for Melanin
Chemistry, Fujita Health University, Toyoake2），Department of Chemical Systems
Engineering, School of Engineering, Nagoya University, Nagoya3），Department of
Biomolecular Engineering, School of Engineering, Nagoya University, Nagoya4），
Department of Dermatology, Sapporo Medical University School of Medicine,
Sapporo5），Department of Pathology, Sapporo Medical University School of Medicine,
Sapporo6）
Generalized Pustular Psoriasis Complicated by Bullous Pemphigoid Responded to Spesolimab○Risa Nakane，Ayaka Obata，Taiyo Hitaka，Natsuko Sasaki，Yu Sawada
Department of Dermatology, University of Occupational and Environmental Health,
Kitakyushu
The Efficacy of Early Pulsed Dye Laser Treatment for Superficial Type Infantile Hemangioma○Eiki Sugimoto，Maiko Fukayama，Jun Omatsu，Hinako Saito，Yurika Osuji，Yusuke Watanabe，Hikari Boki，Tomomi Miyake，Ayumi Yoshizaki，Shinichi Sato
Department of Dermatology, The University of Tokyo Hospital, Tokyo
Brodalumab Rapidly Modulates Psoriasis Pathology○Akimichi Morita1），James G Krueger2），Chiharu Tateishi3），Eisaku Ogawa4），
Koji Masuda5），Yukie Yamaguchi6），Sandra Garcet2），Hong Hur2），
Mona Uchida-Yamada7），Yasumasa Kanai7）
Department of Geriatric and Environmental Dermatology, Nagoya City University
Graduate School of Medical Science, Nagoya1），Laboratory for Investigative
Dermatology, The Rockefeller University, New York2），Department of Dermatology,
Osaka Metropolitan University Graduate School of Medicine, Suita3），Department of
Dermatology, Shinshu University School of Medicine, Matsumoto4），Department of
Dermatology, Kyoto Prefectural University of Medicine, Graduate School of Medical
Science, Kyoto5），Department of Environmental Immuno-Dermatology, Yokohama City
University Graduate School of Medicine, Yokohama6），Medical Affairs, Kyowa Kirin
Co., Ltd., Tokyo7）

EP3-6（E3-5）

EP3-7

EP3-8

EP3-9
（E3-1）

Objective and Subjective Assessment of Effect of Exosomes against Androgenic Alopecia○Yishan Liu1），Cheuk-Kwan Sun2），Ju-Fang Wu3）
I-Shou University College of Medicine；E-Da Hospital Department of Dermatology,
Kaohsiung1），I-Shou University College of Medicine；E-Da Hospital Department ofEmergency Medicine, Ksohsiung2），Kaohsiung Municipal United Hospital Departmentof Pharmacy, Kaohsiung3）
Sebetralstat KONFIDENT Is the First Phase 3 On-demand HAE Trial to Include Japanese Sites○Daisuke Honda1），Michihiro Hide2），Isao Ohsawa3），Yuko Watanabe4），
James Hao5），Michael D. Smith5），Christopher M. Yea5），Paul K. Audhya5），
Marc A. Riedl6），Danny M. Cohn7）
Department of Nephrology, Chiba University Graduate School of Medicine, Chiba1），
Hiroshima City Hiroshima Citizens Hospital, Hiroshima2），Saiyu Soka Hospital, Soka3），
Yokohama City University Graduate School of Medicine, Yokohama4），KalVista
Pharmaceuticals, Salisbury5），University of California - San Diego, San Diego6），
Amsterdam UMC, University of Amsterdam, Amsterdam7）
Safety and Efficacy of 308 nm Excimer Light in Children with Vitiligo○Wei Wu，Li Luo，Bona Zhang，Xiaoli Liu，Wenjing Tang，Yuehua Li，
Shengchun Wang，Shuli Li，Chunying Li，Qiong Shi
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
Polydopamine nanoparticles mitigate UVB-induced skin damage via ferroptosis inhibition○Yuqi Zhou1），Jia Zhang1），Zhaoting Jiang1），Bo Wang1），Qi Wang1），
Zeqian Wang1），Mingfeng Zhang1），Ziwei Deng2），Chunying Li1），Zhe Jian1）
Department of Dermatology, Xijing Hospital Fourth Military Medical University,
Xiʼan1），Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of
Education, Shaanxi Key Laboratory for Advanced Energy Devices, Shaanxi
Engineering Lab for Advanced Energy Technology, School of Materials Science andEngineering, Shaanxi Normal University, Xiʼan2）

Dermatopathology …………………………………………………………………………
EP4-1

EP4-2

Lymph Vascular Obstruction Could Result in Edema, Erythema and Fibrosis of Face
○Shuhei Imayama1），Seiya Momosaki2）
IMAYAYAMA Shuhei Clinic ＆ Lab, DermatoPathology, Fukuoka1），National Hospital
Organization Kyushu Medical Center, Department of Pathology, Fukuoka2）
Patterns and Trends in Skin Cancer in Sri Lanka（2015-2022）○U.M. Navami P. Samaranayake1,2），U.M. Jayami E. Samaranayake1），
Roshana Constantine2），Yasith Mathangasinghe3,4），Modini Jayawickrama2），
Janaka Akarawita2）
Postgraduate Institute of Medicine, University of Colombo, Colombo1），National
Hospital of Sri Lanka, Colombo2），Department of Anatomy, Genetics and Biomedical
Informatics, Faculty of Medicine, University of Colombo, Colombo3），Biomedical
Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash
University, Melbourme4）45

Dermatologic surgery ……………………………………………………………………
EP5-1
EP5-2

Withdrawn
Reconstruction of a Lateral Eyelid Defect following Mohs Surgery○Nerice Ngiam1），Hsi-Wei Chung2），Choon Chiat Oh1）
Department of Dermatology, Singapore General Hospital, Singapore1），Department ofOphthalmology, Singapore National Eye Center, Singapore2）

Inflammatory disease ……………………………………………………………………
EP6-1
EP6-2
（E4-1）

EP6-3

EP6-4
（E4-6）

EP6-5（E4-2）

46

Withdrawn
Inflammatory myopathy following COVID-19 mRNA vaccination in a patient with VEXAS
syndrome○Masakazu Kakurai1），Rie Honda1），Akihiro Kuroda2），Naomi Tsuchida3,4,5），
Ayaka Maeda5），Yuri Uchiyama3,4），Naomichi Matsumoto3），Shusaku Ito1）
Division of Dermatology, Hitachi General Hospital, Hitachi1），Division of Hematology,
Hitachi General Hospital, Hitachi2），Department of Human Genetics, Yokohama City
University Graduate School of Medicine, Yokohama3），Department of Rare Disease
Genomics, Yokohama City University Hospital, Yokohama4），Department of Stem Celland Immune Regulation, Yokohama City University Graduate School of Medicine,
Yokohama5）
Efficacy of pulsed dye laser in facial redness of atopic dermatitis○Yuko Kuriyama1），Sei-ichiro Motegi1），Shinji Noda2）
Department of Dermatology, Gunma University, Maebashi1），Tokyo Dermatology inIkebukuro, Tokyo2）
Schnitzler syndrome with an immunoglobulin A gammopathy exacerbated by COVID-19
infection○Yasuaki Ikuno，Toshifumi Takahashi，Takuya Nagata，Shuji Sugiura，Akihiko Yamaguchi，Noriki Fujimoto
Department of Dermatology, Shiga University of Medical Science, Otsu
Burdock-derived Arctiin may alleviate psoriatic symptoms via PI3K-Akt signaling pathway○Mengyao Yang1,2,3），Tao Wang4），Xuefei Du2,3），Wanchen Zhao1），
Alafate Abudouwanli1），Quan Sun1），Arisa Ikeda1,5），Ge Peng1），
Francois Niyonsaba1,6），Long Geng2,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Dermatology, The First Hospital of China Medical University,
Shenyang2），NHC Key Laboratory of Immunodermatology, Ministry of Education Key
Laboratory of Immunodermatology, National Joint Engineering Research Center for
Diagnosis and Treatment of Immunologic Skin Diseases, The First Hospital of China
Medical University, Shenyang3），Department of Urology, The Peopleʼs Hospital of
Liaoning Province, Shenyang4），Department of Nephrology, Juntendo University
Graduate School of Medicine, Tokyo5），Faculty of International Liberal Arts, Juntendo
University, Tokyo6）

EP6-6（E4-3）

AMP-IBP5 Attenuates Psoriatic Symptoms via LRP1 Signaling○Ge Peng1），Saori Yoshiba1），Lixia Cui2），Wanchen Zhao1），Alafate Abudouwanli1），
Quan Sun1），Ko Okumura1），Hideoki Ogawa1），Shigaku Ikeda1），Francois Niyonsaba1,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Dermatology, the Second Affiliated Hospital of Hainan Medical
University, Hainan2），Faculty of International Liberal Arts, Juntendo University,
Tokyo3）Allergic disease ……………………………………………………………………………
EP7-1（E1-6）

EP7-2（E1-7）

EP7-3（E1-8）

EP7-4

EP7-5

EP7-6

EP7-7

Three Phases of Pathology in Skin Eruptions of Chronic Urticaria using Mathematics○Sungrim Seirin-Lee1,2），Shunsuke Takahagi3），Michihiro Hide3,4）
ASHBi, Kyoto University Institute for Advanced Study, Kyoto University, Kyoto1），
Department of Mathematical Medicine, Graduate School of Medicine, Kyoto University,
Kyoto2），Department of Dermatology, Graduate School of Biomedical and Health
Sciences, Hiroshima University, Hiroshima3），Department of Dermatology, Hiroshima
City Hiroshima Citizens Hospital, Hiroshima4）
Correlation of specific IgE with total IgE in atopic dermatitis patients○Norika Akashi，Mariko Ogawa-Momohara，Tomoki Taki，Ryo Fukaura，Satoshi Kamiya，Yuta Yamashita，Haruka Koizumi，Takuya Takeichi，
Yoshinao Muro，Masashi Akiyama
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya
Real-world effectiveness of abrocitinib and transcriptome analysis in atopic dermatitis○Mayu Ohtaka，Akihiko Uchiyama，Keiji Kosaka，Mai Ishikawa，Yuuta Inoue，Sei-ichiro Motegi
Department of Dermatology, Gunma University, Maebashi
Toxic Epidermal Necrolysis Associated With Cytomegalovirus Infection○Yuki Kobayashi1），Kyoko Kanno1），Kaori Umekage1），Chiaki Takahashi1），
sawa Otsubo1），Mari Kishibe1），Akemi Yamamoto1），Aiko Noguchi2），Kouji Takarada3）
Department of Dermatology, Asahikawa Medical University, Asahikawa1），
Department of Dermatology, Asahikawa Kosei General Hospital, Asahikawa2），
Department of Ophthalmology, Asahikawa Medical University, Asahikawa3）
Voluntary Exercise Alleviates Inflammatory Responses in a Mouse Model of Atopic Dermatitis○Wanchen Zhao，Ge Peng，Alafate Abudouwanli，Arisa Ikeda，Quan Sun，
Shigaku Ikeda，Hideoki Ogawa，Ko Okumura，Francois Niyonsaba
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo
A Study on Drug Patch Testing in Severe Cutaneous Adverse Drug Reactions（SCARs）○Dulini Liyanagama1），Janaka Akarawita2）
Consultant Dermatologist, Base Hospital Rikillagaskada, Rikillagaskada1），Consultanat
Dermatologist, National Hospital of Sri Lanka, Colombo2）
Exposure to Air Hydrocarbons on Visits for Atopic Dermatitis in Central-Southern Taiwan○Hui-Wen Tseng1,2）
Department of Dermatology, Ministry of Health and Welfare Pingtung Hospital, PingTung1），School of Medicine, National Sun Yat-Sen University, Kaohsiung2）47

Autoimmune disease ………………………………………………………………………
EP8-1

EP8-2
（E3-2）

EP8-3（E3-3）

EP8-4

EP8-5
（E3-6）

EP8-6

EP8-7
（E3-4）
EP8-8

EP8-9

48

A case of intractable Pemphigus Vulgaris effectively treated with Rituximab○Hibari Nakajima1），Airi Osawa2），Shoko Watanabe2），Asami Takehana2），
Sonoko Jikuya2），Tadashi Koyama3），Norito Ishii4），Yoshihiro Kuwano2）
Department of Dermatology, Graduate School of Medicine, The University of Tokyo,
Tokyo1），Department of Dermatology, Teikyo University Hospital, Kawasaki2），
Department of Pulmonology, Teikyo University Hospital, Kawasaki3），Department of
Dermatology, Faculty of Medicine, Kurume University, Kurume4）
Anti-eIF2B antibody Detection by ELISA in Japanese Patients with Systemic Sclerosis○Haruka Koizumi1），Yoshinao Muro1），Yuta Yamashita1），Satoshi Kamiya1），
Norika Akashi1），Mariko Ogawa-Momohara1），Takuya Takeichi1），
Yasuhiko Yamano2），Yasuhiro Kondoh2），Masashi Akiyama1）
Department of Dermatology, Nagoya University, Nagoya1），Department of Respiratory
Medicine and Allergy, Tosei General Hospital, Seto2）
Inhibition of IgG Extravasation to Mucous Membranes with TKIs in a Murine Pemphigus
Model○Yukako（Duerna）Akamatsu（Tie）1），Takashi Nomura1,2），Kenji Kabashima1）
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto1），
Department of Drug Development for Intractable Diseases, Graduate School of
Medicine, Kyoto University, Kyoto2）
Analysis for Characteristic Distribution of Vitiligo Lesions on the Hand
○Kazunori Yokoi，Jing Wang，Atsushi Tanemura，Haruna Kawashima，
Narumi Jikihara，Eiji Kiyohara，Manabu Fujimoto
Department of Dermatology, Osaka University Graduate School of Medicine, Suita
DNA methylation analysis Reveals Epigenetic Perturbations of Vitiligo Tregs○Jianru Chen，Xinju Wang，Wei Wu，Qingrong Ni，Kaiqiao He，Luling Huang，Weiwei Sun，Jinrong Fan，Shuli Li，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
Memory and TCF1+ T Cells Aid in Diagnose and Monitor Disease Activity in Vitiligo○Xinju Wang，Jianru Chen，Wei Wu，Jinrong Fan，Luling Huang，Weiwei Sun，
Kaiqiao He，Shuli Li，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
The role of IL-7/IL-7R mediates stem cell-like Hobit+CD8+ TRM in vitiligo recurrence○Yuqian Chang，Shuli Li，Chunying Li
Department of Dermatology, Xijing hospital, Fourth Military Medical University, Xiʼan
TFAP2B：A New Marker of Epidermal Melanocytes and Essential for Melanocyte
Regeneration○Jingjing Ma，Sen Guo，Xiuli Yi，Weinan Guo，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
Efficacy and safety of Janus kinase inhibitors in patients with vitiligo○Linhan Jiang，Weinan Guo，Shuli Li，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, XiʼanEP8-10（E3-7）

EP8-11（E3-8）

Oxidative Stress-Induced S100B：Enhancer of Immune Responses in Vitiligo○Shuli Li，Wei Wu，Xinju Wang，Jianru Chen，Jinrong Fan，Luling Huang，Weiwei Sun，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan
Dimethyl itaconate halts vitiligo depigmentation by suppressing DC-CD8+ T cell responses○Yinghan Wang，Yuhan Chen，Jingjing Ma，Shuli Li，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University（AirForce Military Medical University）, XiʼanTumor …………………………………………………………………………………………
EP9-1

EP9-2

EP9-3
（E2-1）

EP9-4

GAB1：：ABL1 fusion-positive spindle cell neoplasm○Erena Kimura1），Toshihisa Hamada1），Kazuma Ito1），Akari Matsuoka1），
Yuta Norimatsu1），Taro Akatsuka1），Sohshi Morimura1），Mina Komuta2），
Takayuki Shiomi2），Makoto Sugaya1）
Department of Dermatology, International University of Health and Welfare,
Ohtawara1），Department of Diagnostic Pathology, International University of Healthand Welfare, Ohtawara2）
A case of sarcomatoid dedifferentiated melanoma○Taro Akatsuka1），Toshihisa Hamada1），Kazuma Ito1），Akari Matsuoka1），
Erena Kimura1），Yuta Norimatsu1），Sohshi Morimura1），Makoto Sugaya1），
Ryosuke Matsuoka2），Mina Komuta2）
Department of Dermatology, International University of Health and Welfare,Nasushiobara1），Department of Pathology, International University of Health andWelfare, Nasushiobara2）
Activated Akt expression has the prognostic value for relapse in acral melanomas○Takeshi Namiki1），Kohei Nojima1），Masahiro Hayashi2），Atsushi Tanemura3），
Tamio Suzuki2），Masashi Ishikawa4），Naoya Yamazaki5），Ichiro Katayama3），
Yoshiyuki Sasaki6），Naoko Okiyama1）
Department of Dermatology, Tokyo Medical and Dental University, Tokyo1），
Department of Dermatology, Yamagata University, Yamagata2），Department of
Dermatology, Osaka University, Suita3），Department of Dermatology, Saitama Cancer
Center Hospital, Kitaadachi4），Department of Skin Oncology, National Cancer Center
Hospital, Tokyo5），Clinical Dental Research Promotion Unit, Faculty of Dentistry,
Tokyo Medical and Dental University, Tokyo6）
A Case of Signet-Ring Cell Carcinoma, Found Only in the Perianal Lesion○Sayuri Nakano1），Masaaki Kawase1），Ryosuke Hashizume2）
Department of Dermatology, The Jikei University Katsushika Medical Center,
Tokyo1），Department of Surgery, The Jikei University Katsushika Medical Center,
Tokyo2）49

EP9-5

EP9-6（E2-2）

EP9-7（E2-3）
EP9-8

EP9-9（E2-8）

EP9-10（E2-4）

50

Dermatofibrosarcoma protuberance mimicking neurofibroma arising from a conventional
area○Takayuki Suyama1），Megumi Yokoyama1），Jun Matsushima2），Yasunori Matsuki1），
Kazumoto Katagiri1）
Department of Dermatology, Dokkyo Medical University Saitama Medical Center,
Koshigaya1），Department of Pathology, Dokkyo Medical University Saitama Medical
Center, Koshigaya2）
Relationship Between Tumor Thickness and Histological Invasion Level in Acral Melanoma○Shigeru Koizumi1），Yukiko Kiniwa2），Tatsuya Takenouchi3），Jun Asai4），
Takuya Miyagawa5），Takamichi Ito6），Noriki Fujimoto7），Shigeto Matsushita8），
Yosuke Yamamoto9），Yasuhiro Nakamura1）
Department of Skin Oncology/Dermatology, Saitama Medical University International
Medical Center, Hidaka1），Department of Dermatology, Shinshu University School of
Medicine, Matsumoto2），Department of Dermatology, Niigata Cancer Center Hospital,
Niigata3），Department of Dermatology, Kyoto Prefectural University of Medicine,
Kyoto4），Department of Dermatology, The University of Tokyo, Graduate School of
Medicine, Tokyo5），Department of Dermatology, Graduate School of Medical Science,
Kyushu University, Fukuoka6），Department of Dermatology, Shiga University of
Medical Science, Otsu7），Department of Dermato-Oncology/Dermatology, NHO
Kagoshima Medical Center, Kagoshima8），Department of Dermatology, Department of
Dermatology, Chiba University Graduate School of Medicine, Chiba9）
KS-EMPD-1：a novel cell line of primary extramammary Paget’s disease○Takamichi Ito，Yuka Tanaka，Toshio Ichiki，Yumiko Kaku-Ito，Takeshi Nakahara
Department of Dermatology, Kyushu University, Fukuoka
Milia en Plaque on the Face After Electron Therapy for Folliculotropic Mycosis Fungoides○Takuya Kawamura1），Yasuyuki Yamaguchi1），Sho Katayama1），Yu Fujimura1），
Kentaro Izumi1），Motoyasu Shido2），Takayuki Hashimoto2），Hideyuki Ujiie1）
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine,
Hokkaido University, Sapporo1），Department of Radiation Oncology, Faculty of
Medicine, Hokkaido University, Sapporo2）
Sarcopenia is a prognostic factor in advanced BRAF wild-type malignant melanoma in Asians○Kohei Yamakawa1），Yusuke Kurita2），Hideyuki Ishikawa1），Shingo Kato2），
Yukie Yamaguchi1）
Department of Environmental Immuno-Dermatology, Yokohama City University
Graduate School of Medicine, Yokohama1），Department of Gastroenterology andHepatology, Yokohama City University School of Medicine, Yokohama2）
Analysis of surgical margins and prognostic factors in 116 Japanese DFSP patients○Yusuke Muto1,2），Taku Fujimura2），Akira Takahashi3），Kenjiro Namikawa4），
Dai Ogata4），Eiji Nakano4），Shunichi Jinnai3），Akira Hashimoto2），Asano Yoshihide2），
Naoya Yamazaki4）
Department of Dermatology, South Miyagi Medical Center, Shibata1），Department of
Dermatology, Tohoku University Graduate School of Medicine, Sendai2），Dermatologic
Oncology, National Cancer Center Hospital East, Kashiwa3），Dermatologic Oncology,
National Cancer Center Hospital, Tokyo4）

EP9-11EP9-12

EP9-13（E2-6）

EP9-14EP9-15（E2-5）

EP9-16（E2-7）

Investigation of gene specificity in metastatic acral melanoma among Asian patients○Yu-Jen Chiu1），Jai-Sing Yang2）
Department of plastic and reconstructive surgery, Taipei Veterans General Hospital,
Taipei1），China Medical University Hospital, Taichung2）
Granulomatous Mycosis Fungoides：A Diagnostic Challenge○Nurrahma Wahyu Fitriyani1），Arif Widiatmoko1），Diah Prabawati Retnani2）
Department of Dermatology, Faculty of Medicine, Universitas Brawijaya, Malang1），
Department of Pathology, Faculty of Medicine, Universitas Brawijaya, Malang2）
Experimental and clinical evidence suggests S100A7 may be involved in melanoma
development○Quan Sun1），Ge Peng1），Wanchen Zhao1），Alafate Abudouwanli1），Arisa Ikeda1,2），
Ko Okumura1），Hideoki Ogawa1），Shigaku Ikeda1），Francois Niyonsaba1,3）
Atopy（Allergy）Research Center, Juntendo University Graduate School of Medicine,Tokyo1），Department of Nephrology, Juntendo University Graduate School of
Medicine, Tokyo2），Faculty of International Liberal Arts, Juntendo University, Tokyo3）
Endocrine Mucin-Producing Sweat Gland Carcinoma：A Rare Lesion of the Eyelid○Andrea Jing Shi Ang1），Fan Foon Cheo2），Choon Chiat Oh1）
Department of Dermatology, Singapore General Hospital, Singapore1），Department of
Pathology, Singapore General Hospital, Singapore2）
18
F-FDG PET/CT Correlation with Tumor Stage in Acral Melanoma：A Retrospective Study○Wei-Ting Liu，Yi-Han Chang，Tak-Wah Wong
Department of Dermatology, National Cheng Kung University Hospital, College ofMedicine, National Cheng Kung University, Tainan
GSDME promotes melanoma progression by regulating chromatin accessibility of PLK4
○Juan Du，Chunying Li
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xiʼan

Congenital disease…………………………………………………………………………
EP10-1

EP10-2

IgA nephropathy and scalp squamous cell carcinoma associated with epidermolysis bullosa○Ko Sunagawa，Taisuke Kanno，Hitoshi Urakami，Shogo Ikezawa，Mikiko Takigawa，Yoji Hirai，Yoshio Kawakami，Shin Morizane
Department of Dermatology, Okayama University Graduate School of Medicine,
Dentistry, and Pharmaceutical Sciences, Okayama
A Case of Castleman’s disease Associated with Recessive Dystrophic Epidermolysis Bullosa○Satsuki Naruse1），syouta Takashima1），Yasuyuki Fujita2），Hiroshi Kataoka3），
Nobuaki Kawamura4），Ken Natsuga1），Hideyuki Ujiie1）
Department of Dermatology, Hokkaido University, Sapporo1），Department of
Dermatology, Sapporo City General Hospital, Sapporo2），Department of Rheumatolory＆ Clinical Immunology, Sapporo City General Hospital, Sapporo3），Department ofPediatrics, Sapporo City General Hospital, Sapporo4）

51

EP10-3（E1-4）

EP10-4EP10-5（E1-5）

Lesion-specific Loss of Langerhans Cells in Progressive Symmetric Erythrokeratodermia○Umi Tahara1,2），Kyoko Masuda1），Takashi Sasaki1,3），Kazuhiko Nakabayashi4），
Masayuki Amagai1），Akiharu Kubo1,5）
Department of Dermatology, Keio University School of Medicine, Tokyo1），Departmentof Dermatology, Kawasaki Municipal Hospital, Kawasaki2），Center for
Supercentenarian Medical Research, Keio University School of Medicine, Tokyo3），
Department of Maternal-Fetal Biology, National Center for Child Health andDevelopment, Tokyo4），Division of Dermatology, Department of Internal Related, Kobe
University Graduate School of Medicine, Kobe5）
Combination of oral propranolol therapy and laser therapy for infantile hemangioma○Daisuke Omoto，Koji Nishihori
Nishihori Clinic of Plastic Surgery, Nagoya
Real-World Experience of Dupilumab and JAK Inhibitors in Epidermolysis Bullosa Pruriginosa○Ping-Chen Hou1），Wilson Jr Aala2），Wei-Ting Tu1），John A. McGrath1,3），
Chao-Kai Hsu1,2,4）
Department of Dermatology, National Cheng Kung University Hospital, College ofMedicine, National Cheng Kung University, Tainan1），Institute of Clinical Medicine,College of Medicine, National Cheng Kung University, Tainan2），St Johns Institute of
Dermatology, School of Basic and Medical Biosciences, Kings College London,
London3），International Center for Wound Repair and Regeneration, National Cheng
Kung University, Tainan4）

Infectious disease …………………………………………………………………………
EP11-1（E4-7）

EP11-2（E4-4）

EP11-3EP11-452

Disseminated Mucocutaneous Leishmaniasis Coinfected by Two Distinct Species○Yuki Kobayashi1），Takeshi Ouchi1），Takashi Okada2），Kenta Kobayashi1），
Haruka Omasa1），Takayuki Fusumae1），Sayuka Arakawa1），Chizu Sanjoba3），
Yasuyuki Goto3），Takeru Funakoshi1）
Department of Dermatology, Keio University School of Medicine, Tokyo1），Department
of Otorhinolaryngology, Keio University School of Medicine, Tokyo2），Laboratory of
Molecular Immunology, Department of Animal Resource Sciences, Graduate School of
Agricultural and Life Sciences, The University of Tokyo, Tokyo3）
Influence of Risk Factors and Therapies on Prognosis of Herpes Zoster○Marika Matsuya1），Motoshi Sugawara2），Takeshi Iwasaki3），Motoshi Kinouchi1）
Department of Dermatology, Asahikawa Red Cross Hospital, Asahikawa1），
Department of Dermatology, Asahikawa Medical University, Asahikawa2），Nishino
Dermatology Clinic, Sapporo3）
An Illustrative Case of Tuberculous Tenosynovitis Presenting as Subcutaneous Nodules○Jacqueline JL Liew1），Adeline MY Yong2），Chee Hian Tan3）
National University of Singapore, Yong Loo Lin School of Medicine, Singapore1），
Division of Dermatology, Department of Medicine, National University Hospital,
Singapore, Singapore2），National Skin Centre, Singapore, Singapore3）
Pretty leprosy as special characteristics in elderly leprosy patient○Rusmawardiana Rusmawardiana，Fifa Argentina，Raden Pamudji，Rina Novriani
Dermatology Venereology and Aesthetic Medicine, Faculty of Medicine Universitas
Sriwijaya, PalembangEP11-5

EP11-6

EP11-7

Dermoscopic Patterns of Tinea Infections―A Cross-Sectional Study○Thanushah Balendran
Senior Registrar in Dermatology, Postgraduate Institute of Colombo, Colombo
Neglected for 25 Years：A Case Report on Overlooked Cutaneous Tuberculosis○Emy Kusumaningsih
Simpang Lima Gumul General Hospital, Kediri
Anti-GM-CSF autoantibodies in immunocompetent patients with cutaneous cryptococcosis○Li-Wen Chiu1,2），Wei-Cheng Fang3）
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung1），
Department of Dermatology, College of Medicine, Kaohsiung Medical University,
Kaohsiung2），Department of Dermatology, Kaohsiung Municipal Siaogang Hospital,
Kaohsiung3）

Others …………………………………………………………………………………………
EP12-1

EP12-2

EP12-3EP12-4EP12-5

A case of dermatopathic lymphadenopathy with atopic dermatitis○Akira Kaneko1），Ryoko Sakamoto2），Satoshi Fukushima1）
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto
University, Kumamoto1），Kumamoto Regional Medical Center, Kumamoto2）
A Case of Pediatric Cutaneous Sarcoid Vasculitis○Yukino Kase1,2），Ryota Hayashi1），Kanade Shimada1,2），Yuka Tsutsui1），
Osamu Ansai1），Koichi Tomii1），Riichiro Abe1），Utako Kaneko3）
Division of Dermatology, Niigata University Graduate School of Medical and Dental
Sciences, Niigata1），Division of Dermatology, Nagaoka Red Cross Hospital, Niigata2），
Department of Pediatrics, Niigata University Graduate School of Medical and Dental
Sciences, Niigata3）
A case of calciphylaxis associated with hyperparathyroidism and panhypopituitarism○Atsushi Naito1），Yumi Masuo1），Kohdai Furuta1），Ichiro Yamauchi2），
Masakazu Fujimoto3），Saeko Nakajima1），Naotomo Kambe1），Kenji Kabashima1）
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto1），
Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate
School of Medicine, Kyoto2），Department of Diagnostic Pathology, Kyoto University
Graduate School of Medicine, Kyoto3）
The Risk Investigation of Deep Venous Thrombosis Associated with Lower Leg Cellulitis○Romane Teshima，Natsuko Sasaki，Yu Sawada
Depertment of Dermatology, University of Occupational and Environmental Health,
Kitakyushu
Lp Is Superior to Secretome in Enhancing Skin Fibroblast Proliferation in Photoaging○Nora A Nora Ariyati1），Kusworini Kusworini2），Nurdiana Nurdiana3），
Yohanes Widodo Wirohadidjojo4）
Aurell Skin Care Private Clinic by Dermatologist, Malang1），Department of Clinical
Pathology, Faculty of Medicine, Brawijaya University-Dr. Saiful Anwar General
Hospital, Malang2），Department of Pharmacology, Faculty of Medicine, Brawijaya
University, Malang3），Department of Dermatology and Venereology, Faculty of
Medicine, Gadjah Mada University-Sardjito General Hospital, Yogyakarta4）

53

EP12-6

EP12-754

Chronic urticaria―its correlation with autoimmunity and food allergy in Asian population○Zi Teng Chai
Department of Dermatology, Singapore General Hospital, Singapore
Strong Association Between Sjögren’s Syndrome and Vitiligo○Poyuan Wu1），Jing-Xing Li2），Po-Chang Wu5），Teng-Shun Yu3），Shu-Bai Hsu4）
Departement of Dermatology, China Medical University Hospital, Taichung1），
Department of Internal Medicine, Taipei Veteran General Hospital, Taipei2），
Management Office for Health Data, China Medical University Hospital, Taichung3），
Department of Nursing, China Medical University Hospital, Taichung4），Rheumatology
and Immunology Center, China Medical University Hospital, Taichung5）

Dohi Memorial award Lecture

A Commotion in the Skin: Developing Melanoma
Immunotherapies
Martin Röcken

Department of Dermatology, Eberhard Karls Universität Tübingen,Germany

Melanomas are malignant tumors that can partly and very rarely completely regress in response tospontaneous immune responses. The search for the mechanisms underlying this natural immune-mediatedrejection of melanomas strongly influenced the development of cancer immunotherapy in general. Amongst
others, it resulted in the discovery of tumor-specific neoantigens and mutant autoantigens, nowadays calledtumor-associated antigens（TAA）, or the identification of naturally occurring TAA-specific cytotoxic T
lymphocytes. Melanomas paved the way for the development of cancer therapy by adoptive T-cell therapy
and tumor vaccines, namely dendritic cell vaccines. Melanoma therapy with antibodies against CTLA-4
provided the proof of concept that solid cancers can be susceptible to cancer immunotherapy, and anti-PD-1immunotherapy of melanomas resulted in the clinical breakthrough of cancer immunotherapy. Still, about
half of patients die from metastatic melanoma. Combining anti-PD-1 with anti-CTLA-4 or anti-LAG3
antibodies increase antitumor immune responses but improve the long-term survival only partially.
Combining RNA-vaccines with anti-PD-1 antibodies are strategies under development. More recent data
uncovered that efficient cancer-immune control strictly requires the IFN-γ-dependent activation of cell
cycle arrest genes in those cancer cells surviving the immune-mediated cancer cell killing. This may allow
for identifying those patients that respond to immunotherapy and pave the way for novel therapies thatcombine cancer immunotherapy with cell cycle inhibitors to overcome resistance to current cancer
immunotherapies.

56

［Biography］
1976 - 1983

Medical Studies, Freie Universität Berlin（Germany）, Université Libre de Bruxelles（Belgium, 1976 - 1977）, Université de Lausanne（Switzerland, 1980 - 1981）and UniversitätBern（Switzerland, 1982 -1983）

1984 - 1988

Medical training and Consultant, Department of Dermatology and Allergology, City
Hospital Munich Schwabing, Teaching Unit of the Ludwig-Maximilians-Universität
München（Germany）

1988 - 1991

Research grant of the Deutsche Forschungsgemeinschaft, Department of Dermatology,
Université de Genève（Switzerland）

1991 - 1993

Visiting Associate, Laboratory of Immunology, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, Maryland（USA）

1993 - 1998

Assistant Professor, Medical Faculty, Department of Dermatology and Allergology,
Ludwig-Maximilians-Universität München（Germany）

1998 - 2002

C3 Professor for Dermatology and Venereology, Medical Faculty, Department of
Dermatology and Allergology, Ludwig-Maximilians- Universität München（Germany）

2002 - present

C4 Professor for Dermatology and Venereology and Chairman, Medical Faculty,
Department of Dermatology, Eberhard Karls Universität Tübingen（Germany）［Clinical and experimental focus］
・Tumor immune therapy, tumor immunology
・Autoimmune diseases of the skin and psoriasis：Pathogenesis and novel therapies
・Allergology
・Pathogen-host-interactions

duringinfectious

diseasesin

immune-competentandimmune-compromised hosts, HIV-infection
・Immunology
・Translational medicine

57

Special Lecture

SL4
Scary and smelly matters in scarring alopecia：
How fragrances may damage hair follicle stem
cells in frontal fibrosing alopecia
Ralf Paus

Dermatology, University of Miami Miller School of Medicine, Miami,
FL, USAIt has been speculated that some environmental factors may explain why the prevalence of the mostcommon scarring alopecia, frontal fibrosing alopecia（FFA）, has increased over the last decades. FFA and its
sister-disease, lichen planopilaris（LPP）, result from collapse of the hair follicleʼs（HFʼs）bulge immune
privilege（IP）and pathological epithelial-mesenchymal transition（EMT）of HF epithelial stem cells（eHFSCs）.
Since many FFA patients are sensitized to fragrances found in leave-on skin products, and since we had
discovered that scalp HFs can smell , i.e. express functional olfactory receptors（OR）,we have asked if oneof the most frequently FFA-associated allergens, linalool, which is contained in numerous personal careproducts, promotes these core FFA pathogenesis elements. When organ-cultured healthy scalp HFs and/or
non-lesional FFA scalp skin biopsies from patients with linalool sensitization were treated with linalool exvivo , compared to vehicle controls, this significantly a）decreased the number of eHFSCs, b）destabilized
bulge IP, b）upregulated the danger signal, MICA, and d）increased EMT in eHFSCs. In part, this wascounteracted by silencing signaling via linalool-sensitive olfactory receptors in the bulge. We thus identify apreventable chain of disfiguring HF pathology events induced by a very widely used fragrance, andintroduce selected olfactory receptors as novel key regulators of IP and EMT.

［Biography］
Ralf（*1960）is a German physician-scientist（MD, 1987：Free University of Berlin；DSc, 2021：
University of Manchester；H-index：＞113 Scopus）, who became fascinated by basic and translational
hair research as a post-doc at Yale University, USA（1987-90）. After his dermatology residency and ajunior faculty position at the Charité Hospital, Humboldt University, Berlin, he was Professor ＆ Vice
Chair, Dept. of Dermatology, University Hospital Hamburg-Eppendorf, Germany（1999-2004）, Visiting
Professor at the Max-Planck-Institute for Biochemistry, Martinsried（2005）and Head of Experimental
Dermatology, University of Lübeck, Germany（2005-2013）. From 2008-2021, Ralf was also Director of
Research, Centre for Dermatology Research, University of Manchester, Manchester UK, where he is
now the Emeritus Professor of Cutaneous Medicine. He is a Fellow of the Royal Society of Biology（FRSB）,London.
Since 2018, Ralf works as Research Professor of Dermatology and Director of the Dermatology
Academic Training Program at the Dr. Phillip Frost Department of Dermatology ＆ Cutaneous
Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Besides having served as Editor of Experimental Dermatology（2007-2021）and as Associate and Section
Editor of Journal of Investigative Dermatology , Ralf also is the Founder and was CEO/President ofMonasterium Laboratory in his hometown Münster/Germany, is Founder ＆ CEO of CUTANEON Skin ＆ Hair Innovations, Hamburg ＆ Berlin/Germany（www.cutaneon.com）,and has co-founded the
Hidradenitis Suppurativa Foundation（HSF）,USA. He deeply enjoys collaborating with his friends andcolleagues in Japan, who honored him with the JSID s Tanioku Kihei Award（2010）.

58

SL6-1
Interactions between host and pathogens at thebarriers
Cevayir Coban

Division of Malaria Immunology, Department of Microbiology and
Immunology, IMSUT, the University of Tokyo
To maintain equilibrium with the outside world, the human body is protected by barriers such as the skinand mucosa. In addition, there are specialized cellular barriers within the host such as the blood-brainbarrier. These barriers serve as the first line of defense, both physically and immunologically, against
pathogens, although pathogens have evolved mechanisms to evade these barriers.
My laboratory specializes in malaria infection and has developed tools to understand how these intracellularparasites evade host immunity by evading barriers within the host, such as the skin, brain and gut. Other
protozoan parasites that we have recently begun working on are the Leishmania parasites that cause
cutaneous leishmaniasis. Global warming is estimated to cause an additional 4.7 billion people to become
exposed to vector-borne diseases by 2070. Because these protozoan infections begin in the skin with the
inoculation of parasites from the insects, it is extremely important to understand the mechanisms by which
they cause pathology in the host. In my presentation, I will overview our recent findings and summarize ourobservations on how understanding host immunity can eliminate those protozoan parasites.

［Biography］
Education and Appointments
1994

Hacettepe University, Medical School（M. D.）, Ankara, Turkey

1998

Ph.D.
（Clinical Microbiologist）

2000-2003

Post-Doc. Fellow, Johns Hopkins University, School of Public Health2003-2006

Post-Doc. Fellow, Osaka University

2006-2010

Assistant Professor, Osaka University

2010-2015

Associate Professor, Lab Head, Immunology Frontier Research Center（IFReC）,Osaka

2015-2020

Professor, IFReC, Osaka University

2019-present

Professor, IMSUT, University of Tokyo

University

Specialty ＆ Research Field of Interest
Protozoan parasites-host interactions, Immunopathology, Vaccine

59SL8-1
Molecular characterization of genodermatoses：
rare and new phenotypes and prospects for
improved therapies
John A. McGrath

St Johnʼs Institute of Dermatology, Kingʼs College London, London
U.K.
Advances in DNA sequencing and -omics technologies continue to provide new insights into the molecularbasis of inherited skin diseases and how to improve treatments for patients. This presentation will illustrate
three genodermatosis cases to demonstrate ongoing progress in this field. All 3 involve consanguineous
pedigrees. The first case from Kuwait is an unusual form of plantar keratoderma associated with ragged
periungual hyperkeratosis. Molecular characterization revealed a homozygous missense variant in KRT16 ,p.Gln412Pro, thus identifying the first possible autosomal recessive genodermatosis involving keratin 16.
The second case from Egypt initially presented as possible syndromic ectodermal dysplasia but wholeexome sequencing revealed a homozygous splice site variant in PARN , c.246-1G＞A, providing analternative diagnosis of a telomere biology disorder, Hoyeraal-Hreidarsson syndrome, with different
implications for patient management. The third case from Taiwan had features of autosomal recessive
congenital ichthyosis caused by a homozygous missense variant in TGM1 , p.Cys142Pro. Here, the challenge
was not in diagnosis but in improving management. RNA-seq of the patientʼs lesional skin showedenrichment of JAK-STAT pathway signalling, providing a rationale for innovative therapy with a JAK
inhibitor. Use of oral tofacitinib markedly improved pruritus within 3 days of starting treatment；erythema,
fissuring and trans-epidermal water loss also improved. Collectively, these cases underscore the value ofDNA sequencing and molecular investigation of patients with genodermatoses in providing accurate genetic
diagnoses with important implications and options for improving patient management.

［Biography］
John McGrath is the academic head of St Johnʼs Institute of Dermatology in London where he also runs
the Genetic Skin Disease Group. He holds the Mary Dunhill Chair in Cutaneous Medicine at KingʼsCollege London and is Honorary Consultant Dermatologist to the Guyʼs and St Thomasʼ National HealthService Foundation Trust. His expertise is in genodermatoses, discovering genes and testing
experimental therapies to improve patient care. He has held several leadership positions within
European dermatology and been awarded multiple named lectureships around the world, including theDohi Memorial lecture（JDA, 2010）and Tanioku Kihei Memorial lecture（JSID, 2012）.He has published＞550 articles and will become editor-in-chief of the British Journal of Dermatology from July 2024.

60

SL8-2
Severe Cutaneous Adverse Drug Reactions：
Update 2024
Lars E. French1,2）

Department of Dermatology and Allergy, University Hospital,
Ludwig Maximilan University（LMU）Munich, Munich, Germany1），
Dr. Philip Frost Department of Dermatology and Cutaneous
Surgery, University of Miami Miller School of Medicine, Miami, FL,USA2）
The skin is one of the most frequently involved organs by drug side effects, with the incidence of adverse
cutaneous drug reactions（ADR）situated between 0.1-1％ of patients during pre-marketing clinical trials, andpost-marketing analyses suggest that their incidence can be as high as 1-8％ for certain types of drugs（NSAIDS, antibiotics, antiepileptics）. ADR are benign in nature in over 98％ of cases and present mostfrequently as maculo-papular eruptions or urticaria. However, studies suggest that roughly a third of drug
eruptions require hospital management and are considered as severe, although fortunately only 2％ of
cutaneous drug eruptions are life-threatening. Consequently, up to 5 of all hospital costs are related toadverse drug eruptions, of which cutaneous adverse drug eruptions represent 20％, thus representing asignificant burden on the health care system.
ADR can be differentiated into two major subtypes, i）type A reactions which are predictable, represent
15％ of ADRs, and are due to pharmacological proprieties of the causative drug, and ii）type B reactions
which are more frequent, and predominantly immune-mediated, thus difficult to predict. ADR are mostfrequently type B reactions.
Cutaneous ADRs range in severity from the benign self-resolving maculopapular rash to the potentiallylethal ADRs. The most frequently encountered adverse drug reactions involving the skin are of theexanthematous reactions, mostly represented by the maculo-papular exanthem and drug-induced urticaria.
These benign immune-mediated exanthemas typically resolve within days to weeks when the causal
medication is stopped and are not complicated by severe systemic symptoms or internal organ involvement.
In less than 2％ of cases ADR can however be severe and potentially life threatening. This is the case for
Stevens-Johnson syndrome（SJS）and toxic epidermal necrolysis（TEN）, acute generalized exanthematous
pustulosis（AGEP）, and drug rash with eosinophilia and systemic symptoms（DRESS）/drug induced
hypersensitivity syndrome（DIHS）. Their diagnosis, management and recent developments will be
discussed.
Keywords：allergy, drugs, inflammation［Biography］
April 1988 - April 1990
April 1990 - Oct.1993
Oct. 1993 - Dec. 1996
Jan. 1997 - Oct. 2002
Oct.1999 - Oct. 2000
Oct. 2002 - April 2003
May 2003 - Sept. 2006
Oct. 2006 - Oct. 2018
Nov. 2018 -Resident in Internal Medicine, Geneva University Hospital, CH
Research fellow in cell and molecular biology, Geneva University, CH
Resident in Dermatology, Geneva University Hospital, CH
Swiss National Science Foundation Career Development Award, Geneva
University, CH
Visiting Clinical and Research Fellow, Dermatology, University ofPennsylvania, PA, U.S.A
Associate Professor, Dermatology Department, Geneva University Hospital,
CH
Louis-Jeantet Professor of Medicine, Geneva University Hospital, CH
Professor and Chairman, Dermatology Department, Zurich University
Hospital, CH
Professor and Chairman, Department of Dermatology, Ludwig Maximilian
University, Munich, DE

61

SL9
The Golden Age of Dermatologic Drugs FinallyHas Begun
Ervin Epstein, Jr.

San Francisco, California, USA

A half century ago the common wisdom was absolutely right - if we only understood more about the skinand its diseases, we could make better drugs for our patients. The pace of new understanding of basic
biology and correspondingly of skin biology has been unprecedented, and（hooray!）so has the pace of theintroduction of new drugs into clinical Dermatology. As an example, I will discuss the description by Robert
Gorlin of the Basal Cell Nevus Syndrome in 1960, the identification of the PTCH1 gene as the site of themutations that underlie this affliction in 1996, the resulting introduction of the first molecularly-targeted
drug with astonishingly effective anti-basal cell carcinoma activity in 2012, and the effort to reduce the side
effects of the orally-administered drug by administering it directly to the skin - the story moves from one
Dentistʼs office to multiple academic molecular biology labs to Big Pharmaʼs development teams to Biotech
efforts. Yes, basal cell carcinomas are far less common in people of East Asian descent than in those ofEuropean descent but your Japanese patients suffer from poorly treated heritable disorders for which the
BCC story might serve as a model for the development of new, highly effective drugs. Oh yes, why DO the
Gorlin Syndrome and sporadic BCCs, occur at such different rates these two populations, and why should
we care?? And why canʼt we get on the gene therapy bandwagon and not just treat but CURE our patientsʼ
ills? And, and, and…there are so many other questions ripe to be answered right now!

［Biography］

62

1972-2022

Private practitioner, Dermatology, Oakland, CA

1972-1979

Assistant Professor, UCSF School of Medicine, San Francisco, CA

1979-1985

Associate Professor, UCSF School of Medicine, San Francisco, CA

1985-2007

Research Dermatol./Clin. Prof, Derm., UCSF School of Medicine

2007-2017

Senior Scientist, Childrenʼs Hospital Oakland Research Institute（CHORI）, Oakland, CA

2012-2023

Co-Founder, PellePharm Inc

2023-present

Consultant , Sol-Gel Technologies

President Special Lecture
SP1-1
Diagnosis and Targeted
Treatment of Inﬂammatory Skin
Diseases Guided by Immune
Expression Modules

SP1-2
Keratinocyte cancers：Rational
management based on
pathogenesis
Kiarash Khosrotehrani

Michel Gilliet

The University of Queensland

Department of Dermatology,

Frazer Institute, Australia

Lausanne University Hospital
CHUV, Switzerland

Recent scientiﬁc advances have elucidated the immune pathways underlying
inﬂammatory skin diseases, leading to the development of targeted therapies.
However, there remains a gap in established molecular approaches for
personalized diagnostic and therapeutic guidance at the individual patient level.
In our study, we conducted a comprehensive comparison of expression proﬁlesacross various conditions, including psoriasis, atopic dermatitis, lichen planus,
lupus erythematosus, neutrophilic diseases, and Wellʼs disease, with the aim ofidentifying molecular modules deﬁning relevant immune pathways. Seven
modules representing key immune pathways―Th17, Th2, Th1, Type I IFNs,
neutrophilic, macrophagic, and eosinophilic―were identiﬁed. Utilizing thesemodules, we created a cartography demonstrating high diagnostic performance,
particularly for undetermined rashes and erythrodermas, compared to standard
clinical and histopathology methods. Furthermore, we investigated whetheraligning dominant modules with treatment targets could enhance clinicalresponses and guide treatment choices for treatment-naïve patients or nonresponders to targeted therapies. Our ﬁndings revealed that aligning treatment
with dominant immune modules increased the likelihood of clinical responses by
eliminating obligatory failures associated with mismatched lesions. Module
analysis in non-responding lesions provided a rationale for re-matching targeted
therapies, resulting in a signiﬁcant improvement in response rates. In summary,
our study established a precision medicine approach for inﬂammatory skindiseases by identifying core immune modules with diagnostic efficacy for clinicopathologically undetermined cases. Aligning dominant immune modules withtreatment targets offers a rational guide for treatment selection, thereby
enhancing response rates in both treatment-naïve patients and those who fail to
respond initially.

［Biography］
CURRENT POSITIONS（since 2010）
Professor and Chairman, Department of Dermatology, University of Lausanne CHUV
2008-2010 Associate Professor（tenured）, Departments of Dermatology, Melanoma
Oncology and Immunology（triple appointment）, The University of Texas M.D.
Anderson Cancer Center, Houston（TX）
Co-Director, Center for Cancer Inflammation, the University of Texas M.D.
Anderson Cancer Center, Houston（TX）
2004-2008 Assistant Professor（tenure-track）,Departments of Dermatology,
Melanoma Oncology and Immunology, The University of Texas, M.D.
Anderson Cancer Center, Houston（TX）
2001-2004 Senior Resident, Department of Dermatology, Zürich University
Hospital, Zürich, Switzerland
1999-2001 Post-Doctoral Fellow, DNAX Research Institute, Schering Plough,Palo Alto（CA）
1998-1999 Resident, Department of Dermatology, Zürich University
Hospital, Zürich, Switzerland
1996-1998 Postgraduate Fellow, Department of Internal Medicine, Zürich
University Hospital, Zürich, Switzerland

Keratinocyte cancers are the most common
malignancy in mankind and comprise basal andsquamous cell carcinomas. Individual susceptibility
to keratinocyte cancers is mostly driven by the
response to sun exposure with skin colour, ability to
tan being the dominant genetic features. In
addition, the ability of the immune system to fightKCs is highly relevant and immunosuppressed
patients have orders of magnitude higher incidenceof KC. KCs often start from mutation in normal
looking skin, a recent concept that has changed in
the past half-decade. In particular, we will explore
the concept that field cancerisation starts largely
before clinical signs of sun damage are visible,
triggering a co-existence of mutant keratinocyte
clones competing with normal keratinocytes. This
competition can be altered in favour of normal
keratinocytes through sun protection or the use ofmTOR inhibitors. Understanding how mutant
epidermal clones progress to skin cancer allows arationale approach to chemoprevention.
［Biography］
Current Employment
2019-Current Professor of Dermatology, Professorial Research Fellow,
research group leader, The University of Queensland, Frazer Institute2022-Current Director of Dermatology, Princess Alexandra Hospital,
Brisbane, Australia
2014-Current Senior Medical Officer：Department of Dermatology：
Princess Alexandra Hospital
2018-Current Senior Medical Officer：Prince Charles Hospital. Skincancer clinic for lung and heart transplant recipients
2012-Current Visiting Medical Officer：Queensland Skin and Cancer
Foundation（trading as Queensland Institute of Dermatology）

63

SP3-1
Whatʼs New in Pigmentary
Disorders

SP3-2
Lessons from my career inmedical research：how tosucceed without being smart

Seemal R. Desai1,2,3）

John R. Stanley

President, American
1）

Academy of Dermatology ，Department of Dermatology,

Founder ＆ Medical Director,

University of Pennsylvania,

2）

Innovative Dermatology ，Philadelphia, USA

Department of Dermatology,
The University of Texas
Southwestern Medical Center,
Dallas, Texas, USA3）

This lecture will focus on new and emerging
therapies in pigmentary disorders with a particularemphasis on therapeutic updates in managing
vitiligo and melasma. We will discuss new andemerging therapies for vitiligo, including JAK
inhibitors. In addition, clinical cases alongsideclinical literature data from new research will
highlight difficult to treat dilemmas in vitiligo. In
regards to melasma, we will outline clinical signs
and symptoms of melasma, with the ability tocategorize different types of hyperpigmentation.
The lecture will cover new and emerging therapies
for melasma, including Tranexamic Acid, newer
non-hydroquinone based options for treating
hyperpigmentation, and the role of new andemerging therapies.

Medical research does not require genius. Factors that were
instrumental in my career were serendipity, simple observationand not taking rejection too seriously. I will give examples of eachin general medical and dermatologic research, and in my career.
Serendipity, finding valuable things by chance, was instrumental
in the great discoveries of x-rays and surgical anesthesia.
Examples from dermatology include botox for wrinkles andminoxidil for baldness. In my career the discovery of pemphigus
and an anti-desmosomal autoimmune disease was serendipitous.
Simple observation that milkmaids who had cowpox did not get
smallpox allowed Edward Jenner to discover smallpox vaccine.
We discovered how exfoliative toxin causes bullous impetigo by
the observation that the histology of impetigo is identical topemphigus foliaceus. Finally, rejection is mostly inevitable inmedical research. Examples of discoveries initially rejected
include cure of scurvy with ascorbic acid, development of green
fluorescent protein derivatives, handwashing to prevent
postpartum sepsis, radioimmunoassay for insulin, mRNA
modifications for effective therapy. In my career, there weremany rejections, some of which I will complain about. Finally,
mentorship and working as a team were critical for my success.

［Biography］
1981-1994［Biography］

Dermatology, Department of Dermatology,

Postdoctoral Training
2005-2006

Uniformed Services University of the HealthInternship, Internal Medicine, Morehouse School of
Medicine - Department of Internal Medicine, Atlanta,

Sciences（USUHS）
1985-1994

Senior Investigator, Dermatology Branch, National

1/1995-11/2010

Professor and Chair, Department of Dermatology,

2010-

Professor and Professor Emeritus, Department ofGA
2006-2009

Residency, Dermatology, University of Alabama at

Cancer Institute, NIH, Bethesda, MD

Birmingham-School of Medicine（UAB）, Birmingham,AL
2008-2009

University of Pennsylvania, Philadelphia, PA

Chief Resident, Dermatology, University of Alabama

Dermatology, University of Pennsylvania,

at Birmingham-School of Medicine（UAB）,

Philadelphia, PA

Birmingham, AL
Faculty Academic Appointments
2010-Present

Clinical Assistant Professor, Dermatology, University2022-Present

Honorary International Professor, Dermatology,of Texas Southwestern Medical Center at Dallas
Apollo Hospitals Educational and Research
Foundation（AHERF）, India

64

Assistant, Associate, and full Professor ofSP3-3
Risk of cancer and opportunistic
infections：JAK inhibitors
versus biologics

SP3-4
How failure can lead to a careerin scientific dermatology
Alexander Enk

Martin Röcken

Department of Dermatology,

Department of Dermatology,

Heidelberg University

Eberhard Karls Universität

Hospital, Germany

Tübingen, Germany

Innate cytokines like tumor necrosis factor（TNF）and T cell-cytokines
like interleukin（IL-）2, interferon（IFN-）g, IL-4, IL-5, IL-13 and IL-17
critically affect innate and adaptive immune responses. Studies
investigating autoimmune encephalitis first proved that cytokines
produced by autoreactive T cells cause autoimmune diseases and then,that deviating the T cells producing pathogenic cytokines into IL-4producing Th2 cells cured autoimmune encephalitis. This was directlytranslated as IL-4-therapy of psoriasisʼ into humans, proving thathuman autoimmune diseases can be treated by targeting T cell
cytokines. Current therapies modulate T cell cytokines indirectly withcytokine antagonists that have longer half-lives. Many cytokineantagonists were developed as therapy of either psoriasis or atopic
dermatitis, but are now approved for various inflammatory diseases.
The safety concerns depend on the cytokine that is targeted and are
well predictable. When used correctly, most cytokine antagonists cansafely be used.
As many cytokines signal to the nucleus through Janus kinases（JAK）,
orally applicable small molecule JAK inhibitors（JAKi）were developed.
JAKi are approved as therapy of autoimmune and inflammatory
diseases. Yet, only 4 JAK molecules signal the message of ＞ 20
cytokines to the nucleus. Thus, all JAKi impair not one but manycytokine signals, and three of the four JAK transfer signals of thevarious IFN molecules that are needed for immune control of viruses,
intracellular pathogens and tumors. In consequence, JAKi increase therisk of these disease groups, and, in certain patients, the risks ofthrombosis or increased mortality. Regulatory agencies and pharmacompanies jointly published warnings.

［Biography］
1976 - 1983

［Biography］
Scientific education
1984 - 1988 Dissertation at the Dept. of Dermatol. of the
University of Münster
1990 - 1992 Post-doctoral fellowship at the Dermatol.
Branch of the National Institutes of Health1992 - now

Libre de Bruxelles（Belgium, 1976 - 1977）,Université de Lausanne1982 -1983）
Medical training and Consultant, Department of Dermatology andAllergology, City Hospital Munich Schwabing, Teaching Unit of
the Ludwig-Maximilians-Universität München（Germany）
1988 - 1991

Research grant of the Deutsche Forschungsgemeinschaft,1991 - 1993

Visiting Associate, Laboratory of Immunology, National InstituteDepartment of Dermatology, Université de Genève（Switzerland）
of Allergy and Infectious Diseases, National Institutes of Health,

1992 - now

Leader clinical studie, e.g. ADO, DKG andEORTC2015 - now

Speaker Combined Research Grant The skin

as mediator and orchestrator of cutaneous andsystemic immunity
Appointments
1997
Associate Professor and Vice Chairman, Dept.
Of Dermatol, Johannes-Gutenberg Univ.-Mainz
2002

Bethesda, Maryland（USA）
1993 - 1998

（Germany）

Marburg -Maximilians- Universität München（Germany）
2002 - present

2002

C3 Professor for Dermatology and Venereology, Medical Faculty,
Department of Dermatology and Allergology, LudwigC4 Professor for Dermatology and Venereology and Chairman,
Medical Faculty, Department of Dermatology, Eberhard Karls
Universität Tübingen（Germany）

Appointment as Full Professor and Chairman
Dermatology and Venereolgy, Philipps-Univ.

Assistant Professor, Medical Faculty, Department of Dermatology
and Allergology, Ludwig-Maximilians-Universität München

1998 - 2002

Projectleader in Research Group and in
Sonderforschungsbereichen der DFG aboutallergic and immunologic diseases of the skin

Medical Studies, Freie Universität Berlin（Germany）, Université（Switzerland, 1980 - 1981）and Universität Bern（Switzerland,

1984 - 1988

Research is often times driven by serendipity. Even
experimental failures, however, can be very stimulating
if analysed correctly. How an initial experimental failure
lead to a very fulfilling and fertile career for myself will
be pointed out in this lecture. Besides describing myinitial experiments in allergic contact dermatitis andthe role of DC and Treg, I will also cover in more details
my ongoing research on the role of Tregs in
autoimmune bullous disorders in the model of scurvy
mice. Besides describing my own research path, I will
also focus on the satisfiying side effects of life inacademic medicine.

Appointment as Full Professor and Chairman
Dept.of Dermatology and Venerol. Univ. Essen -2002 -2004

Appointment as Full Professor and Chairman
Dermatology and Venereolgy, Ruprecht-KarlsUniv. Heidelberg - acceptance65SP5-1
Messages to Young
Dermatologists：How to
Develop Your Clinical Skills

SP5-2
Messages to youngdermatologists：How todevelop your clinical skills

William D. James

Jean L. Bolognia

Professor Emeritus,

Yale University School of

University of Pennsylvania,

Medicine, New Haven, CT,

PA, USAUSA

We all wish to improve our clinical skills so that the best
outcomes can be achieved for every one of our patients.
How do you ensure this?
1．Read and study so you can generate a differential
diagnosis while speaking with the patient to get a proper
history. If you have never heard of a disease, you will notdiagnose it.
2．Listen to and believe the patient. What is their mainconcern? Cancer, infection, itch, pain, other? Enlist theirhelp, what makes it better/worse/what do they thinkcauses it?
3．Pay attention to enabling conditions such as travel, drugs,
pets, lifestyle, risk factors, sex, age, occupation, heredity.
4．Gather laboratory information. Only order what isindicated. If the biopsy findings are not concordant withyour expectations, and still is the case on re-biopsy, believe
live pathology over dead pathology（clinical over slides）.
Utilize
genetic
testing,
immunohistochemistry,
immunofluorescence, clonality studies as needed.
5．If two or more critical elements to a diagnosis are atypical,
consider an alternative diagnosis.
6．Treatment success depends on patient education about
the drug, the expected course and time of response,
potential side effects. See back when you expect
improvement. If not better and giving appropriate dose,
consider alternative diagnosis or alternative therapy.
Sometimes less is best.

Clinical skills in every medical specialty, including
dermatology, need to be built on a firm foundation.
The latter begins in medical school and includes
caring for sick patients, not just doing multiple
electives in dermatology. The importance offorming logical frameworks within oneʼs mind
cannot be overemphasized. Frameworks are based
upon synthesis not simply reading and require
multi-hour blocks of time without distractions. This
then leads to realistic differential diagnoses andbetter patient care. Additional important concepts
include simplifying not complicating, utilizing
analogues as memory tools, remaining flexible, andrecognizing clinical spectra given that medicine isakin to biology not chemistry. One must remain
curious and a lifetime student as well as
consistently going the extra mile for your patients.
［Biography］［Biography］

Jean Bolognia, MD, is Professor of Dermatology at the Yale

William D. James, M.D. graduated from the United States Military
Academy at West Point in 1972 and the Indiana University Schoolof Medicine in 1977. After his residency training in San Francisco,
Dr. James spent twelve years at the Walter Reed Army Medical
Center the last eight of which was as Chief of Dermatology. In
1995, Dr. James joined the Department of Dermatology at the
University of Pennsylvania School of Medicine where he served
as the Paul R. Gross Professor of Dermatology. He is currently an
Emeritus Professor. Dr. James served as President of theAmerican Academy of Dermatology in 2010. He has delivered
over 350 invited lectures and has received several local andnational teaching awards. He has published 400 articles, 40 bookththchapters
andhas written
or edited 23 books, including the 8 , 9 ,
th
th
th
th
10 , 11 , 12 and 13 editions of Andrewsʼ Disease of the Skin, as
well as two editions of the accompanying Atlas. He is the founding
Editor and co-Editor in Chief of the internet-based MedscapeDermatology reference. He trained over 160 residents and fellows
during 32 years as a residency and fellowship program director.

University School of Medicine. She has served as President

66of the Medical Dermatology Society, the Womenʼs
Dermatologic Society and the American Dermatological
Association, in addition to serving as Vice-President of theSociety of Investigative Dermatology, the American Boardof Dermatology, and the International Society of
Dermatology. She has also been elected to serve on the
Board of Directors of the American Academy ofDermatology and the International League of
Dermatological Societies and was Secretary-General of thelatter organization. Jean is the senior editor of the textbooks
Dermatology and Dermatology Essentials, which are in theirfifth and second editions, respectively.

SP6-1
How to publish your work from
UK

SP6-2
How to publish your work from
China

John A. McGrath

Qianjin Lu

St Johnʼs Institute of

Institute of Dermatology,

Dermatology, Kingʼs College

Chinese Academy of Medical

London, London U.K.

Sciences and Peking Union
Medical College, China

Publishing research and clinical data can be an important
step in advancing your professional career and contributing
to your field. This presentation will offer tips to succeed
including（a）how to choose the right journal,（b）theimportance of understanding journal guidelines, and（c）how
to engage in quality writing. Itʼs vital to read previous
articles in candidate journals to see if your work is a match,and to consider impact factor, reputation, and audience.
Other important factors include（d）creating an effective title（concise）and abstract（comprehensive and compelling）and（e）ensuring citations are accurate for the chosen journal.
Carefully following submission guidelines is essential in
improving the chances of your work being published. In
addition,（ f ） ethical considerations （ stating approvals,
conflicts of interest）（g）peer,
review（responding promptly
and professionally）（h）promotion,of open access（often arequirement）to boost visibility, and（i）engagement withthe academic community（online/meetings/networking）,
are all relevant to sustaining success in publishing. Also,
remember that the publication process can be competitive,
so persistence and continuous improvement are essential.
Seek feedback from mentors and colleagues and be open torefining your work based on constructive criticism.
［Biography］
John McGrath is the academic head of St Johnʼs Institute of
Dermatology in London where he also runs the Genetic Skin
Disease Group. He holds the Mary Dunhill Chair in
Cutaneous Medicine at Kingʼs College London and is
Honorary Consultant Dermatologist to the Guyʼs and St
Thomasʼ National Health Service Foundation Trust. His
expertise is in genodermatoses, discovering genes andtesting experimental therapies to improve patient care. He
has held several leadership positions within European
dermatology and been awarded multiple named
lectureships around the world, including the Dohi Memorial
lecture（JDA, 2010）and Tanioku Kihei Memorial lecture（JSID, 2012）. He has published ＞550 articles and will
become editor-in-chief of the British Journal of Dermatology
from July 2024.

Science entails communicating new and exciting findings todiverse audiences. Providing these audiences with data andfindings is an essential way for scientists to share their results.
The best strategy is to start with an outline, including figuring out
what the topic of my paper is. From there, it is critical to ask thefollowing questions when drafting the paper.
Why is this topic important? How can I formulate my hypothesis?
What are my results? What are my major findings? The next stepis to add context and structure. Here, you will group all your ideas
into sections：Introduction, Methods, Results, and Discussion/
Conclusion. This step will help add coherence to your work andsift your ideas. Moreover, it is also a critical part of the process inwhich we decide which publication we will submit the paper for.
Often people will come up with three choices and discuss themwith their mentors and colleagues. Having a list of journal
priorities can help you quickly resubmit your paper if your paper
is rejected. Moreover, it is respectful（and helpful）to the journalʼs
editors to provide a cover letter that effectively summarizes thework, emphasizes its importance, highlights its impact and future
potential on the community, explains why you feel that yourstudy merits publication, and include information about how thepaper should be of great interest to the journal, requests forexpedited review, or details about potential conflicts of interest.
Spending enough time to draft an informative, comprehensive,and concise cover letter is quite worthwhile；a poorly drafted one
would most likely not persuade the editor that the work is fit for
publication and may lead to immediate rejection.
Be prepared for revisions after the peer review, while respecting
editor and reviewer comments, and potential discussions foraddressing
unreasonable
feedback.
Upon
acceptance,
meticulously proofread the final version, ensuring formatting andcitation criteria adherence. Success in publishing high-impact
work relies on meticulous adherence to these steps, highlighting
the researchʼs significance and meaningful contribution toknowledge advancement.

［Biography］
Dr. Qianjin Lu is currently a Professor and Executive Director of Hospital for
Skin Diseases（Institute of Dermatology）, Chinese Academy of Medical
Sciences and Peking Union Medical College；Professor and Director of Key
Laboratory of Basic and Translational Research on Immune-Mediated Skin
Diseases, Chinese Academy of Medical Sciences；Immediate Past President ofChinese Society of Dermatology. His research focuses on the epigenetics ofautoimmune and inflammatory related skin diseases, including lupus, psoriasis
and atopic dermatitis. He has authored over 200 peer-reviewed manuscripts,
book chapters and review articles including Lancet, JAMA, Blood, Nat Commun,
J Clin Invest, Ann Rheum Dis and J Exp Med, etc. Dr. Lu is on the editorial boardof several journals in his field, and has been appointed as an associate editor of
Clinical Immunology, Experimental Dermatology. He also provides clinical careand teaching in the dermatology, and has accumulated rich clinical experience indermatology, especially in lupus and psoriasis.

67

SP7-1
Recent Advancements and New
Perspectives in Understanding
the Pathogenesis of Vitiligo

SP7-2
Landscape of Psoriasis
Management in Thailand
Pravit Asawanonda

Sang Ho Oh

Chulalongkorn University,

Department of Dermatology,

Bangkok, Thailand

Severance Hospital,
Cutaneous Biology ResearchInstitute, Yonsei University
College of Medicine, Seoul,
Korea

Vitiligo is a common acquired pigmentation disordercharacterized by the loss of pigmentation resulting from theelimination of melanocytes by T cells. Despite extensive past
research on vitiligo, identifying the primary cause has
proven elusive. Recent progress, however, has illuminatedthe mechanisms involved, particularly underscoring the roleof IFN-γ in driving vitiligo progression throughchemokines, facilitating T cell recruitment into the skin.
Through a definitive treatment has been absent for decades,
recent advanced research has confirmed the efficacy of JAK
inhibitors that impede IFN-γ in vitiligo. Consequently,
topical ruxolitinib was introduced as the first approved
treatment for vitiligo by the FDA. Currently, various
potential treatment targets have been proposed, awaiting
clinical trials, offering new hope to vitiligo patients andtreating physicians.
In this talk, I will delve into basic and translational researchstudies that offer insights into the pathogenesis of vitiligo.
Additionally, based on our laboratory works, I will address
new perspectives on vitiligo pathogenesis, focusing on the
key mediator involved induction and amplifying IFN-γ inoxidative stress-induced vitiligo. I will also discuss thepotential roles of ATP-P2X7 signaling in the pathogenesis ofvitiligo. Moreover, I will talk about the pathways by whichmelanocytes adhere to the basement membrane and discuss
any alterations in this attachment to the in the context ofvitiligo development.
［Biography］
1999
1999-20042010
2010-20162014-20162016-2021
2021-present
2023-present

2023-present

68

M.D., Yonsei University College of Medicine
Intern and Dermatology Resident, Severance Hospital,
Yonsei University Health System, Seoul, Korea
Ph.D., Yonsei University College of Medicine
Assistant Professor, Department of Dermatology, Yonsei
University College of Medicine
Visiting Professor, Department of Dermatology, Universityof Pennsylvania, Philadelphia, PA
Associate Professor, Department of Dermatology, Yonsei
University College of Medicine
Professor, Department of Dermatology, Yonsei University
College of Medicine
Chair, Department of Dermatology, Yonsei University
College of Medicine, Director of Cutaneous Biology
Research Institute, Yonsei University College of Medicine
Head of Department of Dermatology, Severance Hospital

Psoriasis, a chronic inflammatory skin disorder, presents a
distinctive set of challenges in its management, influenced
by genetic, environmental, and cultural factors. The actual
prevalence of psoriasis in Thailand, is unknown, yet appears
to be similar to other Asian countries. Genetic studies
suggest a potential role for ethnic factors, contributing to
the diversity of psoriasis manifestations observed in Thai
patients.
The therapeutic landscape for psoriasis in Thailand reflects
a blend of conventional Western medicine and traditional
Thai remedies. Dermatologists often face non-evidencebased locally sourced herbal treatments, while trying toprovide the best of care. Furthermore, the Thai healthcare
system places a strong emphasis on patient education andcommunity outreach programs, aiming to dispel
misconceptions surrounding psoriasis and reduce societal
stigmatization.
In conclusion, the practice of psoriasis management inThailand demonstrates a unique amalgamation of genetic,
cultural, and healthcare system factors. The incorporation of
traditional remedies, emphasis on patient education, andconsideration of the psychosocial impact distinguish theThai approach to psoriasis from global practices. A deeper
exploration of these distinctive features not only contributes
to a more comprehensive understanding of psoriasis but also
paves the way for tailored and culturally sensitive
interventions that address the specific needs of the Thai
population affected by this chronic skin condition.
［Biography］
Dr Pravit Asawanonda is a Professor of Dermatology at Chulalongkorn
University in Bangkok, Thailand. He also practices dermatology at
Bumrungrad International Hospital since 1998. His current
administrative position is Assistant Vice President of his University. He
also served as Associate Dean for Planning and Development at theFaculty of Medicine, Chulalongkorn University, between 2011-2015.
Within the Dermatological Society of Thailand, he now serves as thecurrent President.
Dr Asawanonda attended Chulalongkorn University in Thailand, where
he received his M.D. in 1988 and a Master of Science in Dermatology in1990. He went on to complete a clinical fellowship in Photobiology with
the Division of Dermatology at Ramathibodi Hospital, Thailand, before
heading to Boston for further training. In Boston, Dr Asawanonda
attained a clinical fellowship in Phototherapy and Lasers from
Massachusetts General Hospital, Harvard Medical School. He also
completed a research program with Boston University which
culminated in him receiving a Doctor of Science in Dermatology in 1998.

SP7-3Whatʼs New in the Pipeline forPemphigus?
Dedee F Murrell
Department of Dermatology,

SP7-4
Communication between
internal stem cell niche and theexternal environment：insightfrom hair follicles

St George Hospital, University

Sung-Jan Lin1,2）of NSW, Sydney, Australia

Departments of Biomedical
Engineering and Dermatology andResearch Center for Developmental
Biology and Regenerative Medicine,National Taiwan University1），
Center for Frontier Medicine andDepartment of Dermatology,
National Taiwan University
Hospital, Chinese Taipei2）

Apart from the FDA registration of rituximab for
pemphigus, there have been no approved therapies provenby randomized controlled trials. Systemic steroids were
grandfathered in for pemphigus because prior to theirdevelopment there was a 90％ mortality from the disease.
Traditionally, very high doses of oral glucocorticosteroids
were used, from 1mg/kg/d to 2-3mg/kg/d according to local
experience. The morbidity and mortality in pemphigus
nowadays comes mainly from the GCDs and othertraditional immunosuppressants. Only relatively recently
with the development of systematic reviews and theestablishment of the International Blistering Diseases Group
which has published consensus definitions and validated
outcome measures for pemphigus, have international
multicentre studies become possible, including the French
RCT of rituximab and the Roche sponsored trial of Rituxan
plus GCDs vs MMF plus GCDs. This lecture will focus on anumber of alternative ways of suppressing the innate andacquired immune abnormalities and signaling cascades inpemphigus, including CAART therapy, Bruton Tyrosine
Kinase Inhibitors, FcRN inhibitors, other CD19/20 inhibitors.
Should these trials be performed head to head vs GCDs in a
double-dummy design if there is proof of concept forsuccess, since GCDs are so powerful that adding a safe doseof an adjuvant may mask its beneficial effect and if botharms are given steroids, safety differences will be difficult to
detect.

For most mammals, hair serves as the first barrier that
protects and insulates our body from external insults.
When skin is injured or the hair coat is impaired,
prompt transition from a resting to a growing phase toregenerate new hair enables timely recovery of thisimportant protective barrier. Hair follicle regenerationis powered by epithelial hair follicle stem cells（eHFSC）
whose activity is subject to tight regulation by theirniche. In adaption to the ever-changing external
environment and physiological and non-physiologicalchanges of skin, eHFSC niche must be endowed withthe ability to detect these alterationg and responds
adaptively to modulate eHFSC activity for organismal
needs. In this talk, I will demonstrate how the eHFSC
niche enables eHFSCs to detect external light andtemperature changes for hair follicle regeneration. I will
also talk about how inflammation triggered by skinirritation and injury modulates eHFSC metabolism topromote hair growth. Targeting these pathways can be
new strategies for the treatment of alopecia.
［Biography］［Biography］
Professor Dedee Murrell is Chair of the Department of
Dermatology at St George Hospital, University of NSW, in
Sydney, Australia. She completed medical training at
Cambridge and Oxford Universities, 3 years of internal
medicine in the UK and USA, dermatology training at UNCChapel Hill, a fellowship in dermatopharmacology at Duke,blistering diseases and cell biology at New York University,and then became a clinical scholar at Rockefeller University.
She holds a doctorate on the pathogenesis of blistering
disorders. Her current research focusses on thedevelopment and validation of clinical outcome measures for
autoimmune blistering diseases and epidermolysis bullosa toenable clinical trials to proceed in these orphan diseases.

Dr. Sung-Jan Lin is Chairman of Department of Biomedical Engineering, Taiwan
Bio-development Foundation（TBF）Chair in Biotechnology and Director of
Research Center for Developmental Biology and Regenerative Medicine at
National Taiwan University, Taiwan. He is also a dermatologist and serves as
Director of Center for Frontier Medicine at National Taiwan University Hospital.
He received his MD and PhD from College of Medicine and College ofEngineering in National Taiwan University. He takes hair follicles, a miniorganwith distinct structures and growth cycles, as a model to understand how acomplex organ interacts with the environment and reacts to various insults, suchas radiotherapy and chemotherapy, and to decipher the principles andmachinery of tissue regeneration. His research interest includes hair follicles,
melanocytes, wound healing, radio-/chemo-therapeutic injuries and biomedical
optics. His lab employs a multidisciplinary approach by combing the knowledge
learned in biology and tissue engineering to enhance tissue regeneration. He has
published 〜150 journal papers in associated journals, including Cell, Science,
PNAS, Nature Communications, JID, Biomaterials, Optics Letters, etc. In 2014, he
was elected as Taiwan Bio-development Foundation（TBF）Chair in
Biotechnology. His work has been recognized by Award for Junior Research
Investigators in Life Science of Academia Sinica, Physician Scientist Award of
Taiwan National Health Research Institutes, Distinguished Research Award of
Taiwan Ministry of Science and Technology and Outstanding Professor Awardof Far Eastern Y.Z. Hsu Science and Technology Memorial Foundation.

69

SP9-1
What is ILDS
Lars E. French1,2）
Department of Dermatology andAllergy, University Hospital,
Ludwig Maximilan University（LMU）Munich, Munich,Germany1），Dr. Philip Frost
Department of Dermatology andCutaneous Surgery, University ofMiami Miller School of Medicine,
Miami, FL, USA2）The ILDS is a unique umbrella organization for professionaldermatology organizations of all sizes that represents
dermatology at the highest level through its official relations
status with the World Health Organization（WHO）,championing
dermatology and skin health to ensure its inclusion in global
health policy.
The vision of the ILDS is to attain the best possible skin health for
all people around the world. Its mission is to increase awareness,cooperation, and communication within the global dermatology
community to promote high quality education, clinical care,research and innovation that will improve skin health globally.
The ILDS has several key activities and runs a series of programs
that all have the aim of improving skin health for the world. The
key activities are：i）collaborating with the WHO within our
status of official relations with the WHO, ii）organizing the 4yearly World Congress of Dermatology, and iii）carrying out
humanitarian work through our Foundation, the International
Foundation for Dermatology（IFD）. Details on our key activities
and programs will be presented during my lecture and can also
be found at www.ilds.org.
Amongst our programs, the new kid on the block is the recently
launched ILDS Program Global Partnerships for Education andCare（GPEC）. GPEC aims to improve access to education andcare at a global level by fostering and managing a global programof partnerships between dermatology departments to raise thelevel of education and care worldwide.
With an outstanding board of directors composed of leading
dermatologists worldwide under the direction of ILDS Prof Henry
Lim, and an administrative office led by CEO Arpita Bose, the
ILDS is well positioned to achieve our vision of Skin Health for
the World by working with others in the context of global
partnerships for skin health.
Keywords：skin health, global dermatology, WHO, World
Congress of Dermatology, humanitarian dermatology, policy

SP9-2
25th World Congress of
Dermatology July 2023
Brief report
Roy ChanSkin Research Institute,
Republic of Singapore

The World Congress of Dermatology is a premier event in thefield. It serves as an occasion where experts, both seasoned andemerging, can connect with and inspire one another, paving theway for transformative breakthroughs that can shape the futureof dermatology.
th
The theme for the 25 WCD was - Dermatology Beyond Borders,
Science, Care, Communities . This theme could not have been
more apt in these times of pandemics, geopolitical tensions, andenvironmental disasters. As physicians, healthcare providers,scientists, and advocates we need to strive for the betterment ofmankind by keeping the platforms of discussion and channels ofcommunication open. It was attended by over 12 thousand
delegates from 148 countries.
The scientific programme covered all subspecialties, frommedicine to surgery, from infections to aesthetics, from cancers topigmentation, from paediatrics to the elderly, from basic science
to quality of care to the use of AI, from dermatopathology to STIs,
from universal problems like eczema and psoriasis to tropicaldiseases that affect our region, and everything else in between.
There were 208 sessions for the 60 symposia topics. There weregreater numbers and the proportions of chairs, cochairs sandspeakers from areas outside of North America and Europe thanever before.
We received 5147 abstracts, 4639 abstracts were accepted as eposters；408 were chosen for 51 Free communications oral
sessions, 60 for 12 Residents Sessions, and 40 were presented in 5
Late-breaker sessions. There were 30 sessions organised by the
Dermatological Society of Singapore and the League of ASEAN
Dermatological Societies that shone the spotlight on this part of
the world.

［Biography］
April 1988 - April 1990

Resident in Internal Medicine, Geneva University Hospital, CH

April 1990 - Oct.1993

Research fellow in cell and molecular biology, Geneva
University, CH

Oct. 1993 - Dec. 1996

Resident in Dermatology, Geneva University Hospital, CH

Jan. 1997 - Oct. 2002

Swiss National Science Foundation Career Development

Oct.1999 - Oct. 2000

Visiting Clinical and Research Fellow, Dermatology,

Oct. 2002 - April 2003

Associate Professor, Dermatology Department, Geneva

May 2003 - Sept. 2006

Louis-Jeantet Professor of Medicine, Geneva University

Oct. 2006 - Oct. 2018

Professor and Chairman, Dermatology Department, Zurich

Nov. 2018 -Professor and Chairman, Department of Dermatology,

Award, Geneva University, CH
University of Pennsylvania, PA, U.S.A
University Hospital, CH
Hospital, CH
University Hospital, CH
Ludwig Maximilian University, Munich, DE

70［Biography］
I was born and educated in Singapore. My medical training was at the
University of Singapore. I received post graduate training in internal medicine in
London, in dermatology at St Johns Institute of Dermatology, STI at St Stevens
Hospital, and public health in HIV at UCLA.
My dermatological career started at the Middle Road Hospital in the 1980s andcontinued at the National Skin Centre. I was appointed Director of the NSC from2004 to 2014, where I am currently Senior Consultant and Medical Advisor. I was
inaugural Chairman of the Chapter of Dermatologists, as well as the first
Executive Director（Clinical）of the Skin Research Institute of Singapore（SRIS）.
My other appointments include Clinical Professor at NUS YLL School of
Medicine, Adjunct Professor in NTU-Imperial College LKC School of Medicine,and Adjunct Professor in NUS SSH School of Public Health.

SP9-3
Looking forward to the 26th
World Congress of Dermatology
Guadalajara

SP11-1
Atopic dermatitis from bedside
to bench ＆ beyond：focusing
on itch ＆ environmental exposures

Jorge Ocampo Candiani1,2）

Chih-Hung Lee

Presidente Congreso Mundial

Department of Dermatology,

de Dermatologia Guadalajara

Kaohsiung Chang Gung

1）

2027 ，ExPresidente delMemorial Hospital, Kaohsiung,

CILAD（Colegio

Taiwan2）

Iberolatinoamericano）

The 26th World Congress of Dermatology descends upon the vibrantcity of Guadalajara, Mexico on June 21-26, 2027. Together with the
Mexican Academy of Dermatology, the Mexican Society of
Dermatology, the Mexican Society of Dermatologic Surgery ＆Oncology, the Mexican Society of Dermatological Cosmetic and Laser,
and all the countries of Latin America, we are honoured and proud towelcome the international dermatological community to Guadalajara. Itsworld-class infrastructure and passionate medical community create an
ideal setting for fostering such an important congress. With its
significant landmarks, Guadalajara is the capital of the Mexican state of
Jalisco. According to the World Tourism Organization of the United
Nations, Mexico is the second country in the world in terms of number oftourists, after France, and Guadalajara stands out as one of the safest
cities in Latin America. With direct flights going from Tokyo to Mexico
City, and daily flights coming in from Canada and the USA, the city
offers a wide range of hotel accommodation, with more than 350 hotels
within the city, and thousands of rooms walking distance from the Expo
Convention Center, the largest in Latin America. Lars French, Chair of
the Scientific Program Committee, and Manabu Fujimoto, Vice Chair of
the Scientific Program Committee, are eagerly working on an inclusiveand high-quality scientific program. The overarching theme of WCD
2027, Discover the Dermatology Ecosystem. For a Diverse andInclusive Future, emphasizes the interconnectedness of dermatologyʼsdiverse disciplines and the need for inclusivity to advance the field. The
NOC, composed of 50 important Mexican dermatologists, is alreadyworking to grant the most memorable experience ever.

［Biography］
Chairman at the Dermatology Department University of Nuevo Leon, Monterrey, Mexico.
Assistant Professor of Dermatology University of Nuevo Leon, Monterrey, Mexico.
Director of Dermatologic Surgery
Dermatology Department, University of Nuevo Leon, Monterrey, Mexico.
Private Practice in Dermatology and Dermatologic Surgery Medipiel Centro
Dermatológico, Monterrey, Mexico.
National System Researchers Level III. Conacyt
Member of 19, National and International Societies.
President World Congress of Dermatology WCD Guadalajara 2027
Member of the Executive board of the ISD（international Society of dermatology）
Member of the Mexican Academy of Sciences, the Mexican Academy of Surgery and the
National Academy of Medicine.
Board Member of the International League of Dermatological societies（ILDS）
Former International Board Observer, American Academy of Dermatology.
Former president at the International Society for Dermatologic Surgery.
Former president at the Mexican Society of Dermatologic Surgery.
Former president at the Ibero-latinamerican College of Dermatology.
Former Member of the International Affairs Committee,
American Academy of Dermatology.
Member of the board, Skin Cancer Foundation.
Author of 513 articles in national and international journals. 303 indexed at the Index
Medicus. 3985 citations
Author of 6 books of Dermatology and 55 chapters
Editor of one journal of Dermatology（DCMQ）and member of the board for several
others.

Atopic dermatitis（AD）is a common skin disease with intense
pruritus, featuring the host ＆ environmental interactions. TEWL
＆ blood β-endorphin（BE）are independently associated with itch
intensity. The increased blood BE ＆ IL-31 are significantly
associated. IL-31 activation in keratinocytes induces calcium
influx ＆ BE production. The genetic polymorphisms of ORAI1, an
important molecule in calcium influx, are distinct in AD patientsfrom Japan ＆ Taiwan. By near infra-red spectroscopy, wedemonstrated the temporal and spatial propagation of itch signals
in human cortex. We reported lifetime smoking exposure
increases the AD risk. The aryl hydrocarbon receptor（AhR）acts
an environmental sensor regulating immune responses. AhR
activation by benzopyrenes（BP）, a major PAH in smoke, isaccentuated in AD. In mice, BP increases Langerhans cell（LC）
migration in vivo ＆ increases Th2 cytokines, which are
obliterated in AhR defected mice. We further investigated the-/role of AhR in LC and showed that Langerin-AhR mice harbored
fewer epidermal LC with stunted dendrites, while enhancing Th2
and Tr1 responses. In summary, the advances in thepathophysiology ＆ environmental interactions facilitate thetailored treatments ＆ preventive measures for AD
managements.

［Biography］
2021-present

Chair, History and Literature Committee, Kaohsiung Chang Gung

2021-present

Chair, Center for Medical Humanity, KCGMH, Kaohsiung, Taiwan

Memorial Hospital（KCGMH）
2018-present

Full Professor, Department of Dermatology, Chang Gung University（CGU）, Taoyuan

2017-present

Clinical Professor, Department of Dermatology, KCGMH

2014-2019

Chair, Department of Dermatology, KCGMH, Kaohsiung

2014-2017

Associate Professor, Department of Dermatology, CGU, Taoyuan

2013-present

Attending Physician, Department of Dermatology, KCGMH, Kaohsiung

2008-2013

Chair, Department of Dermatology, Kaohsiung Municipal Hsiao-Kang

2012-2013

Associate Professor, Department of Dermatology, Kaohsiung Medical

2003-2013

Attending Physician, Department of Dermatology, KMU Hospital,

2009-2012

Assistant Professor, Dermatology, KMU, Kaohsiung

2004-2006

Visiting Fellow, Dermatology Branch, Center of Cancer Research, NCI,

1999-2003

Resident, Dermatology, KMU Hospital

Hospital, Kaohsiung
University（KMU）
Kaohsiung

NIH, Bethesda, MD, USA71

SP11-2
Uncovering the Biology ofRegulatory T cells in Skin

SP14-1Skin Deep：The Science of
Aesthetic Dermatology

Michael Rosenblum

Rachel Watson1,2）

UCSF Deptartment of

A*STAR Skin Research

Dermatology, USA

Labs1），Skin ResearchInstitute of Singapore,Republic of Singapore2）

Immune tolerance is maintained in lymphoid organs（LOs）.
Despite the presence of complex immune cell networks in
non-LOs, it is unknown if self-tolerance is maintained inthese tissues. We developed a technique to restrict genetic
recombination to regulatory T cells（Tregs）only in skin.
Selective depletion of skin Tregs resulted in T cell-mediatedinflammation of hair follicles（HF）.Suppression did not relyon CTLA-4, but instead on high affinity interleukin-2（IL2）receptor expression by skin Tregs, functioning
exclusively in a cell-extrinsic manner. In a novel model of HF
stem cell（HFSC）driven autoimmunity, we reveal that skin
Tregs immunologically protect the HFSC niche. Finally, we
utilized spatial transcriptomics to identify aberrant IL-2
signaling at stromal-HF interfaces in a rare form of humanalopecia characterized by HFSC destruction and Alopecia
Areata. Collectively, these results reveal the fundamental
biology of Tregs in skin uncoupled from the systemic pooland elucidate a mechanism of self-tolerance.
［Biography］
Dr. Rosenblum received his medical degree and PhD from
the Medical College of Wisconsin. Subsequently, hecompleted his dermatology residency training at UCSF in
the prestigious Physician-Scientist Training Pathway. He
joined the UCSF faculty in 2012 and since that time has
become one of the worldʼs leading skin immunologists. Dr.
Rosenblum is a recipient of the Burroughs Wellcome Fund
Career Award for Medical Scientists, the NIH Directorʼs
New Innovator Award, the Dermatology Foundationʼs
Charles ＆ Daneen Stiefel Scholar Award in Autoimmune ＆Connective Tissue Diseases, as well as multiple NIH R01 ＆
R21 awards. Dr. Rosenblum was named the William
Montagna Lecturer by the Society for Investigative
Dermatology. He was the scientific co-founder of Delinia Bio.,
which was acquired by Celgene in 2017. Dr. Rosenblum isalso a co-founder of TRex Bio., Radera Bio., and Sitryx Bio.
He is currently the Vice Chair of Research for the UCSF
Department of Dermatology and has authored over 100
basic science research papers.

72

Ageing of human skin is the composite of intrinsic,
natural ageing plus the cumulative exposure to
extrinsic factors, such as ultraviolet radiation（UVR）,which is particularly evident in body sites,
like the face and hands, which are habitually
exposed. These long-term exposures promotewrinkle formation and loss tissue elasticity. Whilstboth ageing processes are associated withphenotypic changes in cutaneous cells, the major
functional manifestations of ageing occur as aconsequence of structural and compositional
remodelling of dermal normally long-lived
extracellular matrix proteins. In this lecture, I will
review remodelling of the dermal extracellularmatrix, its mechanism and further explore
phenotypic differences, both in Caucasian skin andacross ethnicities and comment on how thesechanges to the organisation of the tissue results inaltered cutaneous physiology.
［Biography］
Rachel Watson was Professor of Cutaneous Science at the
University of Manchester, prior to her recent appointment
as Executive Director of both the A*STAR Skin ResearchLabs and the Skin Research Institute of Singapore. She
received her BSc（Anatomy ＆ Cell Biology）and PhD
degrees from the University of Sheffield. Rachel was
instrumental to the development of the MSc in Skin Ageing＆ Aesthetic Medicine at the University of Manchester andcontinues to contribute, via editorial boards, to a number ofprestigious international journals, including the British
Journal of Dermatology . Rachel has served on the Executive
Committee of the British Society for Investigative
Dermatology, the Research Committee of the British
Association of Dermatologist as well as the Steering
Committee for UK-TREND and is currently a Board
Member of the European Society for DermatologicalResearch. In recognition of her scientific achievements, shebecame the first non-clinical scientist to be awarded the
Honorary Fellow of the Hungarian Dermatological Society in2016.

SP14-2
ABO blood type sugars in brickand mortar
Jin Ho Chung

SP15-1
Overcoming Immune
Checkpoint Inhibitor Resistanceto Improve Melanoma Therapy

Department of Dermatology,

Nikolas Haass

Seoul National University

Frazer Institute；Faculty ofCollege of Medicine, Seoul

Medicine；The University of

National University, Seoul,

Queensland；Brisbane,

Korea

Queensland, Australia

Glycosylation is a common post-translational modification ofproteins, which regulates the stability, activity, ligand
affinity, and solubility of target protein. Most cell surface andsecretory proteins are known to be glycosylated. ABH
antigens, determinants of the ABO blood group system, are
one of the most well-known glycans. A and B antigens
consist of six monosaccharides with biantennary structure,
which differ from one terminal sugar unit. In contrast, H
antigen is the precursor glycan of A and B antigens withfive monosaccharides. Even though they were firstly
discovered in red blood cells, many other organs express
ABH antigens, especially in epithelium such as
gastrointestinal tract, respiratory tract, urinary tract andskin.
Skin is the largest organ in the body, which serves as aphysical and permeable barrier against external
environments. ABH antigens are also expressed inepidermis；A and B antigens are expressed in horny layer
and granular layer, whereas H antigen is expressed in horny
layer, granular layer and upper spinous layer. We confirmedthat many proteins, including desmoglein-1, desmoglein-2
and corneodesmosin, are actually conjugated with ABH
blood type antigens. In our laboratory, we are having
interests in the roles of blood type sugars in barrier function
in human skin. In this talk, I will show our results,suggesting that ABH blood type sugars are importantcomponents in brick and mortar structure and play
important roles in barrier functions in our skin.

Despite the unprecedented success of immune checkpoint
inhibitors（ICI）in cancer therapy, one major unresolved
dilemma is treatment resistance. Immunogenic cell death（ICD）constitutes a prominent pathway for the activation ofanti-cancer immunity, which in turn determines the longterm success of anticancer therapies. Only a few agents canelicit bona fide ICD, including the proteasome inhibitor
bortezomib, as demonstrated in malignant myeloma andmantle cell lymphoma, but not yet in melanoma.
We show that bortezomib causes ICD in vitro throughinduction of endoplasmic reticulum stress, autophagy andapoptosis and through translocation and/or secretion ofdamage-associatedmolecular
patterns （ DAMPs ）.
Vaccination with bortezomib-treated apoptotic melanoma
cells induced tumor immunogenicity in vivo . Intralesional
injection of bortezomib synergized with subsequentsystemic treatment with ICI. Re-challenge demonstrated
long-term protection through bortezomib combined with
ICI. Polyfunctional T cell assays revealed that intralesionalbortezomib injection generates a tumor-specific T cell
response. Importantly, ICI resistance was reverted bybortezomib-induced immunogenicity. Bortezomib induces
ICD in vitro and immunogenicity in vivo. Bortezomibinduced ICD recruits inflammatory immune response to thetumor site. Bortezomib-induced ICD improves ICI treatment
and reverts resistance re-sensitizing mice refractory to ICI.
We propose intralesional injection of bortezomib followed bysystemic ICI to improve immune therapy in melanoma.

［Biography］
1985.03-1988.02
1988.03-1991.04
1991.05-1993.02

1993.03-2006.02

1997.03-1999.02
2006.03-Present

Resident, Department of Dermatology, Seoul
National University Hospital, Seoul, Korea
A staff doctor, Department of Dermatology, Capital
Armed Forces General Hospital, Seoul, Korea
Research Fellowship, Department of Dermatology,
Seoul National University College of Medicine,
Seoul, Korea
Instructor, Assistant Prof., and Associate Prof.,
Department of Dermatology, Seoul National
University College of Medicine, Seoul, Korea
Research Fellow, Department of Dermatology,
University of Michigan, USA
Full Professor, Department of Dermatology, Seoul
National University College of Medicine, Seoul,
Korea［Biography］
Nikolas Haass is a clinician scientist and academic leader with researchin melanoma cell biology and experimental melanoma therapy. He
received his degree in medicine from the University of Heidelberg,
Germany（1990-1998）. He graduated summa cum laude with a PhD in
Cell Biology from the University of Heidelberg（1993-1999）and trainedin clinical dermatology at the University of Hamburg, Germany（19992003）. In 2003 he moved to Philadelphia, PA, USA, for a German
Research Foundation（DFG）-sponsored post-doctoral fellowship in
Meenhard Herlynʼs lab at The Wistar Institute at University ofPennsylvania（2003-2007）. From there he was recruited as an associatefaculty member and senior lecturer to Wolfgang Weningerʼs lab at theCentenary Institute and the Department of Dermatology at University
of Sydney（2007-2013）. In 2013 he commenced his current position as
Professor for Cutaneous Oncology at the Frazer Institute at Universityof Queensland.

73

SP15-2
Innovations in Scar
management outline

SP15-3
Hair and nail relationship
Dongyoun Lee

Hong Liang Tey

Department of Dermatology,

National Skin Centre,

Samsung Medical Center,

Republic of Singapore

Sungkyunkwan University,
Seoul, South Korea

Hypertrophic scarring, prevalent post-surgery（40-70％）and
particularly after burn injuries（up to 91％）, poses asignificant clinical challenge. Notably, black and Hispanic
populations exhibit keloid incidence rates of 4-16％,
contrasting with below 1％ in Caucasians. Existingtreatments are limited, with intralesional steroid injections
being the mainstay. However, many patients are unable totolerate intralesional injection due to pain, hyperalgia andallodynia in the pathological scars. Addressing this, wedeveloped
triamcinolone-embedded
dissolvablemicroneedles. Implemented at the National Skin Centre,
Singapore, version 3 of the product is now available topatients, with enhanced effectiveness and usability.
To pre-empt pathological scar formation, we developed asilencing RNA（siRNA）-embedded dissolvable microneedle
patch. This involves siRNA binding to mRNA, inhibiting
SPARC protein translation and reducing formation ofcollagen bundles. The siRNA is encapsulated in a nanoplex,
safeguarding it from degradation and facilitating fibroblast
receptor binding. Administered through dissolvablemicroneedles, this method ensures precise delivery to theright cells in the right organ, overcoming a key challenge in
RNA therapeutics. Positive results from cellular, animal, andclinical studies prompted the commercialization of thesiRNA microneedle patch, indicated for improving postsurgical scarring. Leveraging dissolvable microneedles andRNA therapeutic platforms, we are continuing to further
develop targeted therapeutics for improving the clinicalmanagement of scars and other skin diseases.

The hair follicle（HF）and nail unit are major skinappendages that share various characteristics. In the HF,
the follicular dermal papilla（DP）, a specialized hairmesenchyme at the base of the HF that is histologicallydistinguishable from the surrounding dermis, is comprisedof specialized hair mesenchymal cells that are distinct fromdermal fibroblast and can induce HF development in vivo.
The epithelial components of the nail unit include the nailmatrix, nail bed, and nail plate. The nail plate is produced by
the growth and differentiation of the nail matrix cells and is
attached to the nail bed, which may also contribute to nailformation. We identified and characterized specialized
mesenchyme and mesenchymal cells beneath the nailmatrix and nail bed in the human nail unit, and we proposed
to name them onychodermis（OD）and onychofibroblasts,
respectively.
We recently performed digital spatial profiling and singlecell RNA sequencing to define a spatially resolved
expression profile of the human nail unit and hair follicle.
Our approach showed the presence of a nail-specificmesenchymal population called onychofibroblasts within the
OD. OD and follicular DP both expressed Wnt and BMP
signaling molecules. In addition, nail matrix epithelium andhair matrix showed very similar expressions profile,including the expression of hard keratins and HOXC13, atranscriptional regulator of the hair shaft. Integration of
single-cell RNA sequencing and digital spatial profiling data
through computational deconvolution methods estimatedepithelial and mesenchymal cell abundance in the nail- andhair-specific regions of interest and revealed closetranscriptional similarity between these major skinappendages.
［Biography］［Biography］
A/Prof Hong Liang Tey is the Head of Research at the National
Skin Centre, Singapore, the Clinical Director at the Centre forMedtech and Innovations, National Healthcare Group, and the coDirector of Skin Research Programme at Lee Kong Chian
Medicine, Nanyang Technological University.
A/P Teyʼs clinical and research interest is in neurodermatology,
which comprises itch and sweat disorders. His works include 11
patent family filings, ＞200 international publications, and 20
products across 16 countries. Clinically, he has instituted 4 novel
patent-filed treatments and initiated 3 new clinical services in
Singapore. He is the recipient of the National Medical ResearchCouncil Clinician Scientist Award in 2018 and 2021, and the
National Healthcare Group Outstanding Citizenship Award andInnovator of the Year（2020）Award.

74

Dr. Dongyoun Lee graduated from Seoul National University（M.D., Ph.D.）andcompleted his dermatology residency and fellowship at the Seoul National
University Hospital.
Since 2002, he has been worked at Department of Dermatology, Samsung
Medical Center, Sungkyunkwan University as an assistant professor, associate
professor and professor. He was a chair at Department of Dermatology,
Samsung Medical Center, Sungkyunkwan University between 2017 and 2023.
He studied innate immunity in sebocytes as a research fellow under theguidance of Professor Richard Gallo in the Department of Dermatology, UCSD
from 2006 to 2008.
He is a founder of Korean Nail Society（KNS）. In addition, he is one of foundersof Asian Society of Dermatopathology（ASD）. Now, he is a president of Korean
Society for Investigative Dermatology（KSID）and vice president of Korean
Society for Vitiligo and Pigment Cell Research. He is a director of Korean
Dermatology Association and Korean Society of Dermatopathology. He is also aboard member of Coulcil for Nail Disorders（USA）.

SP15-4
Cutting-edge insights into theuse of photodynamic therapy indermatology

SP15-5
Atopic Dermatitis in Taiwan：
A translational approach
Chia-Yu Chu

Leihong Flora Xiang

Department of Dermatology,

Department of Dermatology,

National Taiwan University

Huashan Hospital, Fudan

Hospital and National Taiwan

University, Shanghai, China

University College ofMedicine, Chinese Taipei

ALA-PDT is a drug-device combination therapy that has been
widely used and rapidly developed in recent years. ALA-PDT
treatment of various cutaneous warts, such as Condyloma
Acuminata, verruca plana and plantaris, verruca vulgaris, offers ahigh cure rate, low recurrence rate, minimal wounding, and noscar formation post-treatment. In China, Condyloma Acuminata isa first approved indication for ALA-PDT. By adjusting the area ofdressing and illumination, ALA-PDT can simultaneously remove
subclinical and latent infections alone with the lesions, thereby
achieving complete removal.
Photodynamic therapy has advantages in the treatment of
precancerous lesions and skin tumors. ALA-PDT for actinic
keratosis（AK）has a high cure rate, low recurrence rate and good
cosmetic effect, particularly for AK on the head and face, and incases of multiple or large area AK. ALA-PDT is suitable forBowenʼs Disease（BD）patients who cannot tolerate surgery, or
are unsuitable or unwilling to undergo it due to the aesthetic andfunctional impacts following the surgical resection in specificareas. ALA-PDT effectively treats superficial BCC and nodular
BCC with an invasive depth of less than 2mm, offering efficacy
comparable to surgery and superior cosmetic results.
PDT can be used to address multiple aspects of acne
pathogenesis. ALA-PDT is effective and safe in treating moderate
to severe acne and severe acne. The Expert Consensus on theClinical Use of Aminolevulinic Acid Photodynamic Therapy for
the Treatment of Acne vulgaris will be shared.
ALA-PDT has been reported in the literature to have significant
efficacy in treating Bowenʼs papulosis, extramammary Pagetʼsdisease（EMPD）, sclerosing atrophic lichen planus, hydradenitis
suppurativa, cellulitis of the scalp, and photodamage.
Photodynamic diagnosis（PDD）has been increasingly used indiagnosising skin diseases, owing to its high selectivity, noninvasiveness and simplicity. Currently, PDD is still in the research
stage, and it is anticipated to have broader prospects indermatological applications.

Atopic dermatitis（AD）is a heterogeneous disease that is clinicallycharacterized by various subtypes based on different populationgroups. AD can be classified into different clinical phenotypes
according to serum IgE levels（extrinsic or intrinsic）, ethnicity（European American, Asian, or African American）, and age（pediatric or adult）. With the understanding of cutaneous
pathomechanisms via translational medicine, there is advanced
classification of AD by tissue molecular features（so called
endotypes）. According to molecular profiling performed inaffected skin, AD is associated with a polarized, type 2 immune
axis. However, several recent studies demonstrate that AD is nota homogenous disease. AD presentations are diverse acrossdifferent populations, and it may be categorized into multiple
clinical phenotypes depending on the underlying endotype.
Asian patients with AD present with a unique immune phenotype
that combines the characteristics of AD and psoriasis and might
require new clinical trials with specific cytokine antagonists, inaddition to TH2-specific therapies. Therapies targeting otherimmune cells, cytokines or chemokines may lead to personalized
or precision medicine approaches for the various AD subtypes.
This fundamental heterogeneity of AD highlights the importanceof recognizing the clinical response to targeted therapeutics could
hypothetically result in the classification of patients with AD into
distinct therapeutic phenotypes.

［Biography］
1998-2002

Resident, Department of Dermatology, National Taiwan

2002-

Attending Doctor, Department of Dermatology, National

2007-2008

Training for interviewer and reviewer,

University Hospital, Taipei, Taiwan
Taiwan University Hospital, Taipei, Taiwan
Dokumentationszentrum schwerer Hautreaktionen（dZh）,
Universitäts-Hautklinik, University Medical Center Freiburg,［Biography］
Dr. Xiang is the executive deputy director of Institute of Dermatology at Fudan
University and a Professor ＆ Vice Chairman of the Department of Dermatology
at Huashan Hospital, Fudan University. She graduated from Shanghai Medical
University in 1992, and completed her residency program and got PhD degree in
Huashan Hospital in 1999. She was trained as clinical observer in department ofdermatology, Harvard Medical School in 2005.
She is currently Vice-President of China Dermatology Association（CDA）,
President of Asian Society of Pigment Cell Research（ASPCR）and Board
member of International Federal of Pigment Cell Society（IFPCS 2017-2020）,
Council member, Asian Dermatology Association（ADA）（2020-2023, 20232026）, and Associate Editor for Journal of Investigative Dermatology（2022.6-）and Photodermatology, Photoimmunology ＆ Photomedicine（2022.2-）.

Freiburg, Germany
2008-2013

Assistant Professor, Department of Dermatology, National

2008

Visiting Professor, Department of Dermatology, University of

2008-2010

Clinical Research Fellow, Department of Dermatology, Henri

2013-2018

Associate Professor, Department of Dermatology, National

2018-

Professor, Department of Dermatology, National Taiwan

Taiwan University College of Medicine
Paris（XII）,France
Mondor Hospital, Paris, France
Taiwan University College of Medicine, Taipei, Taiwan
University College of Medicine, Taipei, Taiwan

75

Educational Lecture
EL24-1EL24-3

How to develop your career and leadership skills

Career and Leadership Development―Lessons forJapanese Dermatologists

Jean L. Bolognia

Pawinee Rerknimitr

Yale University School of Medicine, New Haven, CT, USA

Department of Medicine, Chulalongkorn University, Bangkok,
Thailand

While planning ahead and having future goals can lead tosuccess, one also needs to embrace fate. It is important toself-identify talents, maintain passion, and thencompartmentalize in order to maintain focus and avoid
distractions. Establishing a gig or two based upon hard
work, synthesis, and constant curiosity is an additional key
endeavor. Early on, having confidence may be difficult but
over time and as experience grows, so will confidence but
it must be balanced by humility. One must learn how to
say no and sometimes this is the most difficult skill toacquire. Leaders also question dogma, simplify rather thancomplicate, remain flexible and openminded, help the
careers of others, possess high standards without
becoming elitists, and maintain a strong moral compass.
By combining courage and integrity, one builds trust. The
best compliment one can receive is I trust you and thisis key for any leader.

As a dermatologist in Thailand, career advancement and leadershipskill development require a strategic combination of continuous
learning, practical experience, and targeted research focused on local
dermatological needs. Keeping abreast of the latest advancements
through educational activities is essential. Engaging in research that
addresses specific skin conditions prevalent in Thailand is crucial, as it
not only enriches practical knowledge but also contributes significantly
to the regional healthcare landscape. Developing soft skills, especially incommunication and emotional intelligence, is fundamental for effective
patient interaction and team leadership. Actively seeking feedback,pursuing mentorship, and building networks within the medical
community are vital for professional growth. Embracing leadershiproles in clinical settings and research initiatives enhances hands-on
experience. Maintaining a balance between professional responsibilities
and personal well-being is key to resilience and adaptability in a
dynamic healthcare setting. This comprehensive approach, which
integrates clinical practice with research attuned to local needs, aims toelevate both clinical and leadership excellence in Thai dermatology.

EL24-2EL24-4

How to develop your career and leadership skills

Fostering Gender Equity in Academic Dermatology

John A. McGrath

Dedee F Murrell

St Johnʼs Institute of Dermatology, Kingʼs College London,

The George Institute for Global Health, University of NSW,

London U.K.

Sydney, Australia

Developing career and leadership skills is crucial for
doctors to excel in their profession. Pieces of advice
include（a）engaging in continuous learning（stay up todate, attend meetings, network）, （b）build strong
communication skills（patients, colleagues）,（c）cultivate
leadership skills（take on roles, lead by example）,（d）
networking（join societies and connect）,（e）seek out
mentorship（mentor/mentee, collaborate）（, f）be adaptable（embrace the new）,（f）work on time management skills（prioritize）,（g）embrace leadership training（personal/
team）（, h）engage in quality improvement（patient care,healthcare）,（i）reflect on work-life balance,（j）be an
advocate for patients,（k）seek feedback,（l）deliver on
your professional development plans（assess and adjust）,（m）develop skills in public speaking and writing,（n）bea role model for ethical decision making（maintain codes ofconduct）. Achieve all this and your career will be on a fast
track!

In many western countries it has only been in the lastcentury that women were permitted to study medicine andmany were forbidden from continuing to work whenmarried and when pregnant. Access to specialist training
was therefore initially mainly for spinsters. Dermatology is
now one of the most female-friendly specialties in medicine
and highly competitive to enter compared to other branchesof medicine. Despite the high academic achievements ofwomen entering dermatology, the statistics show that the
majority of female dermatologists work in either public
hospital service positions or private practice and that there
is a gender bias against women in academic dermatology,
particularly in the SE Asian region. This lecture will focus
on the facts and look at ways in which gender equity inacademic dermatology is being fostered in the United States,
Canada, Australia, the UK and the EU. Eastern Europe andsome middle eastern countries, including Israel and Iran,have been fairer to women in dermatology.

76

EL24-5

EL46-4Career and Leadership Development. Lessons forJapanese Dermatologists

Exploring the migration of immune cells in the skin：contributions of Japanese dermatologists to chemokine biology

Akemi Yamamoto

Samuel T. Hwang

Asahikawa Medical University

Dermatology at the University of California Davis School of
Medicine, USA

One common barrier to career development for Japaneseis imposter syndrome, a state in which people are unable
to recognize their abilities and feel that they are deceiving
those around them. Perfectionism and the idea that failure
is not an option are also barriers. Another challenge is how
to get back on your feet after experiencing some sort of
setback. I will talk about how these barriers can beovercome, based on my own experience and knowledge
from books.

Chemotaxis, the migration of cells from one site to another, is driven
largely by a family of seven-transmembrane family of receptors calledchemokine receptors and their cognate chemotactic cytokines known as
chemokines. Chemokine receptors are present on the membranes of all
immune cells and are vital to their physiologic functions. The skin immune
system is dependent on chemokine/chemokine receptors and interactions
in several migratory processes, including：1）the migration of mature
activated dendritic cells such as Langerhans cells from the skin to draining
lymph nodes via interactions of CCR7 and CCL21 and 2）the migration of
T cells out of the blood stream and into inflamed skin via CCR6 and CCL20
in Th17-mediated skin diseases such as psoriasis. Young Japanesedermatologists in my laboratory have made seminal discoveries in these
two areas of cutaneous immunology. Herein, I will describe the early
investigative work in my laboratory of several Japanese dermatologists,
now prominent physician scientists and leaders of their Departments, thathelps to explain how immune responses are generated in the skin and,ultimately, how effector T cells get into the skin in order to trigger skinconditions such as psoriasis that dermatologists see and treat every day.

EL26-1
Update in Autoinflammatory Disease
Lori Broderick1,2）
Division of Allergy, Immunology ＆ Rheumatology, Universityof California, San Diego1），Rady Childrenʼs Hospital, San Diego,
USA2）

Autoinflammatory diseases are inborn errors of immunity characterized
by systemic inflammation independent of infection and autoreactive
antibodies or antigen specific T cells. Genetic discoveries have expanded
the disease spectrum, and led to the recognition of overlap syndromes,
driven by IL-1, type I interferons, and NF-κB activation. Despite thevariable clinical courses, these disorders frequently share cutaneous
inflammation as an initial or persistent manifestation, with skin findings
ranging from cold-induced urticaria, neutrophilic granulomas, and sterile
cellulitis. Beyond the outer layers, diseases secondary to epithelial barrier
defects have recently been included in the autoinflammatory spectrum,including mucocutaneous ulceration. We have recently investigated asevere childhood onset syndrome known as disabling pansclerotic
morphea, and identified STAT4 as a therapeutically targetable genetic
etiology. These mutations act largely through IL-6 signaling secondary topersistent phosphorylation, and suggest consideration of IL-6 as a
primary driver of a new subset of autoinflammatory-fibrotic disorders.

77

Sponsored Symposium
SSY1-2New Opportunity for AD
Treatment - Targeting IL-13
with Lebrikizumab

SSY2-3Mechanism of action and placeof JAKi in the management ofAD

Thomas Bieber1,2）

Stephan Weidinger

Medicine Programs at the

Chair and Director, Depart-

Kühne-Foundation, Medicine

ment of Dermatology and1）Campus Davos, Switzerland ，Allergy, University Hospital

Bieber Dermatology

Schleswig-Holstein, Kiel,
2）

Consulting, Bonn, Germany

Atopic dermatitis（AD）is a common chronic
inflammatoryskindiseasewithacomplex

Germany［Biography］
From 05/2011

pathophysiology that underlies a wide spectrum ofclinical phenotypes. AD remains challenging totreat owing to the limited response to available
therapies.

However,recentadvances

From 04/2011

inunderstanding of disease mechanisms have led tothe discovery of novel potential therapeutic targets
and drug candidates. In addition to regulatory
approval for the IL-4/13 dupilumab, the anti-IL-13
tralokinumab, lebrikizumab and the JAK inhibitors

1999-2011

in Europe, there are still number of compounds indevelopment. In this session, I will share evidence
from global phase 3 trial of IL-13 Lebrikizumab,
which is a new drug launched in Germany in 2023,
ahead of the rest of the world.
［Biography］
Prof. Thomas Bieber, MD, PhD, MDRA
Medicine Programs at the Kühne-Foundation, Medicine Campus Davos, Switzerland
Bieber Dermatology Consulting, Bonn, Germany
Bio sketch：
Prof. Thomas Bieber is professor of Dermatology and Allergy. He received his degrees inmedicine（MD）and biology（PhD in immunology）from the University of Louis Pasteurin Strasbourg, France. From 1997 to 2023, he was chairman of the Department of
Dermatology and Allergy at the University of Bonn, Germany. He earned a masterʼsdegree in drug regulatory affairs（MDRA from the University of Bonn）, achieving
special expertise in preclinical and clinical drug development strategies, as well as in legal
and market access aspects of drug approval. He has special expertise in translational andprecision medicine approaches for skin diseases. He is currently the scientific director of
the medicine programs of the international Kühne-foundation.

78

2006-2011

Department of Dermatology, Venereology
and Allergology, University Hospital
Schleswig-Holstein, Campus Kiel Chairand Director
Department of Dermatology, Venereology
and Allergology, University Hospital
Schleswig-Holstein, Campus Kiel・Deputy Director
・Head, Center for Inflammatory Skin
Diseases・Steering Committee, Excellence Cluster
Precision Medicine in Inflammation
Department of Dermatology and Allergy
University Hospital rechts d. Isar, Technische Universität Munich
・Head, Atopic Dermatitis and Psoriasis
Outpatients Department
・Head, Dermatology KORA populationbased surveys
Center for Allergy and Environment,
Helmholtz Center Munich
Head Genomics and Molecular Epidemiology Work GroupSSY2-4
Understanding the burden of
disease in your patients withatopic dermatitis

SSY3-1
Epithelial barrier theory andallergic skin diseases
Cezmi A. Akdis

Rodney Sinclair

The Swiss Institute of Allergy

Professorial Fellow,

and Asthma Research（SIAF）

University of Melbourne

Zurich University Medical

Department of Medicine

Faculty, Switzerland（St.Vincentʼs Hospital）,
Director, Sinclair
Dermatology［Biography］
Bachelor of Medicine and Bachelor of Surgery, Melbourne
1987
Fellow of the Australasian College of Dermatologists, 1995
Doctor of Medicine（Melb）, 2004
AwardsHonorary Life Member American Dermatology
Association
Honorary Life Member of the British Association of
Dermatologists
Honorary Life Member Ukranian Hair Research Society

Humans are exposed to a variety of toxins andchemicals. The epithelial barrier theory shows that
toxic substances inside cleaning agents, laundry anddishwasher detergents, microplastic,
shampoos,
toothpastes, packaged food and air pollution damage
the epithelium of our skin, lungs and intestine. After
breaking of the epithelial barriers, decreased
biodiversity of the microbiome develops leading tomany chronic diseases, such as allergies, asthma,
dermatitis, diabetes, obesity, multiple sclerosis,
Alzheimerʼs, autism and depression that are only someexamples of more than 100 diseases showing increased
prevalence during the last few decades. Epithelial
Barrier Theory with all perspectives and recent
evidence on allergic skin diseases will be discussed inthis presentation.
［Biography］
Cezmi Akdis is the director of the Swiss Institute of Allergy and Asthma
Research（SIAF）in Davos and Professor in Zurich University Medical
Faculty.
He has honorary and adjunct professorships from Beijing（China）,
Wuhan（China）and Bursa-Uludag University（Turkey）,Harvard
University（USA）.
He is a Senate Member of the Swiss Academy of Medical Sciences.
Cezmi Akdis has published more than 700 peer-reviewed articles. His hindex is 156.
Cezmi Akdis acted as the President of the European Academy ofAllergy ＆ Clinical Immunology（15ʼ000 members）between 2011-2013.
He was the editor of Global Atlases of Allergy, Asthma I-II, Chronic
Rhinosinusitis and Allergic Rhinitis.
He was the founder and organizer of the World Immune Regulation
Meetings, Davos I-XVII.
He is currently the Editor-in-Chief of the Allergy journal.
He has many original discoveries, leading to the development of theEpithelial Barrier Theory , how to avoid epithelial barrier damaging
substances, possibilities for mitigation www.epithelialbarriertheory.com
Immune tolerance to allergens and environmental substances, anddiscovery of novel immune cells.

79

SSY3-2
Specific B cell responses inAllergen-specific
Immunotherapy

SSY3-3
Psoriatic inflammation
Alexander Enk
Department of Dermatology,

Mübeccel Akdis

University of Heidelberg,

The Swiss Institute of Allergy

Germany

and Asthma Research（SIAF）,
Switzerland

Psoriasis is an autoinflammatory disease that
affects millions of patients worldwide. In recent
Cowʼs milk allergy is a common disease in children. Oralallergen-specific immunotherapy（OIT）has shown tobe an effective and curative treatment. Increased
frequency of milk allergen αS1-casein-specific B cells
was observed after OIT and natural tolerance（NT）.
Milk desensitized subjects showed changes in the
direction of OIT induced tolerance, suggesting that
desensitization is an earlier stage of tolerance. IL10RA
and TGFB3 were highly expressed in desensitized OIT
patients. In remission and desensitized groups, B cell
activation, Breg cells, BCR signaling and differentiationrelated genes are activated. The analyses of Ig heavy
chain genes in specific B cells demonstrated that IgG2
in desensitization, IgG1, IgA1, IgA2, IgG4 and IgD inremission, and IgD in NT were predominating.

years a better understanding of the pathogenesis［Biography］［Biography］

Head of ImmuneRegulation of the SIAF in Davos
Honorary and adjunct professorships：Beijing, Wuhan（China）, BursaUludag Univ.（Turkey）, Harvard Univ.（USA）
Published more than 400 peer-reviewed articles（h-index：113）
Received many research grants and collaborative grants from the SNF
and EU
Received numerous awards including Sedat Simavi and Eczacıbası
Medicine Award, ACAAI Distinguished Fellowship, APAAACI Womenin Science Award.
Co-Editor of the Middletonʼs 10th edition
Editorial board of the Journals：Allergy, European Journal of
Immunology, International Archives of Allergy and Immunology
Scientific Committee Chair of the EAACI
Major research contributions：mechanisms of allergen tolerance, highdose allergen exposure models in humans, mechanisms of AIT, functionsof Treg cells, NKreg cells and IL-10 producing human Breg cells

Professor and Chair of Dept. of Dermatology, Univ. of

80

has lead to the notion that psoriasis is not limited toskin, but also affects numerous other organs
including joints, vessels, and many others. It isappreciated

now

that

antimicrobial

peptidestogether with RNA/DNA in complexes lead toinduction of

innateimmuneresponses.

This

includes release of IFN-alpha by pDC. This,
together with complexed RNA will activate local
mDC to migrate to regional lymph nodes. In
regional lymph nodes Th17 cells will be induced by
IL-23-producing DC. The Th17 cells will thenmigrate back to skin.

Heidelberg
Former President of ESDR
Former President of EDF
Former President of ISID
Former President German Derm. Association
Member German Academy of Sciences
Honorary Member JDA and JSID

Leopoldina

SSY3-4
Fine-tuning skin immunity：frominfantile rashes to the microbes
inside us

SSY4-2
Role of Type 2 inflammation in
AD - What have targeted
therapies taught us?

Samuel T. Hwang

Lisa A. Beck

Dermatology, University of

University of Rochester

California Davis School of

Medical Center School of

Medicine, USA

Medicine and Dentistry, USA

This lecture will focus on genetic and environmental
factors that regulate skin immunity. I start with a rare,autosomal-dominant gene mutation in a Ca2+-regulated,cation channel called TRPM4 that causes progressive
symmetric keratodermia（PSEK）, a dermatitis whichstarts in infancy but resolves by adulthood. TRPM4
regulates the migration of dendritic cells and influencesskin inflammation in several murine models of skindisease. Next, I highlight the role of commensal
microbes during the neonatal period in recruiting
specific populations of monocytes into the skin that
affect IL-17A production by skin T cells. Lastly, I will
discuss work showing that specific diets（i.e., theWestern diet）as well as microbes in the gut regulate
skin inflammation in murine models of psoriasis.
［Biography］
MD（Harvard Medical School）, PhD（University ofBasel）
Residency in Dermatology：University of California San
Francisco
Current title（since 2016）：Chair and Professor of
Dermatology, University of California（USA）Davis Schoolof Medicine
Prior positions：（Senior）Investigator, Dermatology
Branch（1997-2008）, Chair and Professor of Dermatology
Medical College of Wisconsin（2008-2015）
Scientific positions：Section Editor, Journal of Investigative
Dermatology, Member of Scientific Advisory Commitee of
the National Psoriasis Foundation and GRAPPA
Awards：Member of American Society for Clinical
Investigation, Psoriasis Research Award（American Skin
Association）, Lu Yao-chin Memorial Award Taiwanese
Dermatological Association
Research Interests：a）chemokines and chemokine
receptors in skin immunity. b）trafficking of T cells in
psoriasis c）role of TRPM4 and other immune-regulating
receptors in the skin and d）role of diets and microbes inskin immunity

The rationale for targeting the canonical type 2 cytokines（IL-4
and IL-13）to treat allergic diseases, like atopic dermatitis, began
in 1987 when Drs. Tim Mosmann and Robert Coffman firstdescribed Th1 and Th2 cells. Thirty years later（2017）, thebiologic called dupilumab, which targets a common receptor
subunit（IL-4Ra）, utilized by both IL-4 and IL-13 was granted
FDA approval to treat adults with atopic dermatitis. It is now
approved to treat children down to 6 months of age withmoderate to severe disease. This highly targeted drug has also
provided us with an opportunity to better understand thebiological actions of IL-4 and IL-13.
At the conclusion of this presentation participants should be able
to：
1. Explain the key characteristics of atopic dermatitis and its
common comorbidities
2. Understand the rationale for targeting type 2 cytokines to Rx
atopic dermatitis（or eczema）
3. Review the benefits and risks of dupilumab［Biography］
EDUCATIONMD Medicine | Stony Brook Univ Health Sciences Center School of Medicine | 1985
BA Chemistry | Mount Holyoke College | Magna cum laude（Chemistry）| 1981
POST-DOCTORAL TRAINING AND RESIDENCY
Fellowship, Immunology Research（Mentor：Robert Schleimer, Ph.D.）, Johns Hopkins
Division of Clinical Immunology | 1992 - 1994
Fellowship, Dermatology（Chief Resident in final year）Duke University Medical Center,
Durham, NC | 1987 - 1990
Internship and 2nd yr of Residency, Internal Medicine Strong Memorial Hospital,
Rochester, NY | 1985 - 1987
FACULTY POSITIONSJohns Hopkins Medical Institution Dept of Dermatology | 1990 - 2006
Johns Hopkins Medical Institution Dept of Medicine（Allergy ＆ Immunology Division）|
1994 - 2006
MENTORING
In the past 20 years, Dr. Beck has mentored and trained 14 undergraduates, 8 medical
students, 11 post-doctoral fellows, 2 PhD students, and served as a thesis committee
advisor for over 9 PhD or MD/PhD and 4 MS students.

81

SSY5-1
Cellular origins of IL-31 in atopic
dermatitis and prurigo nodularis
Takashi Hashimoto
Department of Dermatology,

SSY5-2
Sensory neuronal STAT3 iscritical for IL-31 receptor
expression and inflammatory
itch

National Defense Medical

Takaharu Okada

CollegeLaboratory for Tissue
Dynamics, RIKEN Center for
Integrative Medical Sciences.

IL-31, a pruritogenic cytokine, is believed to play acentral role in chronic itch in pruritic diseases
including atopic dermatitis and prurigo nodularis.

IL-31 receptor blockade suppresses pruritus of

Although activated Th2 cells have been thought toatopicbe the cellular origin of IL-31, recent findings

contributions

suggest that various types of cells other thanexpression

lymphocytes are capable of producing IL-31. Our

signaling pathway to induce itch remain unknown.

group has proposed that the major cellular sources

Using conditional knockout mice, we find that IL-31-

of IL-31 are M2-skewed macrophages in atopic

induced itch requires sensory neuronal IL-31

dermatitis and prurigo nodularis, as well as otherreceptor and STAT3 and that IL-31 receptor

pruritic diseases including ordinary scabies andexpression is dependent on STAT3. In addition,stasis dermatitis. Furthermore, basophils are foundpharmacological experiments suggest that STAT3

to promote IL-31 production from macrophages in

activation is importantthese conditions. This macrophage-basophil axis

signaling downstream of the IL-31 receptor.

presents a promising therapeutic target for chronic

Pruritus associated with dermatitis is partially

itch in atopic dermatitis and prurigo nodularis.

dependent on IL-31 receptor and strongly on STAT

dermatitis.
of

However,
IL-31

mechanism,

cell-type-specificreceptor

toanddownstream

for

the

the

itch,

its

itch-inducing

3 in sensory neurons. Thus, sensory neuronal［Biography］
Education
2004 M.D.,

Tokyo Medical and Dental University（TMDU）, Tokyo,2015 Ph.D,

TMDU, Tokyo, Japan

Japan
Experience
2004-2007

Junior and Senior Resident, TMDU Hospital, Tokyo,

STAT3 is essential for IL-31-induced itch andfurthertoIL-31-independent

inflammatory itch.
［Biography］
1999：

Ph.D., School of Life Science, Graduate University for Advanced

1999-2002：

JSPS Research Fellow, National Institute for PhysiologicalJapan

Studies

2007-2017

Staff Dermatologist, TMDU Hospital and TMDU-

2017-2019

Research Fellow, Miami Itch Center（Director, Dr. Gil

2002-2007：

Postdoctoral Fellow, University of California, San Francisco

Yosipovitch）,University of Miami, FL, USA

2007-2008：

Associate Professor, Graduate School of Engineering, Kyoto

2020-2022

Junior Associate Professor, Department of Dermatology,

2008-2013：

Unit Leader, RIKEN Research Center for Allergy and2022-Present

Associate Professor, Department of Dermatology,

affiliated hospitals

National Defense Medical College, Tokorozawa, Japan
National Defense Medical College, Tokorozawa, Japan82

contributes

Sciences

University
Immunology
2013-present： Team Leader, RIKEN Center for Integrative Medical Sciences

SSY5-3
Recent insights into theimmunopathogenesis of atopic
dermatitis and prurigo nodularis

SSY5-4Itch in the Elderly Patient Origin, Diagnostics,
Management

Bernhard Homey

Martin Steinhoff

Department of Dermatology,

Department of Dermatology

University Hospital

and Venereology, Hamad

Düsseldorf, Medical Faculty,

Medical Corporation, Doha,

Heinrich-Heine-University

Qatar

Düsseldorf, Germany

During the past two decades we are witnessing the
rapidly growing knowledge of the underlying immune
mechanisms of chronic inflammatory skin diseases.
These groundbreaking basic immunological findings
have initiated pivotal clinical trials and the spotlight is
now directed towards pruritic type 2 inflammation.
Driving cytokines of these immune responses include,
among others, thymic stromal lymphopoietin（TSLP）,
IL-4, IL-5, IL-13 and IL-31. We are still learning a lot
from novel single cell RNA sequencing and spatialtranscriptomic studies pointing towards dominant
pathways in pruritic inflammatory skin diseases suchas atopic dermatitis and prurigo nodularis. Here ourcurrent understanding of the immunopathogenesis ofthese pruritic skin diseases is summarized with a
special emphasis on the role of IL-31 signaling inpromoting the itch-scratch-inflammation cycle.

As the elderly population is growing larger, geriatricdiseases pose a challenge to both the healthcare system andsociety worldwide. In particular, chronic pruritic dermatoses
are critical diseases frequently afflicted geriatric patients.
The high prevalence of pruritic disorders in elderly patients
is a consequence of three major（patho）physiologicalchanges that occur with aging：（1）the activated immune
system of elderly patients operates with a defective TH1- but
an enhanced TH2-response；（2）the skin barrier function
declines；and（3）neuro-sensational changes, which may be
peripheral or central. Mediators and pathways of itch inelderly is still poorly understood. These pillars in thepathophysiology may occur single or combined in elderly
pruritus-afflicted patients. Drug-drug interactions

andcomorbidities necessitate and adapted approach to serve
elderly patients with chronic itch.
［Biography］［Biography］
Professional positions
Since 05/2010
Chairman, W3 professsor, Dept. of Dermatology,
University Hospital Düsseldorf
12/2004
Professor for Dermatology, Heinrich-HeineUniversity Düsseldorf（C3 professor）
01/2004
Senior consultant, head of the Allergy Unit, Dept. of
Dermatology, Heinrich-Heine-University Düsseldorf
05/2003
Specialist for Dermatology and Venereal Diseases
11/2001
Resident Department of Dermatology, HeinrichHeine-University Düsseldorf, Head of the ResearchLaboratory for Dermato-Immunology and Oncology
05/1998-10/2001 Visiting scientist Dept. of Immunology, DNAX
Research Institute, Palo Alto, CA, USA；
Supervisor：Albert Zlotnik, PhD
08/1995-04/1998 Resident Department of Dermatology, HeinrichHeine-University Düsseldorf；Director：Prof. Dr.
Dr.h.c. T. Ruzicka
Research interests
Immunology, novel cytokines, chemokines, neuro-immune interaction,
microbe-host interaction

Prof. Martin studied Medicine and Human Biology in Germany where hereceived his MD and PhD from University Marburg.
He received his dermatology training at University in Muenster and Univ.
California San Francisco.
Professor Martin Steinhoff is now Chairman at the Dept. of Dermatology andDirector of the Translational Research Institute as well as Residency Program
Director at Hamad Medical Corporation, Qatar.
He is Full-Professor at Weill-Cornell Universities in New York and Qatar, Hamad
bin Khalifa University and Qatar University.
Prof. Steinhoffʼs main interest is neuroimmunology where his group describedvarious new mechanisms like the first histamine-independent itch pathway,
published in Nature Medicine, and described the first cytokine receptor onhuman sensory nerves which has led to development of new medications.
Prof. Martin published around 300 peer-reviewed articles（H-index：88）, over
40 book chapters, and holds numerous patents.
His research has been funded with ＞60 Mio Euro so far. His group received 2023
the PPM award to study precision medicine based pathways and newtreatments for atopic dermatitis.
Finally, Prof. Martin was also PI on various clinical trials and received several
prestigious international research-awards, and is honorary member of several
Societies for Dermatology.

83

SSY7-4
The pathology and treatment
mechanism of psoriasis

SSY8-3Which AD patients to treat with
AdtralzaⓇ?

Johann E. Gudjonsson1,2,3,4）

Jacob Pontoppidan

Department of Dermatology,

Thyssen1）

University of Michigan ，Faculty of Health and Medical

Department of Internal

Sciences, University of

Medicine, Division of

Copenhagen, Copenhagen,Rheumatology, University ofDenmark2）

Michigan ，Mary H. Weiser

LEO Pharma A/S, Ballerup,

Food Allergy Center,

Denmark
3）

University of Michigan ，Taubman Medical ResearchInstitute, USA4）

Psoriasis is a chronic autoimmune andinflammatory disease of the skin that is foundworldwide and is associated with multiple
comorbidities,
includingarthritis
andcardiovascular disease. In the last two decades, ourunderstanding of the pathogenic mechanisms
involved in psoriasis has greatly expanded throughgenetic studies, data from single-cell and spatialsequencing studies, and the marked advance in thenumber of targeted and highly effective treatmentsfor psoriasis. Remarkably, these advances converge
on a narrow set of inflammatory pathways that are
central to psoriasis pathogenesis, with a central roleof IL-17, along with major contributions from IFN,
TNF, and IL-36 pathways to the inflammatory
network of psoriasis, defining psoriasis as a primarycytokine-driven disease.
［Biography］
MD/PhD University of Iceland, 2003
Residency in Dermatology, Department of Dermatology,
University of Michigan 2003-2007
Endowed Professorship（tenured）at the University ofMichigan Arthur C. Curtis Professor, 2017
Professor of Dermatology（tenured）, 2021
Director, UM Skin Biology and Diseases Resource-based
Center（NIH-P30）, 2019
Professor, Department of Internal Medicine, Division ofRheumatology, 2022
Professor, Mary H. Weiser, Food Allergy Center, 2023
Board of Scientific Counselors of NIH-NIAMS 2021
Member of the American Society for Clinical Investigation（ASCI）
Fellow of the American Association for the Advancement of
Science（AAAS）

84［Biography］
Prof. Thyssen has been with the University of Copenhagenworking as a clinical dermatologist for more than 20 years
and remains a Professor Emeritus and consultant after hejoined LEO Pharma in 2023. He holds a PhD and doctorate
degree（DmSci）obtained through research that examined
the origins of inflammatory skin diseases. He has been a
research fellow/guest professor at Harvard Medical School,
Boston, the University of California, San Francisco and University Spital Zürich, Switzerland. Dr. Thyssen hasreceived prestigious prizes and awards for his research, andpublished ＞650 articles in international peer reviewed
journals. His scientific work has focused on inflammatory
skin diseases, in particular chronic hand eczema, contact
dermatitis and atopic dermatitis.

SSY9-4
Global Perspectives on
Psoriasis Therapy
Diamant Thaci
Comprehensive Center for
Inflammation Medicine,
University of Luebeck,Germany

We have now more than 10 biologic treatment options
for psoriasis, and we can expect good outcome withthem for skin. However, we still need to consider how totake good care of disease progression of PsA.
We, dermatologists, are the gatekeepers of psoriasis
treatment, and it is important for the future of psoriasis
treatment to control the inflammation of psoriasis earlywith highly effective treatments to lead to better
outcomes.
During my presentation, I would like to explorer how
and when to interevent to this disease with myexperience.
［Biography］
Dr. Diamant Thaçi graduated in 1989 with a medical degree from the
University of Pristina, Pristina, Kosovo. He remained in Pristina until
1992, specializing in dermatology and venereology, before taking up a
post in the Department of Dermatology and Venerology at Johann
Wolfgang Goethe University in Frankfurt, Germany. He became a boardcertified dermatologist and venereologist in 1995 and from 1997, Dr.
Thaci has held the roles of Senior Consulting Specialist in Dermatology,
Director of Clinical Research and Head of Photodermatology Division at
the university. He became Associate Professor of Dermatology,
Venerology and Allergology at the Goethe University in Frankfurt/
Main, Germany, and in 2013, he was appointed Professor and Head of theComprehensive Center for Inflammation Medicine, University of
Luebeck, Luebeck, Germany. Dr. Thaci s research experience covers
immunology and all stages of clinical drug development. Between 2002
and 2013, he was involved in more than 200 investigator-driven psoriasis
trials and was the lead investigator on several national and international
multicenter trials. In addition to his clinical commitments, Dr. Thaci
lectures on scoring systems in dermatology and is involved in the
training of study personnel and publishing articles and book chapters indermatology. Dr. Thaci has been a recipient of the Theodore Stern
Foundation Award for excellent clinical research. He is an active
member of the Group for Research and Assessment of Psoriasis andPsoriatic Arthritis（GRAPPA）and the International Psoriasis Council.

85

Sponsored Seminar
LS14-3
Disease Burden of Patients with Focal Hyperhidrosisin the United States and the IHHSʼs Efforts
Dee Anna Glaser
Glaser Dermatology ＆ Aesthetics

Hyperhidrosis（HH）, with a prevalence of 〜 5％worldwide, is one of the most burdensome dermatologic
conditions based on Dermatology Quality of Life Impact
scales. Yet only 〜 50％ of those affected have discussed
hyperhidrosis with a medical professional, and many
report challenges finding a qualified physician or healthcare professional to provide care. The International
Hyperhidrosis Society, founded in 2003, developed
multiple strategies to improve education of, the public,
hyperhidrosis sufferers, and health care providers of thedisease and its management. Strategies to improve
patient/family understanding of HH, education of the
medical community, and to optimize treatment outcomes
will be discussed.

86Oral Presentation in English
E1-1（EP1-6）
Imiquimod-induced oxidative stress and cell death are through p53/
Nrf2 axis.
○Shu-Hao Chang1），Chu-Hsuan Hsueh1），Jeng-Jer Shieh1,2,3）（Institute of Biomedical Sciences, National Chung Hsing University,
Taichung1），Department of Education and Research, Taichung
Veterans General Hospital, Taichung2），Rong Hsing Research Center
for Translational Medicine, National Chung Hsing University,
Taichung3））
Imiquimod（IMQ）, a synthetic TLR 7 ligand, has been used in thetreatment of BCC, melanoma, and various skin malignancies for over
20 years in clinical. IMQ-induced apoptosis in cancer cells is mainly
mediated by ROS. However, no available reports indicated themechanisms of IMQ-acquired resistance. In this study, we found IMQinduced oxidative stress was significantly minor in p53 mutant cancer
cells which were IMQ-resistant. Additionally, we found protein
stability of Nrf2 was maintained in p53 mutant cells but not in p53
wild-type cells upon IMQ treatments. ML385, a potent Nrf2 inhibitor,
not only enhanced IMQ-induced cell death but also increasedoxidative stress in p53 mutant cells. Thus, Nrf2 may serve as a novel
target to improve the clinical application of IMQ.

E1-2
（EP1-4）
Analysis of antigen specificity of tumor-infiltrating B lymphocytes in
TLS+ melanoma○Kanta Hori1,3），Yoshihiko Hirohashi1），Tomoyuki Minowa2），
Kenji Murata1），Hisashi Uhara2），Toshihiko Torigoe1）（Department of Pathology, Sapporo Medical University School of
Medichine, Sapporo1），Department of Dermatology, Sapporo Medical
University School of Medichine, Sapporo2），Department of Urology,
Sapporo Kosei Hospital, Sapporo3））
Tumors with mature tertiary lymphoid structures（mTLS）,
characterized by a dense B cell population, are linked to positive
clinical outcomes. This study explores B cell-generated antibodiesʼ
antigen specificity in a mTLS-positive melanoma case. Single-cell
RNA sequencing（scRNA-seq）and B cell receptor sequencing（BCRseq）were performed on tumor-infiltrating B lymphocytes（BTILs）.
scRNA-seq results revealed BTILs classification into Naive, Switchedmemory, B regulatory（Breg）,Transitional, Cell cycle, Plasma cell, andothers. BCR-seq identified clonal expansion in six BCR clonotypes.
Using this BCR data, artificial antibodies were synthesized andvalidated for reactivity against existing cell lines and an autologous
melanoma cell line.

E1-3（EP1-5）Aryl Hydrocarbon Receptor in Dorsal Root Ganglion May Involve in
Histamine-induced Itching○Alafate Abudouwanli1），Ge Peng1），Wanchen Zhao1），
Arisa Ikeda1,2），Quan Sun1），Ko Okumura1），Shigaku Ikeda1），
Hideoki Ogawa1），Francois Niyonsaba1,3）（Atopy（Allergy）Research Center, Juntendo University Graduate
School of Medicine, Tokyo1），Department of Nephrology, Juntendo
University Graduate School of Medicine, Tokyo2），Faculty ofInternational Liberal Arts, Juntendo University, Tokyo3））
Aryl hydrocarbon receptor（AhR）signaling involves in skinhomeostasis, barrier function, and various biological events. Notably,
tapinarof, an AhR agonist, alleviates itching in patients with atopic
dermatitis. However, the precise role of AhR in regulating itchingremains unclear. Here, we observed heightened scratching responses
to histamine in an AhR-deficient mouse model, but no significant
difference emerged in scratching responses to chloroquine, trypsin,and serotonin, suggesting that AhR signaling is selective to histamineinduced itching. And deficiency of AhR in DRG correlated with higher
levels of TRPV1, nerve growth factor and amphiregulin. Collectively,

we show that AhR may contribute to the histamine-induced itching
involving regulation of TRPV1 and axon guidance molecules.

E1-4（EP10-3）
Lesion-specific Loss of Langerhans Cells in Progressive Symmetric
Erythrokeratodermia○Umi Tahara1,2），Kyoko Masuda1），Takashi Sasaki1,3），
Kazuhiko Nakabayashi4），Masayuki Amagai1），Akiharu Kubo1,5）（Department of Dermatology, Keio University School of Medicine,Tokyo1），Department of Dermatology, Kawasaki Municipal Hospital,
Kawasaki2），Center for Supercentenarian Medical Research, Keio
University School of Medicine, Tokyo3），Department of MaternalFetal Biology, National Center for Child Health and Development,
Tokyo4），Division of Dermatology, Department of Internal Related,
Kobe University Graduate School of Medicine, Kobe5））
Progressive symmetric erythrokeratodermia（PSEK）caused bypathogenic TRPM4 variants is an autosomal dominant disordercharacterized by symmetrically distributed psoriasiform skin lesions.
Here we report a large family with PSEK caused by a recurrent
c.3119T＞C（p.Ile1040Thr）variant in TRPM4 . Several family
members presented with previously undescribed features, i.e.,（1）three patients first developed skin lesions during pregnancy,（2）one
patient had clinical remission at the site covered by a cast for fracture
treatment for two months,（3）immunohistochemical analysis of threepatients revealed lesion-specific loss of intra-epidermal CD1a+
Langerin/CD207+ Langerhans cells. Our study provides new insights
into the clinical and histopathologic features of TRPM4-associated
PSEK.

E1-5
（EP10-5）
Real-World Experience of Dupilumab and JAK Inhibitors in
Epidermolysis Bullosa Pruriginosa○Ping-Chen Hou1），Wilson Jr Aala2），Wei-Ting Tu1），John A. McGrath1,3），Chao-Kai Hsu1,2,4）（Department of Dermatology, National Cheng Kung University
Hospital, College of Medicine, National Cheng Kung University,
Tainan1），Institute of Clinical Medicine, College of Medicine, National
Cheng Kung University, Tainan2），St Johns Institute of Dermatology,
School of Basic and Medical Biosciences, Kings College London,
London3），International Center for Wound Repair and Regeneration,
National Cheng Kung University, Tainan4））
Epidermolysis bullosa pruriginosa（EBP）is a very itchy and difficult
to treat subtype of dystrophic EB in which there is skewed Th2
inflammation. Anecdotally, both dupilumab and JAK inhibitors（JAKi）
can alleviate itch in EBP although clinical experience is limited. In acohort of 9 EBP adults, we compared the impact of dupilumab（n=6）
orJAKi（abrocitinib and upadacitinib；n=7）on pruritus, scored on avisual analogue scale（VAS）. Both treatments improved itch.
However, dupilumab treatment led to a 50％ reduction in VAS in only
3/6 individuals（none reached VAS=0）whereas JAKi led to complete
relief of pruritus（VAS=0）in 5/7 subjects. No significant side effects
were observed in either group. Our observational study indicatespotential superiority of JAKi over dupilumab in treating EBP.

E1-6
（EP7-1）Three Phases of Pathology in Skin Eruptions of Chronic Urticaria
using Mathematics○Sungrim Seirin-Lee1,2），Shunsuke Takahagi3），Michihiro Hide3,4）（ASHBi, Kyoto University Institute for Advanced Study, Kyoto
University, Kyoto1），Department of Mathematical Medicine,
Graduate School of Medicine, Kyoto University, Kyoto2），Departmentof Dermatology, Graduate School of Biomedical and Health Sciences,
Hiroshima University, Hiroshima3），Department of Dermatology,
Hiroshima City Hiroshima Citizens Hospital, Hiroshima4））

87

Chronic spontaneous urticaria（CSU）is characterized by spontaneous
appearing and disappearing of local skin edema called wheal. We
explored a three-stage wheal dynamics, Onset-DevelopmentDisappearance, to understand disease pathogenesis in vivo using
mathematical model and quantitative comparisons of clinical data ofpatients with CSU. We found that CSU onset is critically associatedwith endovascular dynamics triggered by basophil positive feedback.
In contrast, the development phase is regulated by mast cell
dynamics via vascular gap formation. We also found that thedisappearance phase of wheals in CSU may occur via a globally
independent suppression mechanism to mast cells followed by thedevelopment of wheals.

E1-7（EP7-2）
Correlation of specific IgE with total IgE in atopic dermatitis patients○Norika Akashi，Mariko Ogawa-Momohara，Tomoki Taki，
Ryo Fukaura，Satoshi Kamiya，Yuta Yamashita，Haruka Koizumi，Takuya Takeichi，Yoshinao Muro，
Masashi Akiyama（Department of Dermatology, Nagoya University Graduate School of
Medicine, Nagoya）

Hospital, Tokyo5），Clinical Dental Research Promotion Unit, Facultyof Dentistry, Tokyo Medical and Dental University, Tokyo6））
A PTEN deficiency leads to the activation of phospho-Akt at serine473（p-Akt）and promotes melanomagenesis by coupling with NUAK
2 amplification. We tested the prognostic impact of p-Akt and/or
NUAK2 expression on the relapse free survival（RFS）and overall
survival（OS）. Primary tumors from acral melanomas（112）, Lowcumulative sun damage（CSD）melanomas（38）and High-CSD
melanomas（18）were examined using immunohistochemistry. Either
p-Akt or NUAK2 expression was inversely correlated with the RFS ofacral melanomas （ p-Akt ： P = 0.0001 ； NUAK 2 ： P = 0.0001 ）.
Multivariate analyses revealed that p-Akt expression had an inferior
RFS of patients with acral melanomas（Hazard ratio=4.036；P=
0.0005）. We conclude that the expression of p-Akt can predict therelapse of patients with acral melanomas.

E2-2（EP9-6）

Relationship Between Tumor Thickness and Histological Invasion
Level in Acral Melanoma○Shigeru Koizumi1），Yukiko Kiniwa2），Tatsuya Takenouchi3），
Jun Asai4），Takuya Miyagawa5），Takamichi Ito6），
Noriki Fujimoto7），Shigeto Matsushita8），Yosuke Yamamoto9），
We demonstrated the inter-allergenic correlation between total
serum IgE and allergen-specific IgE levels in atopic dermatitis（AD） Yasuhiro Nakamura1）
patients. View 39 was used to examine serum IgE levels specific to （Department of Skin Oncology/Dermatology, Saitama Medical
University International Medical Center, Hidaka1），Department of
individual allergens. 39 patients with AD were included. We
Dermatology, Shinshu University School of Medicine, Matsumoto2），
categorized the 39 allergens into 7 groups：pollen, mold, dander, food,
Department of Dermatology, Niigata Cancer Center Hospital,
latex, arthropods, and mixed house dust. IgE scale values for cedar
Niigata3），Department of Dermatology, Kyoto Prefectural University
pollen and Malassezia showed significant positive correlations withof Medicine, Kyoto4），Department of Dermatology, The University of
IgE scale values for allergens in the same allergen group and one orTokyo, Graduate School of Medicine, Tokyo5），Department of
two allergens in only one other group. In contrast, those for mites andDermatology, Graduate School of Medical Science, Kyushu University,
wheat, which correlated with total serum IgE levels, showed
Fukuoka6），Department of Dermatology, Shiga University of Medicalsignificant positive correlations with IgE scale values for allergens in 4
Science, Otsu7），Department of Dermato-Oncology/Dermatology,
and 5 other allergen groups out of 7 respectively.
NHO Kagoshima Medical Center, Kagoshima8），Department of
Dermatology, Department of Dermatology, Chiba University
E1-8（EP7-3）
Graduate School of Medicine, Chiba9））
Real-world effectiveness of abrocitinib and transcriptome analysis in
atopic dermatitis
Background：Adequate deep excision margin in invasive acral○Mayu Ohtaka，Akihiko Uchiyama，Keiji Kosaka，Mai Ishikawa，melanoma（AM）of the sole is not fully studied. Objective：
Yuuta Inoue，Sei-ichiro Motegi
Relationship between tumor thickness（TT）and histological invasion（Department of Dermatology, Gunma University, Maebashi）
was retrospectively evaluated. Methods：Data of 322 invasive AMs
were collected from 18 Japanese institutions. Results：The mostAtopic dermatitis（AD）is a common chronic inflammatory skinfrequent site of the primary tumor was the heel（49％）, followed bydisease. Herein, we analyzed 12 Japanese patients with AD treated
the thenar and hypothenar eminence（22％）. The rate of dermal
with 100 mg dose of abrocitinib, an oral selective Janus kinase 1
invasion（DI）, subcutaneous invasion（SI）, and invasion beyond
inhibitor, using our real-world data. We also performed transcriptome
subcutaneous fat（IBSF）in an entire cohort was 80％, 19％, and 1％,
analysis with peripheral blood from three patients. After 12 weeks,
respectively. The median TT in DI, SI, and IBSF cohorts was 1.6 mm,
83.3.％ and 41.6％ of the patients reached EASI-50, -75. PP-NRS4 was
5.6 mm, and 6.9 mm. Conclusion：The invasion level in most AM isachieved in 9 patients（75％）at week 12. The most frequent adverse
within the dermis. Excision at the superficial subcutaneous fat layer
event was acne（6 cases［50％］）. Gene Ontology pathway analysis
may be favorable.
using RNA-seq data set revealed attenuation of defense responses tobiotic stimulus and virus by abrocitinib treatment. Our results
E2-3（EP9-7）indicate abrocitinib as a fast-acting and highly antipruritic agent that
KS-EMPD-1：a novel cell line of primary extramammary Pagetʼs
is effective for moderate skin eruptions.
disease○Takamichi Ito，Yuka Tanaka，Toshio Ichiki，Yumiko Kaku-Ito，
E2-1（EP9-3）
Takeshi Nakahara
Activated Akt expression has the prognostic value for relapse in acral（Department of Dermatology, Kyushu University, Fukuoka）
melanomas○Takeshi Namiki1），Kohei Nojima1），Masahiro Hayashi2），
We established the first extramammary Pagetʼs disease（EMPD）cell
Atsushi Tanemura3），Tamio Suzuki2），Masashi Ishikawa4），
line, named KS-EMPD-1, from a primary tumor of an 86-year-old
5）
3）
6）
Naoya Yamazaki ，Ichiro Katayama ，Yoshiyuki Sasaki ，Japanese male. The cells were successfully maintained for more than
Naoko Okiyama1）
1 year, with a doubling time of 31.2 h. KS-EMPD-1 exhibited constant（Department of Dermatology, Tokyo Medical and Dental University,
growth, spheroid formation, and invasiveness, and was confirmed to1）
Tokyo ，Department of Dermatology, Yamagata University,
be identical to the original tumor by short tandem repeat analyses,
2）
3）
Yamagata ，Department of Dermatology, Osaka University, Suita ，whole exome sequencing, and immunohistochemistry. Western
Department of Dermatology, Saitama Cancer Center Hospital,
blotting of the cells revealed the protein expression of HER2, NECTIN
Kitaadachi4），Department of Skin Oncology, National Cancer Center
4, and TROP2, which are potential therapeutic targets for EMPD. KS-

88

EMPD-1 was highly sensitive to docetaxel and paclitaxel on
chemosensitivity test. The KS-EMPD-1 cell line will be a promisingresource for basic and preclinical research on EMPD.

E2-4（EP9-10）Analysis of surgical margins and prognostic factors in 116 Japanese
DFSP patients○Yusuke Muto1,2），Taku Fujimura2），Akira Takahashi3），
Kenjiro Namikawa4），Dai Ogata4），Eiji Nakano4），Shunichi Jinnai3），
Akira Hashimoto2），Asano Yoshihide2），Naoya Yamazaki4）（Department of Dermatology, South Miyagi Medical Center,
Shibata1），Department of Dermatology, Tohoku University Graduate
School of Medicine, Sendai2），Dermatologic Oncology, National
Cancer Center Hospital East, Kashiwa3），Dermatologic Oncology,
National Cancer Center Hospital, Tokyo4））
Wide local excision （ WLE ） is a first-line treatment fordermatofibrosarcoma protuberans（DFSP）,but the clinical outcomesand safety margin have not been evaluated. To clarify the appropriate
surgical margins for each anatomical area and prognostic factors
associated with recurrence-free survival（RFS）, we retrospectively
analyzed 116 DFSP cases. The RFS was 96.6％ at the 10-year period.
There were significant differences in RFS divided by tumor size,
disease stage（primary vs. recurrent lesion）and fibrosarcomatouschange. Two cases（1.7％）with the buccal or head lesion were positive
with the deep margin, while the lateral margin was all negative. Ourpresent study suggests appropriate surgical margins for eachanatomical area and the prognostic factors associated with the RFS.

E2-5
（EP9-15）18

F-FDG PET/CT Correlation with Tumor Stage in Acral Melanoma：
A Retrospective Study○Wei-Ting Liu，Yi-Han Chang，Tak-Wah Wong
（Department of Dermatology, National Cheng Kung University
Hospital, College of Medicine, National Cheng Kung University,
Tainan）
This retrospective study analyzed 116 cutaneous melanoma patients,
focusing on 73 with acral melanomas at National Cheng Kung
University Hospital from Jan. 2011 to Oct. 2022. Among them, 73（63％）underwent 18F-fluorodeoxyglucose（FDG）positron emission
tomography（PET）/computed tomography（CT）scans to correlate
standardized uptake value（SUV）with primary tumor depth, assess
lymph node status, and detect distant metastasis. A moderately
positive correlation between SUV and tumor depth was observed
specifically in acral melanomas（r=0.718, p＜0.001）, with no suchcorrelation in non-acral melanomas. Nodal status evaluation revealed
a 32.1％ false-positive rate and a 20％ false-negative rate. Additionally,3（4.1％）incidental secondary neoplasms and 5（6.8％）distantmelanoma metastases were detected.

E2-6（EP9-13）
Experimental and clinical evidence suggests S100A7 may be
involved in melanoma development○Quan Sun1），Ge Peng1），Wanchen Zhao1），
Alafate Abudouwanli1），Arisa Ikeda1,2），Ko Okumura1），
Hideoki Ogawa1），Shigaku Ikeda1），Francois Niyonsaba1,3）（Atopy（Allergy）Research Center, Juntendo University Graduate
School of Medicine, Tokyo1），Department of Nephrology, Juntendo
University Graduate School of Medicine, Tokyo2），Faculty ofInternational Liberal Arts, Juntendo University, Tokyo3））
Melanoma, the most severe skin cancer which poses global healthchallenges, necessitates an exploration of causal factors. Antimicrobial
protein S100A7 exhibits both antimicrobial and immunomodulatory
properties, including regulation of skin barrier function；however, its
involvement in melanoma progression remains unclear. Our study,

utilizing data from The Cancer Genome Atlas Skin Cutaneous
Melanoma（TCGA SKCM）dataset data and the Genotype-Tissue
Expression project（GTEx）revealed that S100A7 levels are
significantly higher in melanoma tissues than normal skin. Moreover,elevated S100A7 correlated with worse overall survival. Interestingly,
S100A7 enhanced migration and invasion in skin melanoma cell lines,
suggesting its potential tumorigenic role in melanoma progression.

E2-7（EP9-16）
GSDME promotes melanoma progression by regulating chromatin
accessibility of PLK4
○Juan Du，Chunying Li（Department of Dermatology, Xijing Hospital, Fourth Military
Medical University, Xiʼan）
Research has shown that chemotherapy drug mediated caspase 3
activation induces pyroptosis in cell lines with high GSDME
expression. Thus, GSDME is believed to have an anti-tumor effect inmost cancers. However, we found that GSDME is highly expressed inmelanoma compared with nevi. Thus, we supposed GSDME produces
other unknown effects in melanoma. In our study, we demonstrated
that GSDME interacts with NCL and SMARCA5 in nucleus,
mediating cell proliferation, migration and invasion by regulating
chromatin accessibility of PLK4. Abnormal expression level of PLK4
is supposed to facilitate to pathologic centrosomal amplification andcytoskeletal movement. Whatʼs more, methylation sequencing reveals
that hypomethylation of GSDME promoter region in melanoma is
responsible for the different expression level between tumors and
nevi.

E2-8
（EP9-9）Sarcopenia is a prognostic factor in advanced BRAF wild-type
malignant melanoma in Asians○Kohei Yamakawa1），Yusuke Kurita2），Hideyuki Ishikawa1），
Shingo Kato2），Yukie Yamaguchi1）（Department of Environmental Immuno-Dermatology, Yokohama
City University Graduate School of Medicine, Yokohama1），
Department of Gastroenterology and Hepatology, Yokohama City
University School of Medicine, Yokohama2））
It is unclear sarcopenia influences progression of advanced malignant
melanoma in Asians recieved Immune check inhibitor（ICI）. The
purpose of this study is to investigate the effect of sarcopenia on
overall survival（OS）and progression free survival（PFS）in Japanese.
We retrospectively reviewed clinical data of consecutive patients inpatients with advanced BRAF wild-type malignant melanoma inJapanese recieved ICI from 2013 to 2022 at our institution. We
assessed 66 patients. The median OS, in sarcopenia（n=23）and thenon-sarcopenia（n=43）patients was 9.1 and 36.8 months, respectively（hazard ratio［HR］, 3.04；p＜0.001）, and median PFS was 3.3 and120.9 months（HR, 2.14；p=0.015）. In Conclusion, Sarcopenia is apossible poor prognostic factor in malignant melanom treated with
ICI.

E3-1
（EP3-9）Polydopamine nanoparticles mitigate UVB-induced skin damage via
ferroptosis inhibition○Yuqi Zhou1），Jia Zhang1），Zhaoting Jiang1），Bo Wang1），
Qi Wang1），Zeqian Wang1），Mingfeng Zhang1），Ziwei Deng2），
Chunying Li1），Zhe Jian1）（Department of Dermatology, Xijing Hospital Fourth Military
Medical University, Xiʼan1），Key Laboratory of Applied Surface andColloid Chemistry, Ministry of Education, Shaanxi Key Laboratory for
Advanced Energy Devices, Shaanxi Engineering Lab for Advanced
Energy Technology, School of Materials Science and Engineering,
Shaanxi Normal University, Xiʼan2））

89

Photodamage―mainly caused by UVB―is a problem of paramount
impairment to the skin health of the general public. Ferroptosis is anindependent form of regulated cell death responsible for many
diseases, featuring iron accumulation and derailed lipid peroxidation.
However, the underlying role of ferroptosis in UVB-predominatedskin damage has not yet been fully investigated. Polydopamine
nanoparticles（PDA NPs）synthesized to mimic natural melanin are
considered a promising material as a UV filter. Here, we used RNA
sequencing of the skin from UVB-radiated mice, confirming thecritical implication of ferroptosis in UVB exposure. PDA NPs could
target PTGS2 and GPX4, rectify disturbed homeostasis of redox andiron, and inhibit NCOA4-mediated ferritinophagy, ultimately,intervening in UVB-induced ferroptosis. These findings may offer aperspective of PDA NPs functioning as ferroptosis inhibitors inphotoprotection.

E3-2（EP8-2）Anti-eIF2B antibody Detection by ELISA in Japanese Patients with
Systemic Sclerosis○Haruka Koizumi1），Yoshinao Muro1），Yuta Yamashita1），
Satoshi Kamiya1），Norika Akashi1），Mariko Ogawa-Momohara1），
Takuya Takeichi1），Yasuhiko Yamano2），Yasuhiro Kondoh2），
Masashi Akiyama1）（Department of Dermatology, Nagoya University, Nagoya1），
Department of Respiratory Medicine and Allergy, Tosei General
Hospital, Seto2））
Anti-eukaryotic initiation factor 2B（eIF2B）antibodies have been
described as autoantibodies associated with diffuse cutaneous type ofsystemic sclerosis（SSc）
and interstitial lung disease. Although twentyfive European patients have been reported, their frequency andclinical significance are still unclear in Japanese SSc patients. We
screened the 222 serum samples from SSc patients with enzymelinked immunosorbent assay（ELISA）using the recombinant eIF2B
protein. Highly reactive sera in ELISA were further tested byimmunoprecipitation-western blotting. As a result, we detected threepatients with anti-eIF2B antibodies. Clinical characteristics of thesecases were summarized and compared with previously reported
cases.

E3-3（EP8-3）
Inhibition of IgG Extravasation to Mucous Membranes with TKIs in a
Murine Pemphigus Model○Yukako（Duerna）Akamatsu（Tie）1），Takashi Nomura1,2），
Kenji Kabashima1）（Department of Dermatology, Graduate School of Medicine, Kyoto
University, Kyoto1），Department of Drug Development for
Intractable Diseases, Graduate School of Medicine, Kyoto University,
Kyoto2））In our previous murine pemphigus model study, imatinib, a multitarget tyrosine kinase inhibitor（TKI）, effectively reduced IgG
extravasation from endothelial cells, decreasing IgG deposition in
cutaneous tissues. However, the impact on mucous membranes（MM）
was not fully explored. In this study, we intravenously administeredmurine anti-desmoglein（Dsg）3 antibodies, assessing their depositionin MM through flow cytometry and histopathology. Our results
demonstrated that circulating anti-Dsg3 IgG can reach MM underhomeostatic conditions. Additionally, TKIs such as imatinib, asciminib
and sunitinib, prevented in vivo transvascular transport of IgG. Ourfindings suggest that ABL1, VEGFR2, and PDGFR beta TKIs canblock homeostatic transvascular IgG transport to MM tissues.

E3-4（EP8-7）
The role of IL-7/IL-7R mediates stem cell-like Hobit+CD8+ TRM in
vitiligo recurrence○Yuqian Chang，Shuli Li，Chunying Li

90（Department of Dermatology, Xijing hospital, Fourth Military
Medical University, Xiʼan）
TRM cells are key in vitiligo recurrence, yet their roles and regulation
are not fully understood. Our srudy unearthed a distinct expansion of
Hobit-expressing CD8+ TRM cells within stable vitiligo lesions. Notably,
these cells exhibited elevated IL-7RA expression, with IL-7 also
upregulated in inflammatory keratinocytes and fibroblasts within thelesions. IL-7 treatment boosts Hobit expression in vitiligo patientderived CD8+ T cells. Furthermore, Hobit+CD8+ TRM cells uniquely
express TCF7 and LEF1 stem cell transcription factors.
Immunofluorescence of vitiligo lesions shows Hobit+CD127+CD8+ TRM
and Hobit+TCF1+CD8+ TRM cell accumulation at the superficial dermis
and epidermal-dermal junctions. Our findings highlight the criticalrole of Hobit+CD8+ TRM cells in vitiligo recurrence.

E3-5（EP3-6）
Objective and Subjective Assessment of Effect of Exosomes against
Androgenic Alopecia○Yishan Liu1），Cheuk-Kwan Sun2），Ju-Fang Wu3）
（I-Shou University College of Medicine；E-Da Hospital Departmentof Dermatology, Kaohsiung1），I-Shou University College ofMedicine；E-Da Hospital Department of Emergency Medicine,
Ksohsiung2），Kaohsiung Municipal United Hospital Department ofPharmacy, Kaohsiung3））
Introduction：Androgenetic alopecia（AGA）is characterized byprogressive terminal hair loss with psychiatric comorbidities of social
barrier and lower self-esteem. Objectives：The study aims toevaluate exosome in treating AGA physiologically andpsychologically. Method：This was a single-blind treatment-control
side study with enrolling six AGA subjects. Exosome was applied ontreatment side of vertex once weekly for 12 weeks. Hairy area wasassessed by hair covering scalp surface（HCSS）scores andDermatology Life Quality Index（DLQI）was collected before and after
therapy. Results：Objective analysis of HCSS scores showed overt
elevation（p＜0.05）. Subjective survey of DLQI dropped significantly（p＜0.05）indicating remarkable improvement. Conclusion：Exosome
may be an effective treatment option in AGA.

E3-6
（EP8-5）
DNA methylation analysis Reveals Epigenetic Perturbations ofVitiligo Tregs○Jianru Chen，Xinju Wang，Wei Wu，Qingrong Ni，Kaiqiao He，
Luling Huang，Weiwei Sun，Jinrong Fan，Shuli Li，Chunying Li（Department of Dermatology, Xijing Hospital, Fourth Military
Medical University, Xiʼan）
Tregs play pivotal roles in regulating the immune homeostasis invitiligo. DNA methylation is a key epigenetic modification that
controlling cell phenotype and function. Genome-wide DNA
methylation profiling identified 8642 and 887 differentially methylated
regions（DMRs）in vitiligo Tregs from blood and lesions. Enrichment
analysis of DMR-related genes revealed terms related to thedifferentiation or function of Tregs. Multiple genes overlapped withvitiligo risk genes. Additionally, the involvement of TBX21-, STAT1-,STAT5A-, and RUNX3-related transcription factors binding sites in
Th1 cell differentiation highlighted the aberrant Treg phenotype. By
integrating DMRs and scRNA-seq data, we identified a set ofoverlapping genes that potentially affect Tregs cellular fate andfunction.

E3-7（EP8-10）Oxidative Stress-Induced S100B：Enhancer of Immune Responses
in Vitiligo○Shuli Li，Wei Wu，Xinju Wang，Jianru Chen，Jinrong Fan，
Luling Huang，Weiwei Sun，Chunying Li

（Department of Dermatology, Xijing Hospital, Fourth Military
Medical University, Xiʼan）
Vitiligo is an immune-mediated depigmentation skin disorder. Our
previous research indicates an increase of S100B in patients withactive vitiligo with unclear mechanism. In this study, we discoveredthat under H2O2, melanocytes secreted significantly more S100B. This
S100B amplified dendritic cellsʼ antigen uptake potential andpromoted their maturation. Furthermore, S100B directly enhanced
their cytotoxic functionality. In vivo studies demonstrate that the
suppression of S100B hinders the speed of depigmentation
progression. In conclusion, our findings demonstrated the integral role
S100B plays in oxidative stress-mediated vitiligo autoimmunity,
suggesting that S100B could serve as a potential clinical target for
vitiligo treatment.

E3-8（EP8-11）
Dimethyl itaconate halts vitiligo depigmentation by suppressing DCCD8+ T cell responses○Yinghan Wang，Yuhan Chen，Jingjing Ma，Shuli Li，Chunying Li（Department of Dermatology, Xijing Hospital, Fourth Military
Medical University（Air Force Military Medical University）, Xiʼan）
Dendritic cell（DC）and CD8+ T cell-triggered immune responses are
critical for orchestrating epidermal melanocyte destruction causing
vitiligo, which is challenging to treat. Although circulating itaconate
was upregulated in vitiligo patients, deletion of endogenous itaconate
accelerated depigmentation and administration of itaconate
derivative dimethyl itaconate（DI）halted vitiligo development andreversed to repigment. Mechanistically, DI dampened CD8+ T cell
activation, effector function, cytotoxicity, and proliferation, partiallyby suppressing JAK-STAT pathway. DI also hurdled DC cutaneous
infiltration, maturation, and migration. Our findings support that DI
represents a promising pillar to optimize vitiligo therapy bysuppressing DC and CD8+ T cell responses.

E4-1（EP6-2）
Inflammatory myopathy following COVID-19 mRNA vaccination in apatient with VEXAS syndrome○Masakazu Kakurai1），Rie Honda1），Akihiro Kuroda2），
Naomi Tsuchida3,4,5），Ayaka Maeda5），Yuri Uchiyama3,4），
Naomichi Matsumoto3），Shusaku Ito1）（Division of Dermatology, Hitachi General Hospital, Hitachi1），
Division of Hematology, Hitachi General Hospital, Hitachi2），
Department of Human Genetics, Yokohama City University Graduate
School of Medicine, Yokohama3），Department of Rare Disease
Genomics, Yokohama City University Hospital, Yokohama4），
Department of Stem Cell and Immune Regulation, Yokohama City
University Graduate School of Medicine, Yokohama5））
A 75-year-old male with VEXAS syndrome presented with fever,headache, dyspnea, dysphagia, and painful erythematous swelling of
the lower jaw and occipital region 5 days after the third COVID-19
vaccination. Skin biopsy of the occipital region showed partial
inflammatory cell infiltrates in the subcutaneous tissue. Computed
tomography showed swelling of the platysma and occipitalis muscle,suggesting myositis. Three-day methylprednisolone pulse therapy（1000 mg/day）followed by prednisolone（60 mg/day）improved
lesions. Inflammatory myopathy was reported after COVID-19
vaccination in healthy individuals；however, this is the first case in
VEXAS syndrome with myositis following COVID-19 vaccination. We
discuss the possibility of the vaccination causing myopathy in thepresent case.

E4-2（EP6-5）
Burdock-derived Arctiin may alleviate psoriatic symptoms via PI3K-

Akt signaling pathway○Mengyao Yang1,2,3），Tao Wang4），Xuefei Du2,3），Wanchen Zhao1），
Alafate Abudouwanli1），Quan Sun1），Arisa Ikeda1,5），Ge Peng1），
Francois Niyonsaba1,6），Long Geng2,3）（Atopy（Allergy）Research Center, Juntendo University Graduate
School of Medicine, Tokyo1），Department of Dermatology, The First
Hospital of China Medical University, Shenyang2），NHC Key
Laboratory of Immunodermatology, Ministry of Education Key
Laboratory of Immunodermatology, National Joint Engineering
Research Center for Diagnosis and Treatment of Immunologic Skin
Diseases, The First Hospital of China Medical University,
Shenyang3），Department of Urology, The Peopleʼs Hospital of
Liaoning Province, Shenyang4），Department of Nephrology, Juntendo
University Graduate School of Medicine, Tokyo5），Faculty ofInternational Liberal Arts, Juntendo University, Tokyo6））
Arctiin, a compound from burdock exhibits multiple pharmacologicalproperties however, its effect on psoriasis remains unclear. To
understand the mechanisms underlying arctiinʼs therapeutic effects
on psoriasis, 19 intersecting targets between arctiin and psoriasis
were identified based on network pharmacology. KEGG pathway
enrichment analysis showed significant involvement of these targets,particularly the PI3K-Akt signaling. In an imiquimod-induced
psoriasis-like mouse model, arctiin significantly reduced the severityof skin lesions and associated inflammatory cytokines. Arctiin also
effectively inhibited PI3K and Akt phosphorylation in the lesional
skin, suggesting that arctiin may alleviate psoriasis, potentiallythrough the inhibition of the PI3K-Akt signaling pathway.

E4-3（EP6-6）
AMP-IBP5 Attenuates Psoriatic Symptoms via LRP1 Signaling○Ge Peng1），Saori Yoshiba1），Lixia Cui2），Wanchen Zhao1），
Alafate Abudouwanli1），Quan Sun1），Ko Okumura1），
Hideoki Ogawa1），Shigaku Ikeda1），Francois Niyonsaba1,3）（Atopy（Allergy）Research Center, Juntendo University Graduate
School of Medicine, Tokyo1），Department of Dermatology, the Second
Affiliated Hospital of Hainan Medical University, Hainan2），Faculty ofInternational Liberal Arts, Juntendo University, Tokyo3））
Psoriasis is a chronic inflammatory skin disease characterized bydysregulated immune response, abnormal epidermal differentiationand overexpression of antimicrobial peptides. Low density lipoprotein
receptor-related protein 1（LRP1）regulates inflammatory reaction andkeratinocyte differentiation；however, its role in the development ofpsoriasis remains unclear. Genomic data and immunohistochemistryof human skin showed that LRP1 expression was significantly
reduced in psoriatic skin compared to the normal skin or nonlesional
skin. Interestingly, administration of the LRP1 activator, AMP-IBP5,
reduced skin inflammation in control psoriatic mice but not in LRP1deficient psoriatic mice. Our results suggest that LRP1activation
might be a new potential target for psoriasis treatment.

E4-4（EP11-2）
Influence of Risk Factors and Therapies on Prognosis of Herpes
Zoster○Marika Matsuya1），Motoshi Sugawara2），Takeshi Iwasaki3），
Motoshi Kinouchi1）（Department of Dermatology, Asahikawa Red Cross Hospital,
Asahikawa1），Department of Dermatology, Asahikawa Medical
University, Asahikawa2），Nishino Dermatology Clinic, Sapporo3））
To investigate the influence of risk factors and therapies on the
prognosis of herpes zoster（HZ）such as developing postherpetic
neuralgia（PHN）,we used structural equation modelling with a data
set of 305 HZ patients. Characteristic factors of patient（CF）such as
age and immune status strongly affected symptom ＆ therapy-related
factors（STF）：eruption severity, choice of anti-viral drug, and use of
systemic steroid；standardized coefficient β was 0.80［ P ＜.01］. CF

91

tended to influence prognosis of HZ indirectly via STF（β= 0.53；P=.41）rather than in direct（β= 0.37；P =.58）. This model showed agood fit（Tucker-Lewis：1.00；Root Mean Square Error of
Approximation：0.051）. Our findings facilitate understanding of therelationship between risk factors, therapies and the prognosis of HZ.

E4-5（EP2-5）
Monocyte-to-Lymphocyte Ratio and Eosinophils-to-Lymphocyte
Ratio for Scabies diagnosis○Ha Thi Thao Mai1），Nguyen Hoang Viet2），Espinoza Luis3）（Faculty of Medicine, Can Tho University of Medicine and Pharmacy,
Can Tho1），Hanoi Medical University, Hanoi2），Faculty of Health
Sciences, Kanazawa University, Kanazawa3））
Scabies is a neglected tropical disease associated with a large healthburden worldwide. We tested the utility of whole blood cell countparameters obtained at diagnosis in a set of 167 Vietnamese patientswith confirmed scabies as compared with those of urticaria（n=2025）and dermatophytosis（n=800）. Monocyte and eosinophil counts,
monocyte to lymphocyte rate（MLR）and eosinophils to lymphocyte
rate（ELR）were significantly higher in patients with scabies than inthose with urticaria and dermatophytosis. MLR（66％ sensitivity, 79％
specificity）and ELR（75％ sensitivity, 77％ specificity）were usefulfor distinguishing scabies from the above two diseases as assessed by
a ROC analysis. MLR and ELR are low-cost and easily calculatedparameters that may be helpful for the diagnosis of scabies.

E4-6（EP6-4）
Schnitzler syndrome with an immunoglobulin A gammopathy
exacerbated by COVID-19 infection○Yasuaki Ikuno，Toshifumi Takahashi，Takuya Nagata，Shuji Sugiura，Akihiko Yamaguchi，Noriki Fujimoto（Department of Dermatology, Shiga University of Medical Science,
Otsu）
Schnitzler syndrome（SchS）is a rare autoinflammatory diseasecharacterized by chronic urticarial rash and monoclonal IgM or IgG
gammopathy. Viruses, including COVID-19, activate the innate
immune system；therefore, SchS, in which the innate immune
system is improperly activated, is estimated to be exacerbated by
infection. However, there were no reported SchS cases exacerbatedby infection. We reported a SchS case with an unusual IgA
gammopathy manifested and exacerbated by COVID-19 infection.
This report suggests that COVID-19 infection would exacerbate
autoinflammatory diseases via inflammasome activation. We advocate
exacerbation of existing autoinflammatory diseases by COVID-19
infection.

E4-7（EP11-1）
Disseminated Mucocutaneous Leishmaniasis Coinfected by Two
Distinct Species○Yuki Kobayashi1），Takeshi Ouchi1），Takashi Okada2），
Kenta Kobayashi1），Haruka Omasa1），Takayuki Fusumae1），
Sayuka Arakawa1），Chizu Sanjoba3），Yasuyuki Goto3），
Takeru Funakoshi1）（Department of Dermatology, Keio University School of Medicine,Tokyo1），Department of Otorhinolaryngology, Keio University Schoolof Medicine, Tokyo2），Laboratory of Molecular Immunology,
Department of Animal Resource Sciences, Graduate School of
Agricultural and Life Sciences, The University of Tokyo, Tokyo3））
A 54-year-old Japanese man with a travel history to South America
presented with multiple skin and mucosal ulcers, which had
deteriorated under the immunosuppressive treatment at previous
hospitals. PCR analysis of the skin specimen confirmed the presenceof Leishmania（L.）infantum , reaching a diagnosis of disseminatedcutaneous leishmaniasis. Tapering immunosuppressive agents and92

administration of liposomal amphotericin B and itraconazole
significantly improved his general condition and the skin lesions.
Three years after the remission, he developed nasal septal perforation
and PCR analysis from the nasal mucosa identified another species, L.
braziliensis . Response to treatment differs by species and clinicalforms. We review coinfected cases of leishmaniasis by different
species.

E4-8（EP2-2）Clinical and Immunological profiles of BP180 NC16A CLEIA false
negative case of Pemphigoid○Masahiro Tsutsumi1），Hiroshi Koga1），Kwesi Teye2），
Norito Ishii1），Takekuni Nakama1）（Department of Dermatology, Kurume University School of Medicine,
Kurume1），Kurume University Institute of Cutaneous Cell Biology,
Kurume2））
Chemiluminescent enzyme immunoassay（CLEIA）for BP180 NC16
A is a valuable test for pemphigoid, but it causes false negative resultsin rare cases. Among the patients with pemphigoid who wereconsulted to our department, we analyzed 24 BP180 NC16A CLEIAnegative/ELISA-positive cases, including 16 bullous pemphigoid（BP）,
5 mucous membrane pemphigoid（MMP）, and 3 unclassifiable
pemphigoid patients. BP patients had higher ELISA values andpresented more severe phenotypes than the other groups（ELISA
indices；9-88, 9-16, and 16-24/total BPDAI；6-145, 4-20, and 28-67, in
BP, MMP, and unclassifiable, respectively）. Positive findings wereobtained in 88％ of the cases with at least one immunological test. The
BP180 NC16A ELISA is considerable when the BP180 NC16A CLEIA
result is negative.

Oral Presentation in English（Poster）
Poster Venue（1F New Hall, Kyoto International Conference Center）

Presentation number means

EP1-1
Category number

Order

Date and Time：
June 6（Thu.） 13：00〜18：30
June 7（Fri.） 8：30〜19：10
June 8（Sat.） 8：00〜19：00
June 9（Sun.） 8：00〜14：00
Poster discussion is open-ended. Speakers should stand by in front of the poster at the poster discussion
time.
Order Number - Odd numbers
June 6（Thu.） 16：15〜17：45
Order Number - Even numbers
June 7（Fri.） 18：10〜19：10※Please confirm Odd or Even based on the Presentation Order number.

Poster Number

94

Category

EP1-1〜8

Basic researchEP2-1〜5

Diagnosis

EP3-1〜9

Treatment

EP4-1〜2

Dermatopathology

EP5-1〜2

Dermatologic surgery

EP6-1〜6

Inflammatory diseaseEP7-1〜7

Allergic diseaseEP8-1〜11

Autoimmune diseaseEP9-1〜16

Tumor

EP10-1〜5

Congenital disease

EP11-1〜7

Infectious disease

EP12-1〜7

OthersPoster Venue

95EP1-1
On-line Monitoring of Minerals in Human Sweat○Yanbei Zhu1），Kenshin Takemura2），Yuichi Watanabe2），
Wataru Iwasaki2），Kazuya Kikunaga2），Takashi Fukuda2），
Kazumi Inagaki1）（National Institute of Advanced Industrial Science and Technology,
Research Institute for Material and Chemical Measurement,
Tokyo1），National Institute of Advanced Industrial Science andTechnology, Sensing System Research Center, Tsukuba2））
A double-pass online device was developed for measuring sweat, one
pass for mineral analysis and the other for sweat quantitation. Purewater and dry air were used as carriers for mineral analysis by an
inductively coupled plasma mass spectrometer and sweat
quantitation by a humidity sensor, respectively. The accuracies ofmineral analysis and sweat quantitation were confirmed by using aflow injection system, resulting recovery values over 98％ withstandard deviation values under 2％. Online concentration-to-time
profiles of minerals（e.g. Na, Mg, K, and Ca）in sweat samples showed
different trends during the sweating process by riding a stationary
bike, perhaps indicating the source of surface adhesion, stagnant in
the sweat pore, and fresh sweat. Details will be presented on-site.

EP1-2
Inverse relationship between MZB1+B cells and disease severity ofalopecia areata○Takayoshi Komatsu-Fujii，Toshiaki Kogame，Keigo Takase，
Akitaka Hata，Kenji Kabashima（Department of Dermatology, Kyoto University, Kyoto）
Background ： Alopecia
areata （ AA ） involves
autoimmune
mechanisms usually driven by CD8+T cells. Despite few B cells in AA
lesions, evidence suggests their relevance in disease. Methods：To
explore B cell roles in AA, we used a multi-faceted approach,analyzing
publicscRNA-seq
dataandconducting
immunohistochemistry. Results were compared with AA severity.
Results：scRNA-seq identified MZB1+B cell clusters, validated byimmunohistochemistry. MZB1+B cells inversely correlated with
SALT score in AA patients without atopic dermatitis. Conclusion：
This study suggests a potential novel B cell population in AA lesions,revealed by scRNA-seq and immunohistochemistry.

EP1-3
Cholesterol sulfate is increased in the stratum corneum of AD andpsoriasis○Shown Tokoro1），Tadayuki Ogawa2），Ken Igawa1）（Department of Dermatology, Dokkyo Medical University,
Shimotsuga1），Comprehensive Research Facilities for Advanced
Medical Science, Dokkyo Medical University, Shimotsuga2））
In 1984, Epstein et al. reported cholesterol was sulfated in the viableepidermis by cholesterol sulfotransferase and cholesterol sulfate（CS）
was desulfurized in the stratum corneum by steroid sulfatase. Theycoined the term the epidermal cholesterol sulfate cycle for thisphenomenon and we succeeded to clearly visualize this cycle byimaging mass spectrometry. We found this cycle was disrupted in thelesional skin of atopic dermatitis（AD）and psoriasis with excessive
CS in the stratum corneum. CS is reported to increase stratum
corneum retention through its function as a serine protease inhibitor
and abnormal scaling seen in both diseases can be explained by thispathology. Quantification of CS by tape stripping could be a futurebiomarker to assess subclinical inflammation.

EP1-4（E1-2）
Please refer Oral Presentation in English

EP1-5（E1-3）
Please refer Oral Presentation in English

EP1-6（E1-1）
Please refer Oral Presentation in English

EP1-7
Withdrawn

EP1-8
M1 Macrophage may regulate innate immune system in woundhealing through interleukin-1β○Wei-Cheng Fang1），Hsuan Cheng2），Shu-Mei Huang2,3），
Cheng-Che E Lan2,3）（Department of Dermatology, Kaohsiung Municipal Siaogang
Hospital, Kaohsiung1），Department of Dermatology, Kaohsiung
Medical University Hospital, Kaohsiung2），Department of
Dermatology, Collage of Medicine, Kaohsiung Medical University,
Kaohsiung3））
Wound healing is a complex process involving platelets, neutrophils,
and macrophages, fibroblasts, endothelial cells, and keratinocytes.
Macrophages, pro-inflammatory macrophages, are key immune cells
that defense against infections and regulate wound healing throughinfluencing migration and proliferation of keratinocytes. Human βdefensins are antimicrobial peptides secreted by keratinocytes andplay an important role in wound healing. Studies have shown that
increased M1 macrophages and expression of hBDs were found inchronic wounds healing. However, the association between M1
macrophages and hBDs secreted from keratinocytes remains obscure.
We designed an experiment to investigate whether the cytokines
secreted from M1 macrophages affect the expression of hBDs in
keratinocytes.

EP2-1
Tentative new terminology：Initial comedonal phase of acne vulgaris○Ichiro Kurokawa1），Yuko Nomura2），Toshitatsu Nogita3）（Department of Dermatology, Meiwa Hospital, Tokyo1），Nomura
Dermatology Clinic, Yokohama2），Shinjuku Minamiguchi
Dermatology Clinic, Tokyo3））
We report a case of a 12-year-old female with closed and open comedo
without inflammatory lesions at the first visit. She had been treatedwith topical adapalene once daily, and closed and open comedo
subsided without inflammatory lesions one month after the treatment
without any side effects induced by adapalene. The recurrence of
comedo had not been observed afterwards. In the Japanese
Dermatological Association（JDA）guidelines for the treatment of acne
vulgaris, comedonal phase has not been stated. Then we propose thetentative new terminology of a comedonal phase and emphasize its
importance in the early initial treatment for comedo to prevent thedevelopment of the acute inflammatory phase such as red papules
and pustules and formation of acne scars.

EP2-2（E4-8）
Please refer Oral Presentation in English

EP2-3
Clinical significance of papular acne scar
○Toshitatsu Nogita1），Ichiro Kurokawa2），Yuko Nomura3）（Shinjuku Minamiguchi Dermatology Clinic, Tokyo1），Department of
Dermatology Meiwa Hospital, Tokyo2），Nomura Dermatology Clinic,
Yokohama3））
We report seven cases of papular acne scar. Acne scars can present

96with varying morphologies.The morphologic acne scar classification
system includes five main types of scars：ice pick, rolling, boxcar,
hypertrophic, and keloidal. Precise diagnosis of the scar subtype isimportant in guiding therapeutic management. Papular acne scar was
reported as expand the acne scar classification system. Papular acne
scars are 3 to 4mm skin-colored cobblestone-like papules distributed
most commonly on the chin, nose, and back. Papular acne scar canclinically mimic closed comedones, acne and granulomas, leading to an
unnecessary delay in appropriate treatment. Knowledge of this typeof acne scar aids in preventing a misdiagnosis of acne and guides
appropriate scar-directed management.

EP2-4
An elder case of Subcutaneous panniculitis-like T-cell lymphoma○Natsumi Hara，Hikaru Kawahara，Natsuko Sasaki，Yu Sawada（Department of Dermatology, University of Occupational andEnvironmental Health, Kitakyushu）
A 64 years old female experienced persistent fever and generalized
edema for one month. Bone marrow examination denied malignant
lymphoma. A skin biopsy taken from erythematous induration
revealed atypical lymphocytes of various sizes proliferating in the
subcutaneous adipose tissue. Immunohistochemical staining
examination showed positive reactions to CD3, CD5, granzyme B, andTIA-1, and negative for CD20 and CD56. Based on the clinicalmanifestation and histological examination, we diagnosed as
subcutaneous panniculitis-like T-cell lymphoma. We also reviewed theprevious published cases to clarify the prognosis and therapeutic
outcomes.

EP2-5（E4-5）
Please refer Oral Presentation in English

EP3-1
Measurement of Clinical Outcomes of Netherton Syndrome After
Treatment with Upadacitinib○Ryo Fukaura1），Chiaki Murase1），Naoto Yamada2），
Natsuno Izuchi1），Hidesada Adachi2），Tomoki Taki1），
Shinya Hara3），Takuya Takeichi1），Masashi Akiyama1）（Department of Dermatology, Nagoya University, Nagoya1），Toyota
Memorial Hospital Department of Dermatology, Toyota2），Toyota
Memorial Hospital Department of Paediatrics, Toyota3））Netherton Syndrome（NS）is a severe autosomal recessive syndromic
congenital ichthyosis, associated with variants in SPINK5 . We
identified a patient with NS who experienced severe atopic as well as
ichthyotic symptoms, for whom we started upadacitinib, a Janus
kinase（JAK）-1 inhibitor. We monitored the activity of NS subjectively
through scoring systems, and objectively through eosinophil and
TARC levels in peripheral blood, and hair area percentage and hairshaft diameter. In the first month of treatment, her symptoms
improved both subjectively and objectively. However, from month
two onwards, her symptoms worsened, and this was again provenobjectively. This is the first time that changes in NS symptoms
including hair features on upadacitinib have been demonstrated
objectively.

EP3-2
Noble Melanoma Targeted ChemoThermoImmunoTherapy by
Melanogenic NPrCAP Nanoparticle○Kowichi Jimbow1），Shosuke Ito2），Kazumasa Wakamatsu2），
Akira Ito3），Hiroyuki Honda4），Tokimasa Hida5），
Yasuaki Tamura6），Toshihiko Torigoe6）（Institute of Dermatology ＆ Cutaneous Sciences, Sapporo1），
Institute for Melanin Chemistry, Fujita Health University,
Toyoake2），Department of Chemical Systems Engineering, School ofEngineering, Nagoya University, Nagoya3），Department of

Biomolecular Engineering, School of Engineering, Nagoya University,
Nagoya4），Department of Dermatology, Sapporo Medical University
School of Medicine, Sapporo5），Department of Pathology, Sapporo
Medical University School of Medicine, Sapporo6））
Noble ChemoThermoImmunoNanomedicine is developed by
exploiting synthetic melanogenic tyrosinase substrate, N-propionyl
cysteaminylphenol（NPrCAP）as a melanoma-targeted chemoimmunotherapy drug through selective incorporation into melanoma
with highly reactive molecule, which resulted in apoptotic cell deathand heat-shock protein production. The drug was further attached tomagnetite nanoparticles in order to heat melanoma cells by exposing
to alternating magnetic field, which caused non-apoptotic cell deathand heat shock protein（thermo-immunotherapy）that can be further
used for peptide immuno-vaccine. Our studies have clearly shownthat NPrCAP nanoparticle is non-toxic to humans and selectively
incorporated into and disintegrate both primary and metastatic/
unresectable melanomas.

EP3-3
Generalized Pustular Psoriasis Complicated by Bullous Pemphigoid
Responded to Spesolimab○Risa Nakane，Ayaka Obata，Taiyo Hitaka，Natsuko Sasaki，
Yu Sawada（Department of Dermatology, University of Occupational andEnvironmental Health, Kitakyushu）
A 75-year-old male was diagnosed with psoriasis vulgaris in 1985 anddeveloped bullous pemphigoid around the year 2000. His bullous
pemphigoid and psoriasis were well-controlled with betamethasone
and cyclosporine. However, he suddenly experienced erythrodermawith pustules on his whole body. A skin biopsy revealed Kogojʼsspongiform pustule, leading to the diagnosis of generalized pustular
psoriasis. The pustules and erythroderma were quickly improved byspesolimab without the worsening of blister formation.

EP3-4
The Efficacy of Early Pulsed Dye Laser Treatment for Superficial
Type Infantile Hemangioma○Eiki Sugimoto，Maiko Fukayama，Jun Omatsu，Hinako Saito，
Yurika Osuji，Yusuke Watanabe，Hikari Boki，Tomomi Miyake，
Ayumi Yoshizaki，Shinichi Sato
（Department of Dermatology, The University of Tokyo Hospital,
Tokyo）
Although pulsed dye laser treatment has limited efficacy in tumor
reduction, it induces vascular destruction on the skin surface, leading
to discoloration. Therefore, it is often used for superficial type infantile
hemangiomas, either as monotherapy or in combination with
propranolol. In our study, we retrospectively evaluated 100 patientswith superficial infantile hemangiomas, which comprised a total of 105
lesions at our outpatient clinic. For these patients, we started pulsed
dye laser treatment early and assessed the extent to which the color
tone had lightened with image analysis software. Compared toprevious studies, patients treated with early laser intervention
showed significant improvement in color tone.

EP3-5
Brodalumab Rapidly Modulates Psoriasis Pathology○Akimichi Morita1），James G Krueger2），Chiharu Tateishi3），
Eisaku Ogawa4），Koji Masuda5），Yukie Yamaguchi6），
Sandra Garcet2），Hong Hur2），Mona Uchida-Yamada7），
Yasumasa Kanai7）（Department of Geriatric and Environmental Dermatology, Nagoya
City University Graduate School of Medical Science, Nagoya1），
Laboratory for Investigative Dermatology, The Rockefeller
University, New York2），Department of Dermatology, Osaka

97

Metropolitan University Graduate School of Medicine, Suita3），
Department of Dermatology, Shinshu University School of Medicine,
Matsumoto4），Department of Dermatology, Kyoto Prefectural
University of Medicine, Graduate School of Medical Science, Kyoto5），
Department of Environmental Immuno-Dermatology, Yokohama City
University Graduate School of Medicine, Yokohama6），Medical
Affairs, Kyowa Kirin Co., Ltd., Tokyo7））
The IL-17 axis is important in psoriasis. We aimed to characterize themolecular profile of IL-17 receptor A blockade by brodalumab. Skin
specimens and serum samples from Japanese patients who received
brodalumab（n=37 at week 12）were used for RNA sequencing andproteomics. 3419 genes in the lesional skin and 22 proteins in theserum at beseline were upregulated compared to those from healthy
volunteers. The median PASI score at baseline（19.0）significantly
reduced to 0.4 at week 12（P ＜ 0.0001）. Upregulated top 50
differentially expressed genes in baseline lesional skin began to be
suppressed from week 4. Serum proteins also began to be suppressedfrom week 2. In addition to the PASI score improvement, brodalumab
modulated molecular pathology in both skin and serum as early as
week 2.

EP3-6（E3-5）
Please refer Oral Presentation in English

EP3-7
Sebetralstat KONFIDENT Is the First Phase 3 On-demand HAE Trial
to Include Japanese Sites○Daisuke Honda1），Michihiro Hide2），Isao Ohsawa3），
Yuko Watanabe4），James Hao5），Michael D. Smith5），
Christopher M. Yea5），Paul K. Audhya5），Marc A. Riedl6），
Danny M. Cohn7）（Department of Nephrology, Chiba University Graduate School of
Medicine, Chiba1），Hiroshima City Hiroshima Citizens Hospital,
Hiroshima2），Saiyu Soka Hospital, Soka3），Yokohama City University
Graduate School of Medicine, Yokohama4），KalVista Pharmaceuticals,
Salisbury5），University of California - San Diego, San Diego6），
Amsterdam UMC, University of Amsterdam, Amsterdam7））

treatment within the previous 3 months, with a history of melanoma
or other skin cancers, or with immunosuppressive diseases were
excluded.
Main Outcomes and Measures： The percentage change of VASI.
Conclusions and Relevance： 308 nm excimer light therapy is a safeand effective treatment strategy for pediatric vitiligo patients, botholder and younger than 6 years.

EP3-9（E3-1）
Please refer Oral Presentation in English

EP4-1
Lymph Vascular Obstruction Could Result in Edema, Erythema andFibrosis of Face
○Shuhei Imayama1），Seiya Momosaki2）（IMAYAYAMA Shuhei Clinic ＆ Lab, DermatoPathology,
Fukuoka1），National Hospital Organization Kyushu Medical Center,
Department of Pathology, Fukuoka2））
A 71-year-old man presented with persistent swelling of both upper
eyelids together with firmly edematous erythema on his face. Upper
eyelid resection was performed to recover impaired visual field.
Histology of the bulky eyelids showed numerous granulomas
obstructing the lumens of collecting lymph vessels below dermis. The
obstructions led to diffuse edema of the surrounding connective
tissue. Dermal layer above the obstructed vessels exhibited fibrosis
andlymphocytic
infiltration
aroundhair
follicles.
Immunohistochemistry showed macrophages with M1 feature in thelymph vessels.
It is likely that obstruction of the collecting lymph vessels produced
the edematous thickening of the regional skin along with fibrosis andchronic inflammation around the adnexa.

EP4-2

Patterns and Trends in Skin Cancer in Sri Lanka（2015-2022）○U.M. Navami P. Samaranayake1,2），
U.M. Jayami E. Samaranayake1），Roshana Constantine2），
Yasith Mathangasinghe3,4），Modini Jayawickrama2），
Janaka Akarawita2）
KONFIDENT is an international, randomized, double-blind, placebo（Postgraduate Institute of Medicine, University of Colombo,
controlled, 3-way crossover trial evaluating efficacy and safety of theColombo1），National Hospital of Sri Lanka, Colombo2），Department oforal plasma kallikrein inhibitor sebetralstat for on-demand treatment
Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine,of hereditary angioedema（HAE）. 136 participants were randomized
University of Colombo, Colombo3），Biomedical Discovery Institute,to treat 3 attacks of any severity or location（except severe laryngeal）
Faculty of Medicine, Nursing and Health Sciences, Monash
with sebetralstat 300 mg, 600 mg, or placebo. Primary endpoint：time
University, Melbourme4））
to beginning of symptom relief（Patient Global Impression of Change
rating of at least A Little Better 2 time points in a row）within 12
This study reports the dynamic landscape of skin cancer in Sri Lanka,h.
providing the first comprehensive analysis of patterns and trends
Seven adults from 4 sites in Japan randomized：median age 48 y, 6
using consecutive biopsies of suspected neoplastic skin lesions fromfemales, 7 had HAE-1（median 10 y since diagnosis）, 4 taking on2015 to 2022 at the National Hospital of Sri Lanka. Annual incidence
demand therapy with and 3 without prophylaxis at screening. Resultsshows a consistent increase, with a notable dip in 2021 attributed towill be presented at the meeting.
the COVID-19 pandemic. The most prevalent skin cancer, squamouscell carcinoma（SCC）, exhibits age distribution deviations from theEP3-8regional norms. Gender differences primarily manifest in SCC,
Safety and Efficacy of 308 nm Excimer Light in Children with Vitiligo
diverging from the global trend of male preponderance seen in basal○Wei Wu，Li Luo，Bona Zhang，Xiaoli Liu，Wenjing Tang，cell carcinoma. Moreover, the research unveils rarely reported
Yuehua Li，Shengchun Wang，Shuli Li，Chunying Li，Qiong Shi
subtypes, shedding light on the impact of（epi）genetics and diverse（Department of Dermatology, Xijing Hospital, Fourth Militarymodifiable risk factors within the unique context of Sri Lanka.
Medical University, Xiʼan）
Importance： Evidence for the safety and effectiveness of 308 nm
excimer light phototherapy in pediatric vitiligo is limited.
Design： This cohort study retrospectively collected data on the useof 308 nm excimer light phototherapy for pediatric vitiligo between
2010 and 2022.
Participants： In total, 413 stable vitiligo patients aged 侑 14 years
were included for analysis. Patients who received any vitiligo

98

EP5-1
Withdrawn

EP5-2
Reconstruction of a Lateral Eyelid Defect following Mohs Surgery○Nerice Ngiam1），Hsi-Wei Chung2），Choon Chiat Oh1）
（Department of Dermatology, Singapore General Hospital,

Singapore1），Department of Ophthalmology, Singapore National Eye
Center, Singapore2））
A 50 year old male with referred for a histology-proven 3.8mm x 4.2mm endocrine mucin-producing salivary gland carcinoma near thelateral aspect of his right lower eyelid. Excision with clear margins
was achieved with Stage 1 of Mohs micrographic surgery, resulting in
a 20mm x 6mm defect involving the lateral aspect of the lower eyelid.
Hewes procedure for reconstruction of the posterior lamella defectwas used, harvesting a right upper lid tarsal-conjunctival flap of 4mm
and swung down to bridge the lower lid posterior lamella defect,
hinged at lateral angle. This was sutured to the lower lid orbicularisand lateral retractors. The anterior lamella defect was addressed witha skin myocutaneous flap harvested from upper lid. Flaps remained
healthy during his postoperative follow up visits.

EP6-1
Withdrawn

EP6-2（E4-1）
Please refer Oral Presentation in English

EP6-3
Efficacy of pulsed dye laser in facial redness of atopic dermatitis○Yuko Kuriyama1），Sei-ichiro Motegi1），Shinji Noda2）（Department of Dermatology, Gunma University, Maebashi1），Tokyo
Dermatology in Ikebukuro, Tokyo2））
Facial redness of atopic dermatitis（AD）is often intractable since theclinical symptom is affected by multiple factors, including eczematouschange, telangiectasia, and steroid-induced rosacea-like dermatitis.
Although pulsed dye laser（PDL）is an essential treatment for vascularlesions, it is also an FDA-approved treatment for nonvascularinflammatory diseases, such as acne and psoriasis. Here we report
three cases of AD in which PDL was effective for facial lesions. After
five to ten sessions of PDL treatment, facial redness and recurrent
symptoms were significantly reduced. The efficacy of PDL on eczema
has only been reported in non-facial sites or in children, and this is thefirst to show its effect. Our result suggests that PDL could be a novel
therapy for facial redness in AD.

EP6-4（E4-6）
Please refer Oral Presentation in English

EP6-5（E4-2）
Please refer Oral Presentation in English

EP6-6（E4-3）
Please refer Oral Presentation in English

EP7-1（E1-6）
Please refer Oral Presentation in English

EP7-2（E1-7）
Please refer Oral Presentation in English

EP7-3（E1-8）
Please refer Oral Presentation in English

EP7-4
Toxic Epidermal Necrolysis Associated With Cytomegalovirus
Infection○Yuki Kobayashi1），Kyoko Kanno1），Kaori Umekage1），
Chiaki Takahashi1），sawa Otsubo1），Mari Kishibe1），

Akemi Yamamoto1），Aiko Noguchi2），Kouji Takarada3）（Department of Dermatology, Asahikawa Medical University,
Asahikawa1），Department of Dermatology, Asahikawa Kosei General
Hospital, Asahikawa2），Department of Ophthalmology, Asahikawa
Medical University, Asahikawa3））
Toxic Epidermal Necrolysis（TEN）is a severe, life-threatening
dermatological condition that causes extensive epidermal detachment
and mucosal involvement. Although medication is the most common
trigger, infections can also be associated with TEN. We present a caseof an 80-year-old patient with fever, conjunctival injection, anderythema with blisters on the lower extremities caused bycytomegalovirus infection. The clinical features, diagnostic challenges,
treatment approach, and outcome are discussed in detail. This casehighlights the importance of considering viral etiologies in TEN casesand emphasizes the need for early recognition, timely intervention,and multidisciplinary management.

EP7-5
Voluntary Exercise Alleviates Inflammatory Responses in a Mouse
Model of Atopic Dermatitis○Wanchen Zhao，Ge Peng，Alafate Abudouwanli，Arisa Ikeda，Quan Sun，Shigaku Ikeda，Hideoki Ogawa，Ko Okumura，Francois Niyonsaba（Atopy（Allergy）Research Center, Juntendo University Graduate
School of Medicine, Tokyo）
Atopic dermatitis（AD）is a chronic inflammatory skin disorder,
primarily characterized by cycles of eczema flare-ups and itching,with multiple underlying causes involving dysfunctional skin barriers
and abnormal immune regulation. Recent studies indicated thatsedentary life may worsen AD symptoms while exercise can reducechronic inflammatory skin disorders. This study investigated theeffects of voluntary and forced exercise on AD mouse model. The
results showed that AD mice engaging in voluntary exercise but notforced exercise showed reduced ear swelling, decreased
inflammatory cell infiltration and lower serum total IgE levels,
compared to non-exercising controls. These findings suggest thatappropriately tailored exercise may help suppress inflammatory
responses in AD subjects.

EP7-6
A Study on Drug Patch Testing in Severe Cutaneous Adverse Drug
Reactions（SCARs）○Dulini Liyanagama1），Janaka Akarawita2）（Consultant Dermatologist, Base Hospital Rikillagaskada,
Rikillagaskada1），Consultanat Dermatologist, National Hospital of Sri
Lanka, Colombo2））
We have Patch Tested（PT）32 patients with SCAR who presented to
the Dermatology unit of National Hospital Sri Lanka. The PTmaterials were prepared manually from the commercially available
drugs.Overall, Patch Test positivity for the tested drugs was 34.37％（11/32）. 3 out of15 patients with Steven Johnson Syndrome /Toxic
Epidermal Necrolysis, 3 out of 6 patients with Acute Generalized
Exanthematous Pustulosis, 4 out of7 patients with Drug Rash with
Eosinophilia and Systemic Symptoms and 1 out of 3 patients with
Exfoliative Dermatitis showed positive results for the PT culprit drug.
Patch testing did not provoke the initial SCAR in any of our patients.
Drug patch testing can be a useful tool to confirm drug imputability
established on clinical grounds and a safe procedure to perform in
SCARs.

EP7-7
Exposure to Air Hydrocarbons on Visits for Atopic Dermatitis inCentral-Southern Taiwan○Hui-Wen Tseng1,2）

99

（Department of Dermatology, Ministry of Health and Welfare
Pingtung Hospital, Ping-Tung1），School of Medicine, National Sun
Yat-Sen University, Kaohsiung2））

collected in our institution and tracked clinical courses in some cases.

EP8-5（E3-6）
Please refer Oral Presentation in English

This study investigated associations between daily visits of patientswith atopic dermatitis（AD）and exposure to ambient air methane andEP8-6
non-methane hydrocarbons using Poisson regression. The dependent+
variable was visits counts of AD（ICD-9（10）-CM code 691.8, L20） Memory and TCF1 T Cells Aid in Diagnose and Monitor Disease
Activity in Vitiligo
retrieved from Taiwan National Health Insurance Research Database○Xinju Wang，Jianru Chen，Wei Wu，Jinrong Fan，
（NHIRD）from 2008/01/01 to 2018/12/31 in central-southern Taiwan.
Luling Huang，Weiwei Sun，Kaiqiao He，Shuli Li，Chunying Li
Independent variables included one-day 75th-percentile values of air
pollutants and meteorologic data retrieved from Taiwan Air Quality （Department of Dermatology, Xijing Hospital, Fourth Military
Medical University, Xiʼan）
Monitoring Network Databases, and patients with allergic diseases
from NHIRD. The results showed that the air concentrations ofVitiligo is an autoimmune skin disease characterized by immune
methane and non-methane hydrocarbons were significantly postively
memory. TCF1 plays a crucial role in maintaining the pool of memory
affected the total daily visits and subgroup analysis of men andT cells. We analyzed the circulating T-cell profiles and frequencies ofwomen.
TCF1+ T cells in 31 patients with active vitiligo, 22 with stable vitiligo,
and 30 controls. Our findings revealed higher frequencies ofEP8-1
terminally differentiated effector memory T cell（TEMRA）subsets in
A case of intractable Pemphigus Vulgaris effectively treated withactive vitiligo. Vitiligo also showed increased levels of TCF1+ T cell
Rituximab
subsets. Disease activity was correlated with CD8+ and CD4+ central○Hibari Nakajima1），Airi Osawa2），Shoko Watanabe2），, and CD8+ TEMRA subsets. The combination of four CD8+
memory（TCM）
Asami Takehana2），Sonoko Jikuya2），Tadashi Koyama3），+
TCF1 T cell subsets（naive, effector memory, TCM, and TEMRA）had
Norito Ishii4），Yoshihiro Kuwano2）
relatively high diagnostic value, and CD8+ T-cell subsets combination（Department of Dermatology, Graduate School of Medicine, The
performed well in discriminating disease activity.
University of Tokyo, Tokyo1），Department of Dermatology, Teikyo
2）
University Hospital, Kawasaki ，Department of Pulmonology, Teikyo
EP8-7（E3-4）
University Hospital, Kawasaki3），Department of Dermatology,
Please refer Oral Presentation in English
Faculty of Medicine, Kurume University, Kurume4））
A 54-year-old man with Castlemanʼs disease was referred to our
hospital due to erosions and blisters on his armpits and femurs. The
DPP-4 inhibitor was stopped and biopsy was performed. Lab data
showed elevation of Dsg1 and 3. As for DI test, lace-like IgG deposition
on epidermis and acantholysis was observed. Anti-epithelial cellsurface antibody was positive in IIF. Only Dsg3 was positive inWestern Blotting. No antibodies related to Paraneoplastic Pemphigus
was observed. These findings led to the diagnosis of Pemphigus
Vulgaris. This case was intractable though existing treatments suchas prednisolone, IVIg and plasmapheresis were tried. Administrationof Rituximab led to the decrease of blisters and antibody titer. The
symptom has not recurred though prednisolone was decreased.

EP8-2（E3-2）
Please refer Oral Presentation in English

EP8-3（E3-3）
Please refer Oral Presentation in English

EP8-4
Analysis for Characteristic Distribution of Vitiligo Lesions on the
Hand○Kazunori Yokoi，Jing Wang，Atsushi Tanemura，Haruna Kawashima，Narumi Jikihara，Eiji Kiyohara，Manabu Fujimoto（Department of Dermatology, Osaka University Graduate School of
Medicine, Suita）
Vitiligo is a depigmentation disorder with selective loss ofmelanocytes and is sometimes long-lasting due to the difficulty of acomplete cure. Although vitiligo involves any part of the body
distributing symmetrically in non-segmental type, vitiligo lesions on
the face and hands show a significantly higher psychological burden
for patients than those for others. To our knowledge, there are no
detailed reports to characterize vitiligo lesions on the hand, which are
critical in terms of cosmetic impact as well as face. Herein, we
analyzed the unique characteristics of vitiligo lesions on the hand

100

EP8-8
TFAP2B：A New Marker of Epidermal Melanocytes and Essential for
Melanocyte Regeneration○Jingjing Ma，Sen Guo，Xiuli Yi，Weinan Guo，Chunying Li（Department of Dermatology, Xijing Hospital, Fourth Military
Medical University, Xiʼan）
This study was designed to decipher the role of TFAP2B in
mammalian melanocyte regeneration. We found that TFAP2B was
specifically expressed in epidermal melanocytes of human and mouseskin and located in the nucleus. Its expression is significantly andpositively correlated with the expression of melanocyte marker, DCT.
During mouse hair follicle cycle, TFAP2B is present in the nucleus of
McSCs and mature melanocytes in follicle. We observed a decline in
the amount of McSCs in follicle as well as the appearance of white hairin melanocyte lineage-specificity knockout mice of TFAP2B. Also, there was fewer epidermal melanocytes in（miceMC：TFAP2B-/-）
miceMC：TFAP2B-/- after UVA irradiation. Further, TFAP2B enhanced thetranscription of MITF and KIT through binding to their promoters.

EP8-9
Efficacy and safety of Janus kinase inhibitors in patients with vitiligo○Linhan Jiang，Weinan Guo，Shuli Li，Chunying Li（Department of Dermatology, Xijing Hospital, Fourth Military
Medical University, Xiʼan）
Janus kinase（JAK）inhibitors have been used in the treatment of
vitiligo, but no comprehensive meta-analysis has analyzed the efficacy
and safety of JAK inhibitors in vitiligo. We searched 4 databases and 5
randomized clinical trials were included. JAK inhibitors showed asignificantly higher 75％ improvement on the facial Vitiligo Area
Scoring Index response rate compared to placebo（pooled relative risk
（RR）, 3.55；95％ confidence interval（CI）, 2.33-5.40）, and wereassociated with a non-statistically significant higher risk of serious
adverse events（pooled RR, 1.43；95％ CI, 0.48-4.27）. Our analysis
suggests a statistically significant benefit and favorable safety profile
of JAK inhibitors for the treatment of vitiligo, and topical JAK

inhibitors have demonstrated salient efficacy.

EP8-10（E3-7）
Please refer Oral Presentation in English

EP8-11（E3-8）
Please refer Oral Presentation in English

EP9-1
GAB1：：ABL1 fusion-positive spindle cell neoplasm○Erena Kimura1），Toshihisa Hamada1），Kazuma Ito1），
Akari Matsuoka1），Yuta Norimatsu1），Taro Akatsuka1），
Sohshi Morimura1），Mina Komuta2），Takayuki Shiomi2），
Makoto Sugaya1）（Department of Dermatology, International University of Health andWelfare, Ohtawara1），Department of Diagnostic Pathology,
International University of Health and Welfare, Ohtawara2））
A 33-year-old woman presented with a firm subcutaneous tumor of
the right posterior neck that had gradually grown in size for ten
years. MRI imaging of the tumor revealed a contrast-enhancing welldemarcated nodular mass with 5 cm in size, adjacent to the rightsemispinalis capitis muscle. The histopathological examination of theresected tumor showed haphazardly arranged spindle cells with oval
nuclei and a glassy fibrotic stroma. The immunohistochemical studyof the spindle cells revealed positive for CD34 and S-100（partially）,
and negative for α-SMA and desmin with low Ki-67 labelling index.
RNA sequencing revealed a GAB1：：ABL1 fusion. Based on thesefindings, we diagnosed this case as GAB1：：ABL1 fusion-positive
spindle cell neoplasm.

EP9-2
A case of sarcomatoid dedifferentiated melanoma○Taro Akatsuka1），Toshihisa Hamada1），Kazuma Ito1），
Akari Matsuoka1），Erena Kimura1），Yuta Norimatsu1），
Sohshi Morimura1），Makoto Sugaya1），Ryosuke Matsuoka2），
Mina Komuta2）（Department of Dermatology, International University of Health andWelfare, Nasushiobara1），Department of Pathology, International
University of Health and Welfare, Nasushiobara2））
A 54-year-old woman presented with a granulomatous tumor withblack-pigmented nail fold on the left big toe. The nail of her left hallux
fell off one year before and a hemorrhagic tumor had grownprogressively. X-ray revealed osteolysis in the distal part of theproximal phalanx and distal phalanx of the toe. Skin histology in theblack-pigmented area showed an aggregation of atypical cells positive
for S-100, HMB45, Melan-A, and PRAME from the epidermis to theupper dermis. Spindle-shaped cells with eosinophilic cytoplasm in the
deep dermis, however, showed storiform proliferation and negative
for the last three markers, leading to the diagnosis of sarcomatoid
dedifferentiated melanoma. After amputation of the left toe,nivolumab and ipilimumab combination therapy was started.

EP9-3（E2-1）
Please refer Oral Presentation in English

EP9-4
A Case of Signet-Ring Cell Carcinoma, Found Only in the Perianal
Lesion○Sayuri Nakano1），Masaaki Kawase1），Ryosuke Hashizume2）（Department of Dermatology, The Jikei University Katsushika
Medical Center, Tokyo1），Department of Surgery, The Jikei
University Katsushika Medical Center, Tokyo2））
A 79-year-old woman presented to our department with a growing

perianal mass from two years ago. A skin biopsy was obtained, which
revealed a thickened epidermis and numerous atypical cells. Signetring cells were also present in the epidermis, PAS（+）and alcian blue（+）.No obvious tumor was observed in the dermis. Immunostaining
was cytokeratin 7（+）, cytokeratin 20（+）, GCDFP15（-）, androgen
receptor（-）,and CDX2（+）.Computed tomography showed no othertumor masses or lymphadenopathy, and metastatic gastric or lungcancer was unlikely. A colonoscopy revealed no colorectal tumor andonly inflammation. The patient was treated with radiotherapy. Signetring cell carcinoma with only a cutaneous mass is very rare.

EP9-5
Dermatofibrosarcoma protuberance mimicking neurofibroma arisingfrom a conventional area
○Takayuki Suyama1），Megumi Yokoyama1），Jun Matsushima2），
Yasunori Matsuki1），Kazumoto Katagiri1）（Department of Dermatology, Dokkyo Medical University Saitama
Medical Center, Koshigaya1），Department of Pathology, Dokkyo
Medical University Saitama Medical Center, Koshigaya2））
A 21-year-old Japanese man had a tumor in the abdomen Initial
examination revealed a pedunculated soft nodule（size, 30 x 25 x 7mm）on the elastic hard induration（size, 40 x 40 x 6 mm）.According
to the skin biopsy, neurofibroma or other mesenchymal tumor wasconsidered. The tumor was excised. Histopathology revealed that theupper part of the tumor comprised spindle cells with abundant
stroma with low cellularity. At the base, many spindle cells werearranged in a storiform pattern expanding around fat cells with highcellularity. On immunohistochemistry, the tumor cells of both upperand lower parts were positive for CD34, and negative for S-100.
Several histopathologic variants of DFSP are now recognized. In ourcase, the upper part was considered a low cellular type of myxoid
DFSP.

EP9-6
（E2-2）
Please refer Oral Presentation in English

EP9-7（E2-3）
Please refer Oral Presentation in English

EP9-8
Milia en Plaque on the Face After Electron Therapy for
Folliculotropic Mycosis Fungoides○Takuya Kawamura1），Yasuyuki Yamaguchi1），Sho Katayama1），
Yu Fujimura1），Kentaro Izumi1），Motoyasu Shido2），
Takayuki Hashimoto2），Hideyuki Ujiie1）（Department of Dermatology, Faculty of Medicine and Graduate
School of Medicine, Hokkaido University, Sapporo1），Department ofRadiation Oncology, Faculty of Medicine, Hokkaido University,
Sapporo2））
An 81-year-old male presented to our department after a 10-year
history of erythema on the whole body. Histopathological evaluation
lead to the diagnosis of folliculotropic mycosis fungoides（FMF）.Afterelectron beam radiotherapy（ERT）for the erythematous plaques,multiple milia appeared only on his face among all irradiated sites.
Milia en plaque（MEP）is characterized by clumps of milia overlying
erythema. Although the pathogenesis is unclear, secondary milia are
believed to develop from eccrine sweat ducts and hair follicles. In ourcase, MEP appeared only on the face after ERA for the FMF plaques.
An abundance of pilosebaceous units on the face and the damage
caused by atypical lymphocytes and ERT may have been involved inthis unique distribution.

EP9-9（E2-8）
Please refer Oral Presentation in English

101EP9-10（E2-4）
Please refer Oral Presentation in English

EP9-11
Investigation of gene specificity in metastatic acral melanoma among
Asian patients○Yu-Jen Chiu1），Jai-Sing Yang2）（Department of plastic and reconstructive surgery, Taipei Veterans
General Hospital, Taipei1），China Medical University Hospital,
Taichung2））
Melanoma is less common yet more lethal in Asians compared to
Caucasians, often exhibiting severe cases with poor responses totherapies. Our research contrasts genomic profiles in Asian and
Caucasian melanomas, revealing notable differences such as lower UV
signatures and tumor mutational burden in Asians. We explored gene
expression in acral and non-acral Asian melanomas through RNA
Sequencing, finding significant variances in cell cycle andimmunogenic genes, correlating with mutation characteristics andhigher mutational burdens in non-acral types. This study focuses on
RNA Sequencing of metastatic and in situ tumor cells in Asian acralmelanoma, aiming to identify biomarkers for metastatic melanoma in
the Asian population, crucial for new drug development.

EP9-12
Granulomatous Mycosis Fungoides：A Diagnostic Challenge○Nurrahma Wahyu Fitriyani1），Arif Widiatmoko1），
Diah Prabawati Retnani2）（Department of Dermatology, Faculty of Medicine, Universitas
Brawijaya, Malang1），Department of Pathology, Faculty of Medicine,
Universitas Brawijaya, Malang2））
Granulomatous mycosis fungoides（GMF）is a rare variant of Mycosis
fungoides（MF）as subtypes of cutaneous T-cell lymphoma（CTCL）.
Establishing the diagnosis is a challenge for dermatologists. We reporta case of a 42 year old male, with erythematous macula-papules of
45％ BSA and hyperpigmented striae. Erythematous plaques, erosion,and ulcers were found on dorsum manus sinistra. Skin-colorednodules were found in the right cubital fossa. Moon face, enlarged colli
and inguinal lymph nodes were also found. Blood evaluation showedleukocytosis and lymphocytosis with atypical lymphocytes. Sezary
cells were negative. Histopathological evaluation on HE staining
showed a dendritic neoplasm. Immunohistochemistry evaluation werepositive on CD3 and CD-68 which indicated a granulomatous reaction.

EP9-13（E2-6）
Please refer Oral Presentation in English

EP9-14
Endocrine Mucin-Producing Sweat Gland Carcinoma：A Rare
Lesion of the Eyelid○Andrea Jing Shi Ang1），Fan Foon Cheo2），Choon Chiat Oh1）
（Department of Dermatology, Singapore General Hospital,
Singapore1），Department of Pathology, Singapore General Hospital,
Singapore2））
We report a 50-year-old male who presented with a painless,enlarging papule on the right eyelid of 2 years duration. He had aprevious renal transplant and was on Tacrolimus and Prednisolone.
Biopsy revealed a low-grade neoplasm with cribiform architecture
and mucin production. Subsequent immunohistochemistry wassuggestive of Endocrine Mucin-Producing Sweat Gland Carcinoma（EMPSGC）. In view of positive margins, the patient was treated withMohʼs Micrographic Surgery.
EMPSGC is a rare primary cutaneous adnexal neoplasm. This is thefirst reported case in a renal transplant patient, to the best of our102

knowledge. This case highlights the importance of a high index of
suspicion for malignancy in immunocompromised patients with nonresolving lesions, and the need for regular skin checks.

EP9-15（E2-5）
Please refer Oral Presentation in English

EP9-16（E2-7）
Please refer Oral Presentation in English

EP10-1IgA nephropathy and scalp squamous cell carcinoma associatedwith epidermolysis bullosa○Ko Sunagawa，Taisuke Kanno，Hitoshi Urakami，Shogo Ikezawa，Mikiko Takigawa，Yoji Hirai，Yoshio Kawakami，Shin Morizane（Department of Dermatology, Okayama University Graduate Schoolof Medicine, Dentistry, and Pharmaceutical Sciences, Okayama）
A 68-year-old woman, with recurrent bullae on her extremities
accompanied by nail dystrophy, presented with a 30x40 mm tumor on
the occipital region. She was undergoing peritoneal dialysis for IgA
nephropathy. Based on a diagnosis of squamous cell carcinoma（SCC）,
wide excision was performed. Plasma cells infiltrated both the SCC
and the peripheral bullous region. Whole exome sequencing revealed
compound heterozygous mutations c.6216 + 5G＞T and c.6091 G＞A（p.Gly2031Ser）in the COL7A1 gene, consistent with recessive
dystrophic epidermolysis bullosa（RDEB）. Accumulating reports ofIgA nephropathy in RDEB, suggest that recurrent infections from thebullous lesions may have led to the induction of plasma cells
producing abnormal secretory IgA, which subsequently deposited in
the glomeruli.

EP10-2
A Case of Castlemanʼs disease Associated with Recessive
Dystrophic Epidermolysis Bullosa○Satsuki Naruse1），syouta Takashima1），Yasuyuki Fujita2），
Hiroshi Kataoka3），Nobuaki Kawamura4），Ken Natsuga1），
Hideyuki Ujiie1）（Department of Dermatology, Hokkaido University, Sapporo1），
Department of Dermatology, Sapporo City General Hospital,
Sapporo2），Department of Rheumatolory ＆ Clinical Immunology,
Sapporo City General Hospital, Sapporo3），Department of Pediatrics,
Sapporo City General Hospital, Sapporo4））
A Japanese female with recessive dystrophic epidermolysis bullosa（RDEB）, diagnosed based on skin fragility and COL7A1 variants,
developed recurrent anemia, fever, and systemic melaise. At age 16,
flat elevated nodules with plasma cell infiltration appeared on theerosive areas of her back. Elevated IL6 levels in the serum, along withskin and lymph node histopathology, led to the diagnosis ofmulticentric Castelmanʼs disease（MCD）,which possibly developed asa secondary condition to RDEB. Treatment with tocilizumab, an antiIL6 monoclonal antibody, improved her symptoms. MCD is a rareautoinflammatory
disordercharacterizedbyfever,
hypergammaglobulinemia, and lymphadenopathy, driven by IL6
overproduction. To our knowledge, this is the second reported case of
MCD concurrent with RDEB.

EP10-3（E1-4）
Please refer Oral Presentation in English

EP10-4
Combination of oral propranolol therapy and laser therapy for
infantile hemangioma○Daisuke Omoto，Koji Nishihori

（Nishihori Clinic of Plastic Surgery, Nagoya）
In Japan, oral propranolol therapy is now the first choice of treatment
for infantile hemangioma. However, oral therapy carries the risk ofsystemic side effects such as hypoglycemia, and in addition, there aremany cases of residual lesions after treatment is completed. Pulseddye laser therapy is considered to be less effective in shrinking
tumors, there is no concern about systemic side effects, and theimprovement in color tone is significant. Furthermore, a synergistic
effect is now expected when laser therapy is used in combination withoral propranolol therapy. In this study, we report on thecharacteristics of patients with residual lesions after oral propranolol
therapy, and we also report on the results with both oral propranolol
therapy and laser therapy at the same time.

EP10-5（E1-5）
Please refer Oral Presentation in English

EP11-1（E4-7）
Please refer Oral Presentation in English

EP11-2（E4-4）
Please refer Oral Presentation in English

EP11-3An Illustrative Case of Tuberculous Tenosynovitis Presenting as
Subcutaneous Nodules○Jacqueline JL Liew1），Adeline MY Yong2），Chee Hian Tan3）（National University of Singapore, Yong Loo Lin School of Medicine,Singapore1），Division of Dermatology, Department of Medicine,National University Hospital, Singapore, Singapore2），National Skin
Centre, Singapore, Singapore3））
A 70 year-old Chinese female with systemic lupus erythematosus onoral prednisolone and azathioprine presented with 18 days of fever
and multiple enlarging subcutaneous nodules over her right elbow,
lateral right arm and dorsal right hand. Ultrasonography of the righthand nodule revealed evidence of tenosynovitis, for which biopsy
showed multiple non-necrotising granulomas. Acid fast bacilli wereidentified on Ziehl-Neelsen stain. A diagnosis of multifocal tuberculous
tenosynovitis was made. The patient was treated with rifampicin,
isoniazid, pyrazinamide and ethambutol with resolution of lesions.
Tenosynovitis must be considered in the evaluation of dermal nodules
with no surface changes. Atypical infections should be excluded inpatients taking long term oral immunosuppressive drugs.

EP11-4
Pretty leprosy as special characteristics in elderly leprosy patient○Rusmawardiana Rusmawardiana，Fifa Argentina，Raden Pamudji，Rina Novriani（Dermatology Venereology and Aesthetic Medicine, Faculty of
Medicine Universitas Sriwijaya, Palembang）
Background：Leprosy is a chronic granulomatous infectious diseasecaused by Mycobacterium leprae. One of its classification isborderline lepromatous（BL）. BL is characterised by pretty leprosy.
BL Leprosy is managed with multibacillary multidrug therapy（MBMDT）. Case：A man 70-year-old with an erythematous plaque on
face since 3 years ago with lesions extending to trunk and limbs.
Histopathological examination showed typical features of BL leprosy.
Patient received MB MDT therapy, and improvement was observed
after 4 weeks of administration. Discussion：MB MDT may eradicate
more than 50％ of bacteria in BL, which may provide significant
improvement of pretty leprosy. Conclusion：MB MDT for extensive
BL leprosy lesions provide significant improvement of itsʼ special
characteristics.

EP11-5
Dermoscopic Patterns of Tinea Infections―A Cross-Sectional Study○Thanushah Balendran（Senior Registrar in Dermatology, Postgraduate Institute of Colombo,
Colombo）
Curently we are facing an epidemic of tinea infection in Sri Lanka.
Irrational use of topical steroids either alone or in combination with
antifungals has contributed immensely to this development.
Dermoscpoe pattern recognition is a simple bedside assessment
would help to minimize the misdiagnosis and improper treatments. A
cross sectional study was carried out at Teaching Hospital, Batticaloa
for the priod of 3 months. Dermscopic assessment was done using
Dermlite DL4. Different patterns of scales, changes in lesional hairs,
pale pink backgroungs with brown balck dot and globules, evidence ofpruritus and evidence of topical steroid suage were the distintive
observations made by using dermoscope. A distinctive beach wave
pattern scales which is a newer finding observed in this study.

EP11-6
Neglected for 25 Years：A Case Report on Overlooked Cutaneous
Tuberculosis○Emy Kusumaningsih（Simpang Lima Gumul General Hospital, Kediri）
Cutaneous Tuberculosis（TB）is an infection of the skin caused by M.
tuberculosis. Diverse clinical manifestations and rarity present
challenges in global prevalence understanding, diagnostic, andtherapeutic. A 58-year-old man with a neck rash for 25 years, feelsensations of itching, pain, and warmth. History of uncontrolled type 2
diabetes is evident（random blood glucose 323 mg/dL；fasting blood
glucose 114 mg/dL；HbA1C 9.4％）. Diagnosis confirms lupus
vulgaris, a cutaneous TB type, through histopathological finding of
granulomas and Langerhans cells. Treatment involves fusidic acidointment, ibuprofen, metformin, acarbose, and a TB drugs. Lesions
improved after a month but itching persisted. Further care with urea
cream, fusidic acid, and oleum olivarum notably enhanced skincondition.

EP11-7Anti-GM-CSF autoantibodies in immunocompetent patients withcutaneous cryptococcosis○Li-Wen Chiu1,2），Wei-Cheng Fang3）（Department of Dermatology, Kaohsiung Medical University
Hospital, Kaohsiung1），Department of Dermatology, College ofMedicine, Kaohsiung Medical University, Kaohsiung2），Departmentof Dermatology, Kaohsiung Municipal Siaogang Hospital,
Kaohsiung3））
Disseminatedcryptococcosis
occurspredominatelyin
immunocompromised patients. In immunocompetent hosts, even
localized cutaneous cryptococcosis are rare. We present a previously
healthy 50-year-old man who had an incidental finding of a lungnodule during a health examination. A nodule on his left cheek thenemerged. Biopsy of the facial nodule and lung nodules both showed
cryptococcosis. Disseminated cryptococcosis was diagnosed.
Cryptococcus gatti was isolated. Further immunology survey foundanti-GM-CSF antibodies in this patient, which may cause the patient
to be more susceptible to cryptococcus infection. We hereby suggest
further survey for anti-GM-CSF antibodies in immunocompetentpatients with disseminated cryptococcosis, especially if cryptococcus
gatti is isolated.

EP12-1
A case of dermatopathic lymphadenopathy with atopic dermatitis○Akira Kaneko1），Ryoko Sakamoto2），Satoshi Fukushima1）（Department of Dermatology and Plastic Surgery, Faculty of Life103

Sciences, Kumamoto University, Kumamoto1），Kumamoto Regional
Medical Center, Kumamoto2））
A 38-year-old man had a history of severe atopic dermatitis（AD）.
Two weeks before our consultation, lower leg edema appeared andskin condition was worsened. Blood tests showed elevated levels of
eosinophils, IgE, TARC, and sIL2R. Additionally, we confirmed
atypical lymphocytes. CT scan showed axilla and inguinal
lymphadenopathy. This case required differentiation from malignant
lymphoma, however skin and inguinal lymph node biopsies revealed
no malignancy. We diagnosed dermatopathic lymphadenopathy（DL）
with AD and started treatment with cyclosporine. Four months after
that, lymphadenopathy was reduced and skin condition was
improved. Because DL-related AD is relatively rare, we report ourcase with a literature review.

EP12-2
A Case of Pediatric Cutaneous Sarcoid Vasculitis○Yukino Kase1,2），Ryota Hayashi1），Kanade Shimada1,2），
Yuka Tsutsui1），Osamu Ansai1），Koichi Tomii1），Riichiro Abe1），
Utako Kaneko3）（Division of Dermatology, Niigata University Graduate School of
Medical and Dental Sciences, Niigata1），Division of Dermatology,
Nagaoka Red Cross Hospital, Niigata2），Department of Pediatrics,
Niigata University Graduate School of Medical and Dental Sciences,
Niigata3））
An 11-year-old girl presented with a 15-month history of painful
erythema on both legs. She was diagnosed with erythema nodosum（EN）, and prescribed potassium iodide. However, the eruption did not
improve, and ulcers developed on her toe. Skin biopsy showedcollections of epithelioid histiocytes and giant cells in the dermis andsubcutaneous fat tissue. The walls of vessels were surrounded by
infiltrated granulomas. Sarcoidosis was suspected, however otherorgan involvements were not observed. We diagnosed her withcutaneous sarcoid vasculitis（CSV）. She was treated withprednisolone 30mg/day, and her eruption gradually improved. CSV israre and a case of pediatric CSV has not been reported. CSV should
be included in the differential diagnosis when EN like erythema withulcers are shown.

EP12-3
A case of calciphylaxis associated with hyperparathyroidism andpanhypopituitarism○Atsushi Naito1），Yumi Masuo1），Kohdai Furuta1），
Ichiro Yamauchi2），Masakazu Fujimoto3），Saeko Nakajima1），
Naotomo Kambe1），Kenji Kabashima1）（Department of Dermatology, Kyoto University Graduate School of
Medicine, Kyoto1），Department of Diabetes, Endocrinology andNutrition, Kyoto University Graduate School of Medicine, Kyoto2），
Department of Diagnostic Pathology, Kyoto University Graduate
School of Medicine, Kyoto3））
Calciphylaxis is an ischemic vasculopathy often associated withdialysis. Endocrine disorders are also known as contributing factors.
A 58-year-old Japanese woman with hepatorenal syndrome（HRS）
after liver transplantation who was not on dialysis developed painfulwhitish atrophic lesions in both her inner thighs. Skin biopsy revealed
calcium deposition in the lobular septal walls and the small vessels inthe subcutaneous fat, suggesting calciphylaxis. Her blood calcium
level was normal, while her parathyroid hormone and phosphorus
levels were high, suggesting secondary hyperparathyroidism（SHPT）
due to HRS. Close examinations also revealed previously undetectedpanhypopituitarism. Panhypopituitarism may have worsened renal
function and SHPT, and triggered the onset of calciphylaxis.

104

EP12-4The Risk Investigation of Deep Venous Thrombosis Associated withLower Leg Cellulitis○Romane Teshima，Natsuko Sasaki，Yu Sawada（Depertment of Dermatology, University of Occupational andEnvironmental Health, Kitakyushu）
Cellulitis inflammation is believed to increase the risk of deep venous
thrombosis（DVT）.On the contrary, the extended bed rest of the legs
due to cellulitis has also associated with the risk. Therefore, it remains
controversial to conclude the causal influence of DVT formation inpatients with cellulitis. We examined 158 patients over the age of 18
treated with lower leg cellulitis. Seven of these patients（4.4％）（mean
age：78 years, male：female ratio 5：2）had DVT. Three patients had
DVT on the afflicted side and 4 cases on the unaffected side without
significant differences. Because patients with cellulitis of the lower
legs increases the risk of DVT possibly due to the extended bed rest,
the some therapeutic options, such as early mobilization might
prevent DVT development.

EP12-5
Lp Is Superior to Secretome in Enhancing Skin Fibroblast
Proliferation in Photoaging○Nora A Nora Ariyati1），Kusworini Kusworini2），
Nurdiana Nurdiana3），Yohanes Widodo Wirohadidjojo4）（Aurell Skin Care Private Clinic by Dermatologist, Malang1），
Department of Clinical Pathology, Faculty of Medicine, Brawijaya
University-Dr. Saiful Anwar General Hospital, Malang2），Departmentof Pharmacology, Faculty of Medicine, Brawijaya University,
Malang3），Department of Dermatology and Venereology, Faculty of
Medicine, Gadjah Mada University-Sardjito General Hospital,
Yogyakarta4））
Researchers compared Warthonʼs Jelly mesenchymal stem cellsecretome with Platelet Rich Fibrin lysate（L-PRF）, a cheaper andeasier therapy, to improve skin photoaging function. The study
involved human skin fibroblasts from a 12-year-old child and divided
into two groups. The combination of HA crosslinking 3％+LP
significantly improved skin photoaging function, including
proliferation rates, collagen deposits, and TGF-β consumption. The
difference was statistically significant（p＜0.05）. This suggests that
HA and LP can be a promising treatment for skin photoaging.

EP12-6Chronic urticaria―its correlation with autoimmunity and food allergy
in Asian population○Zi Teng Chai
（Department of Dermatology, Singapore General Hospital, Singapore）
There has always been public perception on certain foods as triggerof urticaria in Asia. We performed a prospective study looking at
contributing factors of chronic urticaria in Asian adults in Singapore.
Food-specific serum IgE, skin prick test（SPT）and autologous serum
skin test（ASST）were performed for all 16 patients. ASST was
positive in 2 patients（12.5％）who did not suspect food as trigger, with
UAS score of 3, UCT ＜12, and highest CUQ2OL and DLQI score.
Twelve patients（75％）perceived food as trigger of urticaria. Foodallergy was confirmed in only 2 patients（12.5％）, both to shrimp,
prawn and crab. The prevalence of food being trigger of chronic
urticaria is indeed lower than perceived in Asian population.

EP12-7
Strong Association Between Sjögrenʼs Syndrome and Vitiligo○Poyuan Wu1），Jing-Xing Li2），Po-Chang Wu5），Teng-Shun Yu3），
Shu-Bai Hsu4）（Departement of Dermatology, China Medical University Hospital,
Taichung1），Department of Internal Medicine, Taipei VeteranGeneral Hospital, Taipei2），Management Office for Health Data, China
Medical University Hospital, Taichung3），Department of Nursing,
China Medical University Hospital, Taichung4），Rheumatology and
Immunology Center, China Medical University Hospital, Taichung5））
A total of 266,292 individuals with SS and 19,466,177 controls were
included in this study. Following propensity-score matching at a 1：1
ratio, 265,792 pairs of SS and control cohorts were established. The
adjusted hazard ratio for developing vitiligo was 2.14（95％ confidence
interval, 1.90­2.42）in the SS cohort. Age-stratified analysis showed asignificantly greater risk of vitiligo in every age group for those with
SS. The cumulative risk of vitiligo was significantly higher in the SS
cohort than in the non-SS cohort during the 12-year follow-up（logrank P ＜0.001）.

105

MEMO

MEMO